<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta http-equiv="Content-Style-Type" content="text/css" />
		<meta name="generator" content="MediaWiki 1.15alpha" />
		<meta name="keywords" content="Prostate cancer,2006,2007,2009,Agency for Healthcare Research and Quality,American Cancer Society,Annals of Internal Medicine,April 5,August 31,BBC,Centers for Disease Control and Prevention" />
		<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Prostate_cancer&amp;action=edit" />
		<link rel="edit" title="Edit this page" href="/w/index.php?title=Prostate_cancer&amp;action=edit" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
		<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=rss" />
		<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
		<title>Prostate cancer - Wikipedia, the free encyclopedia</title>
		<link rel="stylesheet" href="/skins-1.5/common/shared.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/common/commonPrint.css?207xx" type="text/css" media="print" />
		<link rel="stylesheet" href="/skins-1.5/monobook/main.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/chick/main.css?207xx" type="text/css" media="handheld" />
		<!--[if lt IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE50Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE55Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 6]><link rel="stylesheet" href="/skins-1.5/monobook/IE60Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 7]><link rel="stylesheet" href="/skins-1.5/monobook/IE70Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Common.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Print.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="print" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Handheld.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="handheld" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Monobook.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=-&amp;action=raw&amp;maxage=2678400&amp;gen=css" type="text/css" />
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?207xx"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->

		<script type= "text/javascript">/*<![CDATA[*/
		var skin = "monobook";
		var stylepath = "/skins-1.5";
		var wgArticlePath = "/wiki/$1";
		var wgScriptPath = "/w";
		var wgScript = "/w/index.php";
		var wgVariantArticlePath = false;
		var wgActionPaths = {};
		var wgServer = "http://en.wikipedia.org";
		var wgCanonicalNamespace = "";
		var wgCanonicalSpecialPageName = false;
		var wgNamespaceNumber = 0;
		var wgPageName = "Prostate_cancer";
		var wgTitle = "Prostate cancer";
		var wgAction = "view";
		var wgArticleId = "88078";
		var wgIsArticle = true;
		var wgUserName = null;
		var wgUserGroups = null;
		var wgUserLanguage = "en";
		var wgContentLanguage = "en";
		var wgBreakFrames = false;
		var wgCurRevisionId = 282009217;
		var wgVersion = "1.15alpha";
		var wgEnableAPI = true;
		var wgEnableWriteAPI = true;
		var wgSeparatorTransformTable = ["", ""];
		var wgDigitTransformTable = ["", ""];
		var wgMWSuggestTemplate = "http://en.wikipedia.org/w/api.php?action=opensearch\x26search={searchTerms}\x26namespace={namespaces}\x26suggest";
		var wgDBname = "enwiki";
		var wgSearchNamespaces = [0];
		var wgMWSuggestMessages = ["with suggestions", "no suggestions"];
		var wgRestrictionEdit = [];
		var wgRestrictionMove = [];
		/*]]>*/</script>

		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?207xx"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?207xx"></script>
		<script type="text/javascript" src="/skins-1.5/common/mwsuggest.js?207xx"></script>
<script type="text/javascript">/*<![CDATA[*/
var wgNotice='';var wgNoticeLocal='';
/*]]>*/</script>		<script type="text/javascript" src="http://upload.wikimedia.org/centralnotice/wikipedia/en/centralnotice.js?207xx"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
	</head>
<body class="mediawiki ltr ns-0 ns-subject page-Prostate_cancer skin-monobook">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
		<div id="siteNotice"><script type='text/javascript'>if (wgNotice != '') document.writeln(wgNotice);</script></div>		<h1 id="firstHeading" class="firstHeading">Prostate cancer</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table class="infobox" width="200" cellspacing="0" style="font-size: 95%; text-align:left">
<tr>
<td style="text-align: center; background: lightgrey; font-size: 95%;" colspan="2"><b>Prostate cancer</b><br />
<i>Classification and external resources</i></td>
</tr>
<tr>
<th><a href="/wiki/ICD" title="ICD" class="mw-redirect">ICD</a>-<a href="/wiki/List_of_ICD-10_codes" title="List of ICD-10 codes" class="mw-redirect">10</a></th>
<td><a href="/wiki/ICD-10_Chapter_C" title="ICD-10 Chapter C" class="mw-redirect">C</a><a href="http://www.who.int/classifications/apps/icd/icd10online/?gc60.htm+c61" class="external text" title="http://www.who.int/classifications/apps/icd/icd10online/?gc60.htm+c61" rel="nofollow">61.</a></td>
</tr>
<tr>
<th><a href="/wiki/ICD" title="ICD" class="mw-redirect">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9</a></th>
<td><a href="http://www.icd9data.com/getICD9Code.ashx?icd9=185" class="external text" title="http://www.icd9data.com/getICD9Code.ashx?icd9=185" rel="nofollow">185</a></td>
</tr>
<tr>
<th><a href="/wiki/OMIM" title="OMIM" class="mw-redirect">OMIM</a></th>
<td><a href="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176807" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176807" rel="nofollow">176807</a></td>
</tr>
<tr>
<th><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a href="http://www.diseasesdatabase.com/ddb10780.htm" class="external text" title="http://www.diseasesdatabase.com/ddb10780.htm" rel="nofollow">10780</a></td>
</tr>
<tr>
<th><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a href="http://www.nlm.nih.gov/medlineplus/ency/article/000380.htm" class="external text" title="http://www.nlm.nih.gov/medlineplus/ency/article/000380.htm" rel="nofollow">000380</a></td>
</tr>
<tr>
<th><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a href="http://www.emedicine.com/radio/topic574.htm" class="external text" title="http://www.emedicine.com/radio/topic574.htm" rel="nofollow">radio/574</a>&#160;</td>
</tr>
<tr>
<th><b><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></b></th>
<td><a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?field=uid&amp;term=D011471" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?field=uid&amp;term=D011471" rel="nofollow">D011471</a></td>
</tr>
</table>
<p><b>Prostate cancer</b> is a <a href="/wiki/Disease" title="Disease">disease</a> in which <a href="/wiki/Cancer" title="Cancer">cancer</a> develops in the <a href="/wiki/Prostate" title="Prostate">prostate</a>, a gland in the <a href="/wiki/Male" title="Male">male</a> <a href="/wiki/Reproductive_system" title="Reproductive system">reproductive system</a>. It occurs when <a href="/wiki/Cell_(biology)" title="Cell (biology)">cells</a> of the prostate <a href="/wiki/Mutation" title="Mutation">mutate</a> and begin to multiply out of control. These cells may spread (<a href="/wiki/Metastasis" title="Metastasis">metastasize</a>) from the prostate to other parts of the body, especially the <a href="/wiki/Bone" title="Bone">bones</a> and <a href="/wiki/Lymph_node" title="Lymph node">lymph nodes</a>. Prostate cancer may cause pain, difficulty in <a href="/wiki/Urination" title="Urination">urinating</a>, problems during sexual intercourse, <a href="/wiki/Erectile_dysfunction" title="Erectile dysfunction">erectile dysfunction</a> and other <a href="/wiki/Symptoms" title="Symptoms" class="mw-redirect">symptoms</a>. However those symptoms are present only in an advanced stage of the disease.</p>
<p>Rates of detection of prostate cancers vary widely across the world with South and East Asia detecting less frequently than in Europe, and especially the United States.<sup id="cite_ref-web.archive.org_0-0" class="reference"><a href="#cite_note-web.archive.org-0" title=""><span>[</span>1<span>]</span></a></sup> Prostate cancer develops most frequently in men over fifty. This cancer can occur only in men, as the prostate is exclusively of the male reproductive tract. It is one of the most common types of cancer in men. However, many men who develop prostate cancer never have symptoms, undergo no therapy, and eventually die of other causes. That is because malignant <a href="/wiki/Neoplasm" title="Neoplasm">neoplasms</a> of the prostate are, in most cases, slow-growing, and because most of those affected are over 60. Hence they often die of causes unrelated to the prostate cancer, such as heart/circulatory disease, pneumonia, other unconnected cancers, or old age. Many factors, including <a href="/wiki/Genetics" title="Genetics">genetics</a> and <a href="/wiki/Diet_(nutrition)" title="Diet (nutrition)">diet</a>, have been implicated in the development of prostate cancer.</p>
<p>The presence of prostate cancer may be indicated by PSA (<a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">prostate specific antigen</a>) testing or by <a href="/wiki/Physical_examination" title="Physical examination">physical examination</a> or by symptoms and confirmed by biopsy. There is some current concern about the accuracy of the PSA test and its usefulness in screening. Suspected prostate cancer is typically confirmed by taking a <a href="/wiki/Biopsy" title="Biopsy">biopsy</a> of the prostate and examining it under a <a href="/wiki/Microscope" title="Microscope">microscope</a>. Further tests, such as <a href="/wiki/CT_scan" title="CT scan" class="mw-redirect">CT scans</a> and <a href="/wiki/Bone_scan" title="Bone scan">bone scans</a>, may be performed to determine whether prostate cancer has spread.</p>
<p>Treatment options for prostate cancer with intent to cure are primarily <a href="/wiki/Surgery" title="Surgery">surgery</a> and <a href="/wiki/Radiation_therapy" title="Radiation therapy">radiation therapy</a>. Other treatments such as <a href="/wiki/Hormonal_therapy" title="Hormonal therapy" class="mw-redirect">hormonal therapy</a>, <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a>, <a href="/wiki/Proton_therapy" title="Proton therapy">proton therapy</a>, cryosurgery, high intensity focused ultrasound (HIFU) also exist depending on the clinical scenario and desired outcome.</p>
<p>The age and underlying health of the man as well as the extent of spread, appearance under the microscope and response of the cancer to initial treatment are important in determining the outcome of the disease. The decision whether or not to treat localized prostate cancer (a tumor that is contained within the prostate) with curative intent is a <a href="/wiki/Patient_trade-off" title="Patient trade-off">patient trade-off</a> between the expected beneficial and harmful effects in terms of patient survival and quality of life.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Prostate"><span class="tocnumber">1</span> <span class="toctext">Prostate</span></a></li>
<li class="toclevel-1"><a href="#Classification"><span class="tocnumber">2</span> <span class="toctext">Classification</span></a></li>
<li class="toclevel-1"><a href="#Symptoms"><span class="tocnumber">3</span> <span class="toctext">Symptoms</span></a></li>
<li class="toclevel-1"><a href="#Causes"><span class="tocnumber">4</span> <span class="toctext">Causes</span></a>
<ul>
<li class="toclevel-2"><a href="#Genetics"><span class="tocnumber">4.1</span> <span class="toctext">Genetics</span></a></li>
<li class="toclevel-2"><a href="#Diet"><span class="tocnumber">4.2</span> <span class="toctext">Diet</span></a></li>
<li class="toclevel-2"><a href="#Medication_exposure"><span class="tocnumber">4.3</span> <span class="toctext">Medication exposure</span></a></li>
<li class="toclevel-2"><a href="#Ejaculation"><span class="tocnumber">4.4</span> <span class="toctext">Ejaculation</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Pathophysiology"><span class="tocnumber">5</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1"><a href="#Diagnosis"><span class="tocnumber">6</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2"><a href="#Biopsy"><span class="tocnumber">6.1</span> <span class="toctext">Biopsy</span></a>
<ul>
<li class="toclevel-3"><a href="#Gleason_score"><span class="tocnumber">6.1.1</span> <span class="toctext">Gleason score</span></a></li>
<li class="toclevel-3"><a href="#Tumor_markers"><span class="tocnumber">6.1.2</span> <span class="toctext">Tumor markers</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Diagnostic_tools_under_investigation"><span class="tocnumber">6.2</span> <span class="toctext">Diagnostic tools under investigation</span></a>
<ul>
<li class="toclevel-3"><a href="#PCA3"><span class="tocnumber">6.2.1</span> <span class="toctext">PCA3</span></a></li>
<li class="toclevel-3"><a href="#Early_prostate_cancer"><span class="tocnumber">6.2.2</span> <span class="toctext">Early prostate cancer</span></a></li>
<li class="toclevel-3"><a href="#Prostate_mapping"><span class="tocnumber">6.2.3</span> <span class="toctext">Prostate mapping</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Prostasomes"><span class="tocnumber">6.3</span> <span class="toctext">Prostasomes</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Prevention"><span class="tocnumber">7</span> <span class="toctext">Prevention</span></a>
<ul>
<li class="toclevel-2"><a href="#Vitamins_and_medication"><span class="tocnumber">7.1</span> <span class="toctext">Vitamins and medication</span></a></li>
<li class="toclevel-2"><a href="#Ejaculation_frequency"><span class="tocnumber">7.2</span> <span class="toctext">Ejaculation frequency</span></a></li>
<li class="toclevel-2"><a href="#Oils_and_fatty_acids"><span class="tocnumber">7.3</span> <span class="toctext">Oils and fatty acids</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Screening"><span class="tocnumber">8</span> <span class="toctext">Screening</span></a>
<ul>
<li class="toclevel-2"><a href="#Digital_rectal_examination"><span class="tocnumber">8.1</span> <span class="toctext">Digital rectal examination</span></a></li>
<li class="toclevel-2"><a href="#Prostate_specific_antigen"><span class="tocnumber">8.2</span> <span class="toctext">Prostate specific antigen</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Treatment"><span class="tocnumber">9</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2"><a href="#Active_surveillance"><span class="tocnumber">9.1</span> <span class="toctext">Active surveillance</span></a></li>
<li class="toclevel-2"><a href="#Hormonal_therapy"><span class="tocnumber">9.2</span> <span class="toctext">Hormonal therapy</span></a></li>
<li class="toclevel-2"><a href="#Surgery"><span class="tocnumber">9.3</span> <span class="toctext">Surgery</span></a>
<ul>
<li class="toclevel-3"><a href="#Radical_prostatectomy"><span class="tocnumber">9.3.1</span> <span class="toctext">Radical prostatectomy</span></a></li>
<li class="toclevel-3"><a href="#Transurethral_resection_of_the_prostate"><span class="tocnumber">9.3.2</span> <span class="toctext">Transurethral resection of the prostate</span></a></li>
<li class="toclevel-3"><a href="#Orchiectomy"><span class="tocnumber">9.3.3</span> <span class="toctext">Orchiectomy</span></a></li>
<li class="toclevel-3"><a href="#Cryosurgery"><span class="tocnumber">9.3.4</span> <span class="toctext">Cryosurgery</span></a></li>
<li class="toclevel-3"><a href="#Complications_of_surgery"><span class="tocnumber">9.3.5</span> <span class="toctext">Complications of surgery</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Radiation_therapy"><span class="tocnumber">9.4</span> <span class="toctext">Radiation therapy</span></a>
<ul>
<li class="toclevel-3"><a href="#Overview"><span class="tocnumber">9.4.1</span> <span class="toctext">Overview</span></a></li>
<li class="toclevel-3"><a href="#Uses"><span class="tocnumber">9.4.2</span> <span class="toctext">Uses</span></a></li>
<li class="toclevel-3"><a href="#Side_Effects"><span class="tocnumber">9.4.3</span> <span class="toctext">Side Effects</span></a></li>
<li class="toclevel-3"><a href="#Comparison_to_surgery"><span class="tocnumber">9.4.4</span> <span class="toctext">Comparison to surgery</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#High_intensity_focused_ultrasound_.28HIFU.29"><span class="tocnumber">9.5</span> <span class="toctext">High intensity focused ultrasound (HIFU)</span></a></li>
<li class="toclevel-2"><a href="#Palliative_care"><span class="tocnumber">9.6</span> <span class="toctext">Palliative care</span></a></li>
<li class="toclevel-2"><a href="#Alternative_therapies"><span class="tocnumber">9.7</span> <span class="toctext">Alternative therapies</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Prognosis"><span class="tocnumber">10</span> <span class="toctext">Prognosis</span></a></li>
<li class="toclevel-1"><a href="#Epidemiology"><span class="tocnumber">11</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">12</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Prostate_cancer_models"><span class="tocnumber">13</span> <span class="toctext">Prostate cancer models</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">14</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">15</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Prostate" id="Prostate"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=1" title="Edit section: Prostate">edit</a>]</span> <span class="mw-headline">Prostate</span></h2>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Prostate" title="Prostate">Prostate</a></div>
<p>The <a href="/wiki/Prostate" title="Prostate">prostate</a> is a part of the male <a href="/wiki/Reproductive_system" title="Reproductive system">reproductive</a> <a href="/wiki/Organ_(anatomy)" title="Organ (anatomy)">organ</a> which helps make and store <a href="/wiki/Seminal_fluid" title="Seminal fluid" class="mw-redirect">seminal fluid</a>. In adult men a typical prostate is about three centimeters long and weighs about twenty grams.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1" title=""><span>[</span>2<span>]</span></a></sup> It is located in the <a href="/wiki/Pelvis" title="Pelvis">pelvis</a>, under the <a href="/wiki/Urinary_bladder" title="Urinary bladder">urinary bladder</a> and in front of the <a href="/wiki/Rectum" title="Rectum">rectum</a>. The prostate surrounds part of the <a href="/wiki/Urethra" title="Urethra">urethra</a>, the tube that carries <a href="/wiki/Urine" title="Urine">urine</a> from the bladder during <a href="/wiki/Urination" title="Urination">urination</a> and semen during <a href="/wiki/Ejaculation" title="Ejaculation">ejaculation</a>.<sup id="cite_ref-2" class="reference"><a href="#cite_note-2" title=""><span>[</span>3<span>]</span></a></sup> Because of its location, prostate diseases often affect urination, ejaculation, and rarely <a href="/wiki/Defecation" title="Defecation">defecation</a>. The prostate contains many small <a href="/wiki/Gland" title="Gland">glands</a> which make about twenty percent of the fluid constituting semen.<sup id="cite_ref-3" class="reference"><a href="#cite_note-3" title=""><span>[</span>4<span>]</span></a></sup> In prostate cancer the cells of these prostate glands <a href="/wiki/Mutation" title="Mutation">mutate</a> into cancer cells. The prostate glands require male <a href="/wiki/Hormone" title="Hormone">hormones</a>, known as <a href="/wiki/Androgen" title="Androgen">androgens</a>, to work properly. Androgens include <a href="/wiki/Testosterone" title="Testosterone">testosterone</a>, which is made in the <a href="/wiki/Testes" title="Testes" class="mw-redirect">testes</a>; <a href="/wiki/Dehydroepiandrosterone" title="Dehydroepiandrosterone">dehydroepiandrosterone</a>, made in the <a href="/wiki/Adrenal_gland" title="Adrenal gland">adrenal glands</a>; and <a href="/wiki/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a>, which is converted from testosterone within the prostate itself. Androgens are also responsible for <a href="/wiki/Secondary_sex_characteristic" title="Secondary sex characteristic">secondary sex characteristics</a> such as facial hair and increased muscle mass.</p>
<p><a name="Classification" id="Classification"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=2" title="Edit section: Classification">edit</a>]</span> <span class="mw-headline">Classification</span></h2>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Prostate_cancer_staging" title="Prostate cancer staging">Prostate cancer staging</a></div>
<p>An important part of evaluating prostate cancer is determining the <a href="/wiki/Cancer_staging" title="Cancer staging">stage</a>, or how far the cancer has spread. Knowing the stage helps define <a href="/wiki/Prognosis" title="Prognosis">prognosis</a> and is useful when selecting therapies. The most common system is the four-stage <a href="/wiki/TNM" title="TNM">TNM</a> system (abbreviated from Tumor/Nodes/Metastases). Its components include the size of the tumor, the number of involved <a href="/wiki/Lymph_node" title="Lymph node">lymph nodes</a>, and the presence of any other <a href="/wiki/Metastasis" title="Metastasis">metastases</a>.</p>
<p>The most important distinction made by any staging system is whether or not the cancer is still confined to the prostate. In the TNM system, clinical T1 and T2 cancers are found only in the prostate, while T3 and T4 cancers have spread elsewhere. Several tests can be used to look for evidence of spread. These include <a href="/wiki/Computed_tomography" title="Computed tomography">computed tomography</a> to evaluate spread within the pelvis, <a href="/wiki/Bone_scan" title="Bone scan">bone scans</a> to look for spread to the bones, and <a href="/wiki/Endorectal_coil_magnetic_resonance_imaging" title="Endorectal coil magnetic resonance imaging">endorectal coil magnetic resonance imaging</a> to closely evaluate the prostatic capsule and the <a href="/wiki/Seminal_vesicles" title="Seminal vesicles" class="mw-redirect">seminal vesicles</a>. Bone scans should reveal osteoblastic appearance due to <i>increased</i> bone density in the areas of bone metastasis - opposite to what is found in many other cancers that metastasize.</p>
<p><a href="/wiki/Computed_tomography" title="Computed tomography">Computed tomography</a> (CT) and <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a> (MRI) currently do not add any significant information in the assessment of possible lymph node metastases in patients with prostate cancer according to a meta-analysis.<sup id="cite_ref-pmid17936849_4-0" class="reference"><a href="#cite_note-pmid17936849-4" title=""><span>[</span>5<span>]</span></a></sup> The <a href="/wiki/Sensitivity_(tests)" title="Sensitivity (tests)" class="mw-redirect">sensitivity</a> of CT was 42% and <a href="/wiki/Specificity_(tests)" title="Specificity (tests)" class="mw-redirect">specificity</a> of CT was 82%. The <a href="/wiki/Sensitivity_(tests)" title="Sensitivity (tests)" class="mw-redirect">sensitivity</a> of MRI was 39% and the <a href="/wiki/Specificity_(tests)" title="Specificity (tests)" class="mw-redirect">specificity</a> of MRI was 82%. For patients at similar risk to those in this study (17% had positive pelvic lymph nodes in the CT studies and 30% had positive pelvic lymph nodes in the MRI studies), this leads to a <a href="/wiki/Positive_predictive_value" title="Positive predictive value">positive predictive value</a> (PPV) of 32.3% with CT, 48.1% with MRI, and <a href="/wiki/Negative_predictive_value" title="Negative predictive value">negative predictive value</a> (NPV) of 87.3% with CT, 75.8% with MRI.It is easy to treat if found early After a prostate biopsy, a <a href="/wiki/Pathology" title="Pathology">pathologist</a> looks at the samples under a microscope. If cancer is present, the pathologist reports the <a href="/wiki/Grading_(tumors)" title="Grading (tumors)">grade</a> of the tumor. The grade tells how much the tumor tissue differs from normal prostate tissue and suggests how fast the tumor is likely to grow. The Gleason system is used to grade prostate tumors from 2 to 10, where a <a href="/wiki/Gleason_score" title="Gleason score">Gleason score</a> of 10 indicates the most abnormalities. The pathologist assigns a number from 1 to 5 for the most common pattern observed under the microscope, then does the same for the second most common pattern. The sum of these two numbers is the Gleason score. The <a href="/wiki/Whitmore-Jewett_stage" title="Whitmore-Jewett stage" class="mw-redirect">Whitmore-Jewett stage</a> is another method sometimes used. Proper grading of the tumor is critical, since the grade of the tumor is one of the major factors used to determine the treatment recommendation.</p>
<p><a name="Symptoms" id="Symptoms"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=3" title="Edit section: Symptoms">edit</a>]</span> <span class="mw-headline">Symptoms</span></h2>
<p>Early prostate cancer usually causes no symptoms. Often it is diagnosed during the workup for an elevated <a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">PSA</a> noticed during a routine checkup. Sometimes, however, prostate cancer does cause symptoms, often similar to those of diseases such as <a href="/wiki/Benign_prostatic_hypertrophy" title="Benign prostatic hypertrophy" class="mw-redirect">benign prostatic hypertrophy</a>. These include <a href="/wiki/Urinary_frequency" title="Urinary frequency" class="mw-redirect">frequent urination</a>, <a href="/wiki/Nocturia" title="Nocturia">increased urination at night</a>, difficulty starting and maintaining a steady stream of urine, <a href="/wiki/Hematuria" title="Hematuria">blood in the urine</a>, and <a href="/wiki/Dysuria" title="Dysuria">painful urination</a>. Prostate cancer is associated with urinary dysfunction as the prostate gland surrounds the prostatic urethra. Changes within the gland therefore directly affect urinary function. Because the <a href="/wiki/Vas_deferens" title="Vas deferens">vas deferens</a> deposits seminal fluid into the prostatic urethra, and secretions from the prostate gland itself are included in semen content, prostate cancer may also cause problems with sexual function and performance, such as difficulty achieving <a href="/wiki/Erection" title="Erection">erection</a> or painful <a href="/wiki/Ejaculation" title="Ejaculation">ejaculation</a>.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5" title=""><span>[</span>6<span>]</span></a></sup></p>
<p>Advanced prostate cancer can spread to other parts of the body and this may cause additional symptoms. The most common symptom is <a href="/wiki/Bone_pain" title="Bone pain">bone pain</a>, often in the <a href="/wiki/Vertebrae" title="Vertebrae" class="mw-redirect">vertebrae</a> (bones of the spine), <a href="/wiki/Pelvis" title="Pelvis">pelvis</a> or <a href="/wiki/Rib" title="Rib">ribs</a>. Spread of cancer into other bones such as the <a href="/wiki/Femur" title="Femur">femur</a> is usually to the proximal part of the bone. Prostate cancer in the <a href="/wiki/Vertebral_column" title="Vertebral column">spine</a> can also compress the <a href="/wiki/Spinal_cord" title="Spinal cord">spinal cord</a>, causing leg weakness and <a href="/wiki/Urinary_incontinence" title="Urinary incontinence">urinary</a> and <a href="/wiki/Fecal_incontinence" title="Fecal incontinence">fecal incontinence</a>.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6" title=""><span>[</span>7<span>]</span></a></sup></p>
<p><a name="Causes" id="Causes"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=4" title="Edit section: Causes">edit</a>]</span> <span class="mw-headline">Causes</span></h2>
<p>The specific causes of prostate cancer remain unknown.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7" title=""><span>[</span>8<span>]</span></a></sup> A man's risk of developing prostate cancer is related to his <a href="/wiki/Aging" title="Aging" class="mw-redirect">age</a>, <a href="/wiki/Genetics" title="Genetics">genetics</a>, <a href="/wiki/Race_(classification_of_human_beings)" title="Race (classification of human beings)">race</a>, <a href="/wiki/Diet_(nutrition)" title="Diet (nutrition)">diet</a>, <a href="/wiki/Lifestyle" title="Lifestyle">lifestyle</a>, <a href="/wiki/Medication" title="Medication" class="mw-redirect">medications</a>, and other factors. The primary risk factor is age. Prostate cancer is uncommon in men less than 45, but becomes more common with advancing age. The average age at the time of diagnosis is 70.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8" title=""><span>[</span>9<span>]</span></a></sup> However, many men never know they have prostate cancer. Autopsy studies of Chinese, German, Israeli, Jamaican, Swedish, and Ugandan men who died of other causes have found prostate cancer in thirty percent of men in their 50s, and in eighty percent of men in their 70s.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9" title=""><span>[</span>10<span>]</span></a></sup> In the year 2005 in the United States, there were an estimated 230,000 new cases of prostate cancer and 30,000 deaths due to prostate cancer.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10" title=""><span>[</span>11<span>]</span></a></sup></p>
<p><a name="Genetics" id="Genetics"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=5" title="Edit section: Genetics">edit</a>]</span> <span class="mw-headline">Genetics</span></h3>
<p>A man's genetic background contributes to his risk of developing prostate cancer. This is suggested by an increased <a href="/wiki/Incidence_(epidemiology)" title="Incidence (epidemiology)">incidence</a> of prostate cancer found in certain racial groups, in identical <a href="/wiki/Twin" title="Twin">twins</a> of men with prostate cancer, and in men with certain <a href="/wiki/Gene" title="Gene">genes</a>. In the United States, prostate cancer more commonly affects black men than white or Hispanic men, and is also more deadly in black men.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11" title=""><span>[</span>12<span>]</span></a></sup> Men who have a brother or father with prostate cancer have twice the usual risk of developing prostate cancer.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12" title=""><span>[</span>13<span>]</span></a></sup> <a href="/wiki/Twin_study" title="Twin study">Studies of twins</a> in <a href="/wiki/Scandinavia" title="Scandinavia">Scandinavia</a> suggest that forty percent of prostate cancer risk can be explained by <a href="/wiki/Heritability" title="Heritability">inherited factors</a>.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13" title=""><span>[</span>14<span>]</span></a></sup> However, no single gene is responsible for prostate cancer; many different genes have been implicated. Two genes (<i><a href="/wiki/BRCA1" title="BRCA1">BRCA1</a></i> and <i><a href="/wiki/BRCA2" title="BRCA2">BRCA2</a></i>) that are important risk factors for <a href="/wiki/Ovarian_cancer" title="Ovarian cancer">ovarian cancer</a> and <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a> in women have also been implicated in prostate cancer.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14" title=""><span>[</span>15<span>]</span></a></sup></p>
<p><a name="Diet" id="Diet"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=6" title="Edit section: Diet">edit</a>]</span> <span class="mw-headline">Diet</span></h3>
<p>Dietary amounts of certain <a href="/wiki/Food" title="Food">foods</a>, <a href="/wiki/Vitamin" title="Vitamin">vitamins</a>, and <a href="/wiki/Dietary_mineral" title="Dietary mineral">minerals</a> can contribute to prostate cancer risk. Men with higher serum levels of the short-chain <a href="/wiki/Omega-6_fatty_acid" title="Omega-6 fatty acid">omega-6 fatty acid</a> <a href="/wiki/Linoleic_acid" title="Linoleic acid">linoleic acid</a> have higher rates of prostate cancer. However, the same series of studies showed that men with elevated levels of long-chain <a href="/wiki/Omega-3_fatty_acid" title="Omega-3 fatty acid">omega-3 fatty acids</a> (<a href="/wiki/Eicosapentaenoic_acid" title="Eicosapentaenoic acid">EPA</a> and <a href="/wiki/Docosahexaenoic_acid" title="Docosahexaenoic acid">DHA</a>, found in fatty fishes like <a href="/wiki/Salmon" title="Salmon">salmon</a>) had lowered incidence.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15" title=""><span>[</span>16<span>]</span></a></sup> A long-term study reports that "blood levels of trans fatty acids, in particular <a href="/wiki/Trans_fats" title="Trans fats" class="mw-redirect">trans fats</a> resulting from the hydrogenation of vegetable oils, are associated with an increased prostate cancer risk."<sup id="cite_ref-16" class="reference"><a href="#cite_note-16" title=""><span>[</span>17<span>]</span></a></sup> Other dietary factors that may increase prostate cancer risk include low intake of <a href="/wiki/Vitamin_E" title="Vitamin E">vitamin E</a> (Vitamin E is found in <a href="/wiki/Green,_leafy_vegetables" title="Green, leafy vegetables" class="mw-redirect">green, leafy vegetables</a>), and the mineral <a href="/wiki/Selenium" title="Selenium">selenium</a>. A study in 2007 cast doubt on the effectiveness of <a href="/wiki/Lycopene" title="Lycopene">lycopene</a> (found in tomatoes) in reducing the risk of prostate cancer.<sup id="cite_ref-pmid17507623_17-0" class="reference"><a href="#cite_note-pmid17507623-17" title=""><span>[</span>18<span>]</span></a></sup> Lower <a href="/wiki/Blood" title="Blood">blood</a> levels of <a href="/wiki/Vitamin_D" title="Vitamin D">vitamin D</a> also may increase the risk of developing prostate cancer. This may be linked to lower exposure to <a href="/wiki/Ultraviolet_radiation" title="Ultraviolet radiation" class="mw-redirect">ultraviolet (UV) light</a>, since UV light exposure can increase vitamin D in the body.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18" title=""><span>[</span>19<span>]</span></a></sup></p>
<p>A large study has implicated dairy, specifically low-fat <a href="/wiki/Milk" title="Milk">milk</a> and other dairy products to which <a href="/wiki/Vitamin_A_palmitate" title="Vitamin A palmitate" class="mw-redirect">vitamin A palmitate</a> has been added. This form of synthetic vitamin A has been linked to prostate cancer because it reacts with zinc and protein to form an unabsorbable complex.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19" title=""><span>[</span>20<span>]</span></a></sup></p>
<p>Prostate cancer risk can be decreased by modifying known risk factors for prostate cancer, such as decreasing intake of animal fat.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20" title=""><span>[</span>21<span>]</span></a></sup></p>
<p><a name="Medication_exposure" id="Medication_exposure"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=7" title="Edit section: Medication exposure">edit</a>]</span> <span class="mw-headline">Medication exposure</span></h3>
<p>There are also some links between prostate cancer and medications, medical procedures, and medical conditions. Daily use of <a href="/wiki/Non-steroidal_anti-inflammatory_drugs" title="Non-steroidal anti-inflammatory drugs" class="mw-redirect">anti-inflammatory medicines</a> such as <a href="/wiki/Aspirin" title="Aspirin">aspirin</a>, <a href="/wiki/Ibuprofen" title="Ibuprofen">ibuprofen</a>, or <a href="/wiki/Naproxen_sodium" title="Naproxen sodium" class="mw-redirect">naproxen</a> may decrease prostate cancer risk.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21" title=""><span>[</span>22<span>]</span></a></sup> Use of the <a href="/wiki/Hypolipidaemic_agent" title="Hypolipidaemic agent" class="mw-redirect">cholesterol-lowering drugs</a> known as the <a href="/wiki/Statin" title="Statin">statins</a> may also decrease prostate cancer risk.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22" title=""><span>[</span>23<span>]</span></a></sup> More frequent ejaculation also may decrease a man's risk of prostate cancer. One study showed that men who ejaculated five times a week in their 20s had a decreased rate of prostate cancer, though others have shown no benefit.<sup id="cite_ref-pmid12887469_23-0" class="reference"><a href="#cite_note-pmid12887469-23" title=""><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24" title=""><span>[</span>25<span>]</span></a></sup> <a href="/wiki/Infection" title="Infection">Infection</a> or <a href="/wiki/Inflammation" title="Inflammation">inflammation</a> of the prostate (<a href="/wiki/Prostatitis" title="Prostatitis">prostatitis</a>) may increase the chance for prostate cancer. In particular, infection with the <a href="/wiki/Sexually_transmitted_infection" title="Sexually transmitted infection" class="mw-redirect">sexually transmitted infections</a> <a href="/wiki/Chlamydia_infection" title="Chlamydia infection">chlamydia</a>, <a href="/wiki/Gonorrhea" title="Gonorrhea">gonorrhea</a>, or <a href="/wiki/Syphilis" title="Syphilis">syphilis</a> seems to increase risk.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25" title=""><span>[</span>26<span>]</span></a></sup> Finally, <a href="/wiki/Obesity" title="Obesity">obesity</a><sup id="cite_ref-26" class="reference"><a href="#cite_note-26" title=""><span>[</span>27<span>]</span></a></sup> and elevated blood levels of <a href="/wiki/Testosterone" title="Testosterone">testosterone</a><sup id="cite_ref-27" class="reference"><a href="#cite_note-27" title=""><span>[</span>28<span>]</span></a></sup> may increase the risk for prostate cancer.</p>
<p>Research released in May 2007, found that US war veterans who had been exposed to <a href="/wiki/Agent_Orange" title="Agent Orange">Agent Orange</a> had a 48% increased risk of prostate cancer recurrence following surgery.<sup id="cite_ref-aorange_28-0" class="reference"><a href="#cite_note-aorange-28" title=""><span>[</span>29<span>]</span></a></sup></p>
<p><a name="Ejaculation" id="Ejaculation"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=8" title="Edit section: Ejaculation">edit</a>]</span> <span class="mw-headline">Ejaculation</span></h3>
<p>One research study, by the <a href="/wiki/The_Cancer_Council_Australia" title="The Cancer Council Australia">Cancer Council Victoria</a>, has shown that men who report that they regularly ("more than five times per week") <a href="/wiki/Masturbation" title="Masturbation">masturbate</a> have up to one third fewer occurrences of prostate cancer.<sup id="cite_ref-BBC_NEWS_Masturbation_29-0" class="reference"><a href="#cite_note-BBC_NEWS_Masturbation-29" title=""><span>[</span>30<span>]</span></a></sup><sup id="cite_ref-pmid12887469_23-1" class="reference"><a href="#cite_note-pmid12887469-23" title=""><span>[</span>24<span>]</span></a></sup> The researchers <a href="/wiki/Hypothesis" title="Hypothesis">hypothesize</a> that this could be because regular ejaculation reduces the buildup of <a href="/wiki/Cancer" title="Cancer">carcinogenic</a> deposits such as 3-<a href="/wiki/Methylcholanthrene" title="Methylcholanthrene">methylcholanthrene</a>, produced from the breakdown of cholesterol, which could damage the cells lining the prostate. The researchers also speculated that frequent ejaculation may cause the prostate to mature fully, making it less susceptible to carcinogens. It is also possible that there is another factor (such as hormone levels) that is a <a href="/wiki/Correlation_does_not_imply_causation" title="Correlation does not imply causation">common cause</a> of both a reduced susceptibility to prostate cancer and a tendency toward frequent masturbation. There is also some evidence that frequent sexual intercourse is associated with reduced risk of prostate cancer, although contrarily the risks associated with STDs have been shown to increase the risk of prostate cancer.<sup id="cite_ref-BBC_NEWS_Masturbation_29-1" class="reference"><a href="#cite_note-BBC_NEWS_Masturbation-29" title=""><span>[</span>30<span>]</span></a></sup><sup id="cite_ref-pmid12887469_23-2" class="reference"><a href="#cite_note-pmid12887469-23" title=""><span>[</span>24<span>]</span></a></sup> Once the lining of the prostate is affected with cancer, the only known treatments are surgery and radiation therapy. Both may limit the ability to have erections afterward.</p>
<p><a name="Pathophysiology" id="Pathophysiology"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=9" title="Edit section: Pathophysiology">edit</a>]</span> <span class="mw-headline">Pathophysiology</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Normal_cancer_cell_division_from_NIH-2.svg" class="image" title="When normal cells are damaged beyond repair, they are eliminated by apoptosis. Cancer cells avoid apoptosis and continue to multiply in an unregulated manner."><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/2/20/Normal_cancer_cell_division_from_NIH-2.svg/180px-Normal_cancer_cell_division_from_NIH-2.svg.png" width="180" height="379" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Normal_cancer_cell_division_from_NIH-2.svg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
When normal cells are damaged beyond repair, they are eliminated by <a href="/wiki/Apoptosis" title="Apoptosis">apoptosis</a>. Cancer cells avoid apoptosis and continue to multiply in an unregulated manner.</div>
</div>
</div>
<p>Prostate cancer is classified as an <a href="/wiki/Adenocarcinoma" title="Adenocarcinoma">adenocarcinoma</a>, or glandular cancer, that begins when normal semen-secreting prostate gland cells <a href="/wiki/Mutation" title="Mutation">mutate</a> into cancer cells. The region of prostate gland where the adenocarcinoma is most common is the peripheral zone. Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as <a href="/wiki/Carcinoma_in_situ" title="Carcinoma in situ">carcinoma in situ</a> or <a href="/wiki/Prostatic_intraepithelial_neoplasia" title="Prostatic intraepithelial neoplasia">prostatic intraepithelial neoplasia</a> (PIN). Although there is no proof that PIN is a cancer precursor, it is closely associated with cancer. Over time these cancer cells begin to multiply and spread to the surrounding prostate tissue (the <a href="/wiki/Stroma" title="Stroma">stroma</a>) forming a <a href="/wiki/Tumor" title="Tumor">tumor</a>. Eventually, the tumor may grow large enough to invade nearby organs such as the <a href="/wiki/Seminal_vesicles" title="Seminal vesicles" class="mw-redirect">seminal vesicles</a> or the <a href="/wiki/Rectum" title="Rectum">rectum</a>, or the tumor cells may develop the ability to travel in the <a href="/wiki/Blood" title="Blood">bloodstream</a> and <a href="/wiki/Lymphatic_system" title="Lymphatic system">lymphatic system</a>. Prostate cancer is considered a <a href="/wiki/Malignant" title="Malignant">malignant</a> tumor because it is a mass of cells which can invade other parts of the body. This invasion of other organs is called <a href="/wiki/Metastasis" title="Metastasis">metastasis</a>. Prostate cancer most commonly metastasizes to the <a href="/wiki/Bone" title="Bone">bones</a>, <a href="/wiki/Lymph_node" title="Lymph node">lymph nodes</a>, rectum, and bladder.</p>
<p><a name="Diagnosis" id="Diagnosis"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=10" title="Edit section: Diagnosis">edit</a>]</span> <span class="mw-headline">Diagnosis</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Prostatehistopath.jpg" class="image" title="Normal prostate (A) and prostate cancer (B). In prostate cancer, the regular glands of the normal prostate are replaced by irregular glands and clumps of cells, as seen in these pictures taken through a microscope."><img alt="" src="http://upload.wikimedia.org/wikipedia/en/thumb/0/0f/Prostatehistopath.jpg/180px-Prostatehistopath.jpg" width="180" height="131" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Prostatehistopath.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<b>Normal prostate (A) and prostate cancer (B).</b> In prostate cancer, the regular glands of the normal prostate are replaced by irregular glands and clumps of cells, as seen in these pictures taken through a microscope.</div>
</div>
</div>
<p>When a man has symptoms of prostate cancer, or a screening test indicates an increased risk for cancer, more invasive evaluation is offered.</p>
<p>The only test which can fully confirm the diagnosis of prostate cancer is a <a href="/wiki/Biopsy" title="Biopsy">biopsy</a>, the removal of small pieces of the prostate for microscopic examination. However, prior to a biopsy, several other tools may be used to gather more information about the prostate and the urinary tract. <a href="/wiki/Cystoscopy" title="Cystoscopy">Cystoscopy</a> shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted down the <a href="/wiki/Urethra" title="Urethra">urethra</a>. <a href="/wiki/Transrectal_ultrasonography" title="Transrectal ultrasonography">Transrectal ultrasonography</a> creates a picture of the prostate using sound waves from a probe in the rectum.</p>
<p><a name="Biopsy" id="Biopsy"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=11" title="Edit section: Biopsy">edit</a>]</span> <span class="mw-headline">Biopsy</span></h3>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Prostate_biopsy" title="Prostate biopsy">Prostate biopsy</a></div>
<p>If cancer is suspected, a biopsy is offered. During a biopsy a <a href="/wiki/Urology" title="Urology">urologist</a> or <a href="/wiki/Radiology" title="Radiology">radiologist</a> obtains tissue samples from the prostate via the rectum. A biopsy gun inserts and removes special hollow-core needles (usually three to six on each side of the prostate) in less than a second. Prostate biopsies are routinely done on an outpatient basis and rarely require hospitalization. Fifty-five percent of men report discomfort during prostate biopsy. <sup id="cite_ref-30" class="reference"><a href="#cite_note-30" title=""><span>[</span>31<span>]</span></a></sup></p>
<p><a name="Gleason_score" id="Gleason_score"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=12" title="Edit section: Gleason score">edit</a>]</span> <span class="mw-headline">Gleason score</span></h4>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Gleason_score" title="Gleason score">Gleason score</a></div>
<p>The tissue samples are then examined under a microscope to determine whether cancer cells are present, and to evaluate the microscopic features (or <a href="/wiki/Gleason_score" title="Gleason score">Gleason score</a>) of any cancer found.</p>
<p><a name="Tumor_markers" id="Tumor_markers"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=13" title="Edit section: Tumor markers">edit</a>]</span> <span class="mw-headline">Tumor markers</span></h4>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Tumor_markers" title="Tumor markers" class="mw-redirect">Tumor markers</a></div>
<p>Tissue samples can be stained for the presence of PSA and other tumor markers in order to determine the origin of maligant cells that have metastasized.<sup id="cite_ref-pmid17667550_31-0" class="reference"><a href="#cite_note-pmid17667550-31" title=""><span>[</span>32<span>]</span></a></sup></p>
<p><br /></p>
<p><a name="Diagnostic_tools_under_investigation" id="Diagnostic_tools_under_investigation"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=14" title="Edit section: Diagnostic tools under investigation">edit</a>]</span> <span class="mw-headline">Diagnostic tools under investigation</span></h3>
<p>Currently, an active area of research involves non-invasive methods of prostate tumor detection. Adenoviruses modified to transfect tumor cells with harmless yet distinct genes (such as luciferase) have proven capable of early detection. So far, though, this area of research has only been tested in animal and <a href="/wiki/LNCaP" title="LNCaP">LNCaP</a> models.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32" title=""><span>[</span>33<span>]</span></a></sup></p>
<p><a name="PCA3" id="PCA3"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=15" title="Edit section: PCA3">edit</a>]</span> <span class="mw-headline">PCA3</span></h4>
<p>Another potential non-invasive method of early prostate tumor detection is through a molecular test that detects the presence of cell-associated <a href="/wiki/PCA3" title="PCA3">PCA3</a> mRNA in urine. <a href="/wiki/PCA3" title="PCA3">PCA3</a> mRNA is expressed almost exclusively by prostate cells and has been shown to be highly over-expressed in prostate cancer cells. <a href="/wiki/PCA3" title="PCA3">PCA3</a> is not a replacement for PSA but an additional tool to help decide if, in men suspected of having prostate cancer, a biopsy is really needed. The higher the expression of <a href="/wiki/PCA3" title="PCA3">PCA3</a> in urine, the greater the likelihood of a positive biopsy, i.e. the presence of cancer cells in the prostate.</p>
<p><a name="Early_prostate_cancer" id="Early_prostate_cancer"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=16" title="Edit section: Early prostate cancer">edit</a>]</span> <span class="mw-headline">Early prostate cancer</span></h4>
<p>It was reported in April 2007 that a new blood test for <a href="/wiki/Early_prostate_cancer_antigen-2" title="Early prostate cancer antigen-2">early prostate cancer antigen-2</a> (EPCA-2) is being researched that may alert men if they have prostate cancer and how aggressive it will be.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33" title=""><span>[</span>34<span>]</span></a></sup><sup id="cite_ref-pmid17437801_34-0" class="reference"><a href="#cite_note-pmid17437801-34" title=""><span>[</span>35<span>]</span></a></sup></p>
<p><a name="Prostate_mapping" id="Prostate_mapping"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=17" title="Edit section: Prostate mapping">edit</a>]</span> <span class="mw-headline">Prostate mapping</span></h4>
<p>Prostate Mapping is a method of diagnosis which may be accurate in determining the precise location and aggressiveness of cancer. It uses a combination of multi-sequence MRI imaging techniques and a template guided biopsy system and involves taking multiple biopsies through the skin that lies in front of the back passage rather than through the back passage. The procedure is carried out under general anaesthetic.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35" title=""><span>[</span>36<span>]</span></a></sup></p>
<p><a name="Prostasomes" id="Prostasomes"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=18" title="Edit section: Prostasomes">edit</a>]</span> <span class="mw-headline">Prostasomes</span></h3>
<p>Epithelial cells of the prostate secrete <a href="/wiki/Prostasomes" title="Prostasomes">prostasomes</a> as well as <a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">PSA</a>. Prostasomes are membrane –surrounded, prostate-derived organelles that appear extracellularly and one of their physiological functions is to protect the sperm from attacks by the female immune system. Cancerous prostate cells continue to synthesize and secrete prostasomes and may be shielded against immunological attacks by these prostasomes. Research of several aspects of prostasomal involvement in prostate cancer has been performed.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36" title=""><span>[</span>37<span>]</span></a></sup></p>
<p><a name="Prevention" id="Prevention"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=19" title="Edit section: Prevention">edit</a>]</span> <span class="mw-headline">Prevention</span></h2>
<p><a name="Vitamins_and_medication" id="Vitamins_and_medication"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=20" title="Edit section: Vitamins and medication">edit</a>]</span> <span class="mw-headline">Vitamins and medication</span></h3>
<p>Evidence from epidemiological studies supports protective roles in reducing prostate cancer for dietary <a href="/wiki/Selenium" title="Selenium">selenium</a>, <a href="/wiki/Vitamin_E" title="Vitamin E">vitamin E</a>, <a href="/wiki/Lycopene" title="Lycopene">lycopene</a>, and <a href="/wiki/Soy" title="Soy" class="mw-redirect">soy</a> foods. High plasma levels of <a href="/wiki/Vitamin_D" title="Vitamin D">Vitamin D</a> may also have a protective effect.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37" title=""><span>[</span>38<span>]</span></a></sup> Estrogens from fermented <a href="/wiki/Soybeans" title="Soybeans" class="mw-redirect">soybeans</a> and other plant sources (called <a href="/wiki/Phytoestrogen" title="Phytoestrogen" class="mw-redirect">phytoestrogens</a>) may also help prevent prostate cancer.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38" title=""><span>[</span>39<span>]</span></a></sup> The <a href="/wiki/Selective_estrogen_receptor_modulator" title="Selective estrogen receptor modulator">selective estrogen receptor modulator</a> drug <a href="/wiki/Toremifene" title="Toremifene">toremifene</a> has shown promise in early trials.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39" title=""><span>[</span>40<span>]</span></a></sup><sup id="cite_ref-40" class="reference"><a href="#cite_note-40" title=""><span>[</span>41<span>]</span></a></sup> Two medications which block the conversion of <a href="/wiki/Testosterone" title="Testosterone">testosterone</a> to <a href="/wiki/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a>, <a href="/wiki/Finasteride" title="Finasteride">finasteride</a><sup id="cite_ref-41" class="reference"><a href="#cite_note-41" title=""><span>[</span>42<span>]</span></a></sup> and <a href="/wiki/Dutasteride" title="Dutasteride">dutasteride</a>,<sup id="cite_ref-42" class="reference"><a href="#cite_note-42" title=""><span>[</span>43<span>]</span></a></sup> have also shown some promise. The use of these medications for primary prevention is still in the testing phase, and they are not widely used for this purpose. The initial problem with these medications is that they may preferentially block the development of lower-grade prostate tumors, leading to a relatively greater chance of higher grade cancers, and negating any overall survival improvement. More recent research found that <a href="/wiki/Finasteride" title="Finasteride">finasteride</a> did not increase the percentage of higher grade cancers. A 2008 study update found that finasteride reduces the incidence of prostate cancer by 30%. In the original study it turns that that the smaller prostate caused by finasteride means that a doctor is more likely to hit upon cancer nests and more likely to find aggressive-looking cells. Most of the men in the study who had cancer — aggressive or not — chose to be treated and many had their prostates removed. A pathologist then carefully examined every one of those 500 prostates and compared the kinds of cancers found at surgery to those initially diagnosed at biopsy. Finasteride did not increase the risk of High-Grade prostate cancer.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43" title=""><span>[</span>44<span>]</span></a></sup><sup id="cite_ref-cancerpreventionresearch.aacrjournals.org_44-0" class="reference"><a href="#cite_note-cancerpreventionresearch.aacrjournals.org-44" title=""><span>[</span>45<span>]</span></a></sup></p>
<p><a href="/wiki/Green_tea" title="Green tea">Green tea</a> may be protective (due to its <a href="/wiki/Polyphenol" title="Polyphenol">polyphenol</a> content),<sup id="cite_ref-45" class="reference"><a href="#cite_note-45" title=""><span>[</span>46<span>]</span></a></sup> although the most comprehensive clinical study indicates that it has no protective effect.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46" title=""><span>[</span>47<span>]</span></a></sup> A 2006 study of green tea derivatives demonstrated promising prostate cancer prevention in patients at high risk for the disease.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47" title=""><span>[</span>48<span>]</span></a></sup> Recent research published in the Journal of the <a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a> suggests that taking <a href="/wiki/Multivitamins" title="Multivitamins" class="mw-redirect">multivitamins</a> more than seven times a week can increase the risks of contracting the disease.<sup id="cite_ref-BBC_NEWS_Multivitamin_48-0" class="reference"><a href="#cite_note-BBC_NEWS_Multivitamin-48" title=""><span>[</span>49<span>]</span></a></sup><sup id="cite_ref-pmid17505071_49-0" class="reference"><a href="#cite_note-pmid17505071-49" title=""><span>[</span>50<span>]</span></a></sup> This research was unable to highlight the exact vitamins responsible for this increase (almost double), although they suggest that vitamin A, vitamin E and beta-carotene may lie at its heart. It is advised that those taking multivitamins never exceed the stated daily dose on the label. Scientists recommend a healthy, well balanced diet rich in fiber, and to reduce intake of meat. A 2007 study published in the Journal of the National Cancer Institute found that men eating <a href="/wiki/Cauliflower" title="Cauliflower">cauliflower</a>, <a href="/wiki/Broccoli" title="Broccoli">broccoli</a>, or one of the other <a href="/wiki/Cruciferous_vegetables" title="Cruciferous vegetables">cruciferous vegetables</a>, more than once a week were 40% less likely to develop prostate cancer than men who rarely ate those vegetables.<sup id="cite_ref-CBS_News_Broccoli_50-0" class="reference"><a href="#cite_note-CBS_News_Broccoli-50" title=""><span>[</span>51<span>]</span></a></sup><sup id="cite_ref-pmid17652276_51-0" class="reference"><a href="#cite_note-pmid17652276-51" title=""><span>[</span>52<span>]</span></a></sup> The <a href="/wiki/Phytochemical" title="Phytochemical">phytochemicals</a> <a href="/wiki/Indole-3-carbinol" title="Indole-3-carbinol">indole-3-carbinol</a> and <a href="/wiki/Diindolylmethane" title="Diindolylmethane" class="mw-redirect">diindolylmethane</a>, found in cruciferous vegetables, has <a href="/wiki/Antiandrogen" title="Antiandrogen">antiandrogenic</a> and immune modulating properties.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52" title=""><span>[</span>53<span>]</span></a></sup><sup id="cite_ref-53" class="reference"><a href="#cite_note-53" title=""><span>[</span>54<span>]</span></a></sup></p>
<p><a name="Ejaculation_frequency" id="Ejaculation_frequency"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=21" title="Edit section: Ejaculation frequency">edit</a>]</span> <span class="mw-headline">Ejaculation frequency</span></h3>
<p>In 2003, an Australian research team led by Graham Giles of The Cancer Council Australia concluded that frequent <a href="/wiki/Masturbation" title="Masturbation">masturbation</a> by males appears to help prevent the development of prostate cancer.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54" title=""><span>[</span>55<span>]</span></a></sup><sup id="cite_ref-BBC_NEWS_Masturbation_29-2" class="reference"><a href="#cite_note-BBC_NEWS_Masturbation-29" title=""><span>[</span>30<span>]</span></a></sup> Australian research concluded that the more men ejaculate between the ages of 20 and 50, the less likely they are to develop prostate cancer. The protective effect is greatest while men are in their twenties: those who had ejaculated more than five times per week in their twenties, for instance, were one-third less likely to develop aggressive prostate cancer later in life. The results contradict those of previous studies, which have suggested that having had many sexual partners, or a high frequency of sexual activity, increases the risk of prostate cancer by up to 40 percent. The key difference is that these earlier studies defined sexual activity as sexual intercourse, whereas this study focused on the number of ejaculations, whether or not intercourse was involved.<sup id="cite_ref-New_Scientist_55-0" class="reference"><a href="#cite_note-New_Scientist-55" title=""><span>[</span>56<span>]</span></a></sup> Another study completed in 2004 reported that "Most categories of ejaculation frequency were unrelated to risk of prostate cancer. However, high ejaculation frequency was related to decreased risk of total prostate cancer." The report abstract concluded, "Our results suggest that ejaculation frequency is not related to increased risk of prostate cancer." <sup id="cite_ref-56" class="reference"><a href="#cite_note-56" title=""><span>[</span>57<span>]</span></a></sup></p>
<p>A 2008 study showed that frequent masturbation, of about two to seven times a week, at the ages of 20s and 30s, increases the risk of having prostate cancer. While frequent masturbation, once a week, at the age of 50s decreases the disease risk.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57" title=""><span>[</span>58<span>]</span></a></sup></p>
<p><a name="Oils_and_fatty_acids" id="Oils_and_fatty_acids"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=22" title="Edit section: Oils and fatty acids">edit</a>]</span> <span class="mw-headline">Oils and fatty acids</span></h3>
<p>In experimental models using mice, <a href="/wiki/Omega-6" title="Omega-6" class="mw-redirect">omega-6</a> <a href="/wiki/Polyunsaturated_fatty_acids" title="Polyunsaturated fatty acids" class="mw-redirect">polyunsaturated fatty acids</a> (PUFAs), which are found in most types of <a href="/wiki/Vegetable_oil" title="Vegetable oil" class="mw-redirect">vegetable oil</a> (<a href="/wiki/Corn_oil" title="Corn oil">corn oil</a>, <a href="/wiki/Soybean_oil" title="Soybean oil" class="mw-redirect">soybean oil</a>, <a href="/wiki/Sunflower_oil" title="Sunflower oil">sunflower oil</a>), increased prostate tumor growth, sped up histopathological progression, and decreased survival, while the <a href="/wiki/Omega-3" title="Omega-3" class="mw-redirect">omega-3</a> <a href="/wiki/Fatty_acids" title="Fatty acids" class="mw-redirect">fatty acids</a> (<a href="/wiki/Fish_oil" title="Fish oil">fish oil</a>) had the opposite, beneficial effect.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58" title=""><span>[</span>59<span>]</span></a></sup></p>
<p>Some researches have indicated that some specific saturated fatty acids (<a href="/wiki/Myristic_acid" title="Myristic acid">myristic acid</a><sup id="cite_ref-pmid14693732_59-0" class="reference"><a href="#cite_note-pmid14693732-59" title=""><span>[</span>60<span>]</span></a></sup><sup id="cite_ref-palmiticmyristic_60-0" class="reference"><a href="#cite_note-palmiticmyristic-60" title=""><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-saturated_61-0" class="reference"><a href="#cite_note-saturated-61" title=""><span>[</span>62<span>]</span></a></sup> and <a href="/wiki/Palmitic_acid" title="Palmitic acid">palmitic acid</a><sup id="cite_ref-palmiticmyristic_60-1" class="reference"><a href="#cite_note-palmiticmyristic-60" title=""><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-saturated_61-1" class="reference"><a href="#cite_note-saturated-61" title=""><span>[</span>62<span>]</span></a></sup> are associated with increased risk of prostate cancer in a dose-dependent manner. Another study further investigated these and other saturated fatty acids.<sup id="cite_ref-saturated_61-2" class="reference"><a href="#cite_note-saturated-61" title=""><span>[</span>62<span>]</span></a></sup> However it's still uncertain if this association is a cause or consequence of the disease.</p>
<p><a name="Screening" id="Screening"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=23" title="Edit section: Screening">edit</a>]</span> <span class="mw-headline">Screening</span></h2>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Prostate_cancer_screening" title="Prostate cancer screening">Prostate cancer screening</a></div>
<p>Prostate cancer <a href="/wiki/Screening_(medicine)" title="Screening (medicine)">screening</a> is an attempt to find unsuspected cancers. Screening tests may lead to more specific follow-up tests such as a <a href="/wiki/Biopsy" title="Biopsy">biopsy</a>, where small cores of the prostate are removed for closer study. Prostate cancer screening options include the <a href="/wiki/Rectal_examination" title="Rectal examination">digital rectal exam</a> and the <a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">prostate specific antigen</a> (PSA) blood test. Screening for prostate cancer is controversial because it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments.</p>
<p>Prostate cancer is usually a slow-growing cancer, very common among older men. In fact, most prostate cancers never grow to the point where they cause symptoms, and most men with prostate cancer die of other causes before prostate cancer has an impact on their lives. The PSA screening test may detect these small cancers that would never become life threatening. Doing the PSA test in these men may lead to <a href="/wiki/Overdiagnosis" title="Overdiagnosis">overdiagnosis</a>, including additional testing and treatment. Follow-up tests, such as <a href="/wiki/Prostate_biopsy" title="Prostate biopsy">prostate biopsy</a>, may cause pain, bleeding and infection. Prostate cancer treatments may cause urinary <a href="/wiki/Urinary_incontinence" title="Urinary incontinence">incontinence</a> and <a href="/wiki/Erectile_dysfunction" title="Erectile dysfunction">erectile dysfunction</a>. A large randomized study in which 76,000 men were randomized to receive either PSA screening or conventional care found that more men who underwent PSA screening were diagnosed with prostate cancer, but that there was no difference in mortality between the two groups. <sup id="cite_ref-62" class="reference"><a href="#cite_note-62" title=""><span>[</span>63<span>]</span></a></sup></p>
<p>The results from two of the largest randomized trials regarding the efficacy of screening have now been published. <sup id="cite_ref-63" class="reference"><a href="#cite_note-63" title=""><span>[</span>64<span>]</span></a></sup> In one of these trials, the death rate from prostate cancer was actually higher in the group that had total screening compared to the control group which had only normal rates of screening. The other showed some benefit from screening but the reduction in deaths was minor compared to the level of intervention needed to prevent it.</p>
<p>In the European Randomized Study of Screening for Prostate Cancer initiated in the early 1990s the intention was to evaluate the effect of screening with prostate-specific antigen (PSA) testing on death rates from prostate cancer. The trial involved 182,000 men between the ages of 50 and 74 years in seven European countries randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive such screening. During a median follow-up of almost 9 years, the cumulative detected incidence of prostate cancer was 820 per 10,000 in the screening group and 480 per 10,000 in the control group. Deaths from these cancers in this time was much lower. There were 214 prostate cancer deaths in the screening group and 326 in the control group, a difference of 71 men per 10,000 in the tested group compared to the control. The researchers concluded that PSA-based screening did reduce the rate of death from prostate cancer by 20% but that this was associated with a high risk of overdiagnosis. Statistically, it means that 1410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent just one death from prostate cancer. <sup id="cite_ref-64" class="reference"><a href="#cite_note-64" title=""><span>[</span>65<span>]</span></a></sup></p>
<p>A US study looked at the general effectiveness of a screening program involving both PSA and DRE methods. This was conducted between 1993 thu 2001, in which 76,693 men at 10 U.S. study centers 38,343 subjects received screening (an annual PSA testing for 6 years and DRE for 4 years) and a control group of 38,350 subjects reveived 'usual care' with subjects and health care providers receiving the results and deciding on the type of follow-up evaluation. 'Usual care' means that some in this group would have received some screening, as some organizations have recommended. After 7 years of follow-up, the incidence of prostate cancer per 10,000 person-years was 116 (2,820 cancers) in the screening group and 95 (2,322 cancers) in the control group. The incidence of death attributed to prostate cancer per 10,000 person-years was 2.0 (50 deaths) in the screening group and 1.7 (44 deaths) in the control group (rate ratio, 1.13; 95% CI, 0.75 to 1.70). The data at 10 years were 67% complete and consistent with these overall findings. The researchers concluded that after 7 to 10 years of follow-up, the rate of death from prostate cancer was very low and did not differ significantly between the two study groups.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65" title=""><span>[</span>66<span>]</span></a></sup></p>
<p>Commenting on the findings, the Chief Medical Officer of the American Cancer Society, Otis W. Brawley, MD, said</p>
<blockquote>
<p>many experts had anticipated these studies would show a small number of men will benefit from prostate screening, but a large number of men will be treated unnecessarily. And that's what these studies show. However, the question is not as simple as: 'does prostate cancer screening work?' What we need to know is: what are benefits of prostate cancer screening and are they large enough to outweigh the harms associated with it? And despite the release of this early data, we still cannot say whether the benefits outweigh the risk.<sup id="cite_ref-66" class="reference"><a href="#cite_note-66" title=""><span>[</span>67<span>]</span></a></sup>"</p>
</blockquote>
<p>His Deputy chief medical officer, Len Lichtenfeld, MD, MACP said</p>
<blockquote>
<p>"When one considers all of the problems associated with treatment for prostate cancer -- urine incontinence, impotence, pain and bleeding among others -- that is a lot of men left with a lot of symptoms to save one life."</p>
</blockquote>
<p>The American Urological Association said that "The decision to screen is one that a man should make in conjunction with his physician, and should incorporate known prostate cancer risk factors, such as family history of prostate cancer, age, ethnicity/race and whether or not a man has had a previous negative prostate biopsy. These factors are different for every man and, therefore, the benefits of screening should be considered in the broader perspective."<sup id="cite_ref-67" class="reference"><a href="#cite_note-67" title=""><span>[</span>68<span>]</span></a></sup> The organization will review its best practice guidlines later this year.</p>
<ul>
<li>In 2002, the <a href="/wiki/US_Preventive_Services_Task_Force" title="US Preventive Services Task Force" class="mw-redirect">U.S. Preventive Services Task Force</a> (USPSTF) concluded that the evidence was insufficient to recommend for or against routine screening for prostate cancer using PSA testing or digital rectal examination (DRE).<sup id="cite_ref-USPSTF_2002_68-0" class="reference"><a href="#cite_note-USPSTF_2002-68" title=""><span>[</span>69<span>]</span></a></sup> The previous 1995 USPSTF recommendation was against routine screening.</li>
<li>In 1997, <a href="/wiki/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a> (ACS) guidelines began recommending that beginning at age 50 (age 45 for African-American men and men with a family history of prostate cancer, and since 2001, age 40 for men with a very strong family history of prostate cancer), PSA testing and DRE be <i>offered</i> annually to men who have a life-expectancy of 10 or more years (average life expectancy is 10 years or more for U.S. men under age 76)<sup id="cite_ref-US_life_table_2003_69-0" class="reference"><a href="#cite_note-US_life_table_2003-69" title=""><span>[</span>70<span>]</span></a></sup> along with information on the risks and benefits of screening.<sup id="cite_ref-ACS_guidelines_70-0" class="reference"><a href="#cite_note-ACS_guidelines-70" title=""><span>[</span>71<span>]</span></a></sup> The previous ACS recommendations since 1980 had been for routine screening for prostate cancer with DRE annually beginning at age 40, and since 1992 had been for routine screening with DRE and PSA testing annually beginning at age 50.<sup id="cite_ref-ACS_history_71-0" class="reference"><a href="#cite_note-ACS_history-71" title=""><span>[</span>72<span>]</span></a></sup></li>
<li>The 2007 <a href="/wiki/National_Comprehensive_Cancer_Network" title="National Comprehensive Cancer Network">National Comprehensive Cancer Network</a> (NCCN) guideline recommends <i>offering</i> a baseline PSA test and DRE at ages 40 and 45 and annual PSA testing and DRE beginning at age 50 (with annual PSA testing and DRE beginning at age 40 for African-American men, men with a family history of prostate cancer, and men with a PSA ≥ 0.6 ng/mL at age 40 or PSA &gt; 0.6 ng/mL at age 45) through age 80, along with information on the risks and benefits of screening. Biopsy is recommended if DRE is positive or PSA ≥ 4 ng/mL, and biopsy considered if PSA &gt; 2.5 ng/mL or PSA velocity ≥ 0.35 ng/mL/year when PSA ≤ 2.5 ng/mL.<sup id="cite_ref-NCCN_2007_72-0" class="reference"><a href="#cite_note-NCCN_2007-72" title=""><span>[</span>73<span>]</span></a></sup></li>
<li>Some U.S. radiation oncologists and medical oncologists who specialize in treating prostate cancer recommend obtaining a baseline PSA in all men at age 35<sup id="cite_ref-D.27Amico_2004_73-0" class="reference"><a href="#cite_note-D.27Amico_2004-73" title=""><span>[</span>74<span>]</span></a></sup> or beginning annual PSA testing in high risk men at age 35.<sup id="cite_ref-Strum_2005_74-0" class="reference"><a href="#cite_note-Strum_2005-74" title=""><span>[</span>75<span>]</span></a></sup></li>
<li>The American Urological Association Patient Guide to Prostate Cancer.<sup id="cite_ref-AUA_Patient_Guide_2008_75-0" class="reference"><a href="#cite_note-AUA_Patient_Guide_2008-75" title=""><span>[</span>76<span>]</span></a></sup></li>
</ul>
<p>Since there is no general agreement that the benefits of PSA screening outweigh the harms, the consensus is that clinicians use a process of shared decision-making that includes discussing with patients the risks of prostate cancer, the potential benefits and harms of screening, and involving the patients in the decision.<sup id="cite_ref-Ross_2004_76-0" class="reference"><a href="#cite_note-Ross_2004-76" title=""><span>[</span>77<span>]</span></a></sup></p>
<p>However, because PSA screening is widespread in the United States, following the recommendations of major scientific and medical organizations to use shared decision-making is legally perilous in some <a href="/wiki/U.S._state" title="U.S. state">U.S. states</a>.<sup id="cite_ref-Lewis_2007_77-0" class="reference"><a href="#cite_note-Lewis_2007-77" title=""><span>[</span>78<span>]</span></a></sup> In 2003, a <a href="/wiki/Virginia" title="Virginia">Virginia</a> <a href="/wiki/Jury" title="Jury">jury</a> found a <a href="/wiki/General_practitioner#United_States" title="General practitioner">family practice</a> <a href="/wiki/Residency_(medicine)" title="Residency (medicine)">residency program</a> guilty of <a href="/wiki/Medical_malpractice" title="Medical malpractice">malpractice</a> and liable for $1 million for following national <a href="/wiki/Medical_guideline" title="Medical guideline">guidelines</a> and using shared decision-making, thereby allowing a patient (subsequently found to have a high PSA and incurable advanced prostate cancer) to decline a screening PSA test, instead of routinely ordering without discussion PSA tests in all men ≥ 50 years of age as four local physicians testified was their practice, and was accepted by the jury as the local <a href="/wiki/Standard_of_care" title="Standard of care">standard of care</a>.<sup id="cite_ref-Mernstein_2004_78-0" class="reference"><a href="#cite_note-Mernstein_2004-78" title=""><span>[</span>79<span>]</span></a></sup></p>
<p>An estimated 20 million PSA tests are done per year in North America and possibly 20 million more outside of North America.<sup id="cite_ref-De_Angelis_2007_79-0" class="reference"><a href="#cite_note-De_Angelis_2007-79" title=""><span>[</span>80<span>]</span></a></sup></p>
<ul>
<li>In 2000, 34.1% of all U.S. men age ≥ 50 had a <i>screening</i> PSA test within the past year and 56.8% reported ever having a PSA test.<sup id="cite_ref-Ross_2004_76-1" class="reference"><a href="#cite_note-Ross_2004-76" title=""><span>[</span>77<span>]</span></a></sup></li>
<li>In 2000, 33.6% of all U.S. men age 50–64 and 51.3% of men age ≥ 65 had a PSA test within the past year.<sup id="cite_ref-Swan_2003_80-0" class="reference"><a href="#cite_note-Swan_2003-80" title=""><span>[</span>81<span>]</span></a></sup></li>
<li>In 2005, 33.5% of all U.S. men age 50–64 had a PSA test in the past year.
<ul>
<li>37.5% of men with private <a href="/wiki/Health_insurance#Health_insurance_in_the_United_States" title="Health insurance">health insurance</a>, 20.8% of men with <a href="/wiki/Medicaid" title="Medicaid">Medicaid</a> insurance, 14.0% of currently <a href="/wiki/Health_care_in_the_United_States#Inequities" title="Health care in the United States">uninsured</a> men, and 11.5% of men uninsured for &gt; 12 months.<sup id="cite_ref-Ward_2008_81-0" class="reference"><a href="#cite_note-Ward_2008-81" title=""><span>[</span>82<span>]</span></a></sup></li>
</ul>
</li>
<li>In 2000–2001, 34.1% of all <a href="/wiki/Canada" title="Canada">Canadian</a> men age ≥ 50 had a <i>screening</i> PSA test within the past year and 47.5% reported ever having a <i>screening</i> PSA test.<sup id="cite_ref-Beaulac_2006_82-0" class="reference"><a href="#cite_note-Beaulac_2006-82" title=""><span>[</span>83<span>]</span></a></sup></li>
<li>Canadian men in <a href="/wiki/Ontario" title="Ontario">Ontario</a> were most likely to have had a PSA test within the past year and men in <a href="/wiki/Alberta" title="Alberta">Alberta</a> were least likely to have had a PSA test with the past year or ever.<sup id="cite_ref-Gibbons_2003_83-0" class="reference"><a href="#cite_note-Gibbons_2003-83" title=""><span>[</span>84<span>]</span></a></sup></li>
</ul>
<p><a name="Digital_rectal_examination" id="Digital_rectal_examination"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=24" title="Edit section: Digital rectal examination">edit</a>]</span> <span class="mw-headline">Digital rectal examination</span></h3>
<p><a href="/wiki/Rectal_examination" title="Rectal examination">Digital rectal examination</a> (DRE) is a procedure where the examiner inserts a gloved, lubricated finger into the rectum to check the size, shape, and texture of the prostate. Areas which are irregular, hard or lumpy need further evaluation, since they may contain cancer. Although the DRE only evaluates the back of the prostate, 85% of prostate cancers arise in this part of the prostate. Prostate cancer which can be felt on DRE is generally more advanced.<sup id="cite_ref-84" class="reference"><a href="#cite_note-84" title=""><span>[</span>85<span>]</span></a></sup> The use of DRE has never been shown to prevent prostate cancer deaths when used as the only screening test.<sup id="cite_ref-85" class="reference"><a href="#cite_note-85" title=""><span>[</span>86<span>]</span></a></sup></p>
<p><a name="Prostate_specific_antigen" id="Prostate_specific_antigen"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=25" title="Edit section: Prostate specific antigen">edit</a>]</span> <span class="mw-headline">Prostate specific antigen</span></h3>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">Prostate specific antigen</a></div>
<p>The PSA test measures the blood level of <a href="/wiki/Prostate-specific_antigen" title="Prostate-specific antigen" class="mw-redirect">prostate-specific antigen</a>, an <a href="/wiki/Enzyme" title="Enzyme">enzyme</a> produced by the prostate. Specifically, PSA is a <a href="/wiki/Serine_protease" title="Serine protease">serine protease</a> similar to <a href="/wiki/Kallikrein" title="Kallikrein">kallikrein</a>. Its normal function is to liquify gelatinous semen after ejaculation, allowing <a href="/wiki/Spermatozoon" title="Spermatozoon">spermatozoa</a> to more easily navigate through the uterine <a href="/wiki/Cervix" title="Cervix">cervix</a>.</p>
<p>The risk of prostate cancer increases with increasing PSA levels.<sup id="cite_ref-Catalona_2007_86-0" class="reference"><a href="#cite_note-Catalona_2007-86" title=""><span>[</span>87<span>]</span></a></sup> 4 ng/mL was chosen arbitrarily as a decision level for biopsies in the clinical trial upon which the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">FDA</a> in 1994 based adding prostate cancer detection in men age 50 and over as an approved indication for the first commercially available PSA test.<sup id="cite_ref-Kolota_2004_87-0" class="reference"><a href="#cite_note-Kolota_2004-87" title=""><span>[</span>88<span>]</span></a></sup> 4 ng/mL was used as the biopsy decision level in the <a href="/wiki/Prostate_cancer_screening#Randomized_controlled_trials" title="Prostate cancer screening">PLCO</a> trial, 3 ng/mL was used in the <a href="/wiki/Prostate_cancer_screening#Randomized_controlled_trials" title="Prostate cancer screening">ERSPC</a> and <a href="/wiki/Prostate_cancer_screening#Randomized_controlled_trials" title="Prostate cancer screening">ProtecT</a> trials, and 2.5 ng/mL is used in the 2007 NCCN guideline.</p>
<p>PSA levels can change for many reasons other than cancer. Two common causes of high PSA levels are enlargement of the prostate (<a href="/wiki/Benign_prostatic_hypertrophy" title="Benign prostatic hypertrophy" class="mw-redirect">benign prostatic hypertrophy</a> (BPH)) and infection in the prostate (<a href="/wiki/Prostatitis" title="Prostatitis">prostatitis</a>). It can also be raised for 24 hours after ejaculation and several days after catheterization. PSA levels are lowered in men who use medications used to treat BPH or <a href="/wiki/Baldness" title="Baldness">baldness</a>. These medications, <a href="/wiki/Finasteride" title="Finasteride">finasteride</a> (marketed as Proscar or Propecia) and <a href="/wiki/Dutasteride" title="Dutasteride">dutasteride</a> (marketed as Avodart), may decrease the PSA levels by 50% or more.</p>
<p>Several other ways of evaluating the PSA have been developed to avoid the shortcomings of simple PSA screening. The use of age-specific reference ranges improves the sensitivity and specificity of the test. The rate of rise of the PSA over time, called the PSA velocity, has been used to evaluate men with PSA levels between 4 and 10 ng/ml, but it has not proven to be an effective screening test.<sup id="cite_ref-88" class="reference"><a href="#cite_note-88" title=""><span>[</span>89<span>]</span></a></sup> Comparing the PSA level with the size of the prostate, as measured by <a href="/wiki/Medical_ultrasonography" title="Medical ultrasonography">ultrasound</a> or <a href="/wiki/Magnetic_resonance_imaging" title="Magnetic resonance imaging">magnetic resonance imaging</a>, has also been studied. This comparison, called PSA density, is both costly and has not proven to be an effective screening test.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89" title=""><span>[</span>90<span>]</span></a></sup> PSA in the blood may either be free or bound to other <a href="/wiki/Protein" title="Protein">proteins</a>. Measuring the amount of PSA which is free or bound may provide additional screening information, but questions regarding the usefulness of these measurements limit their widespread use.<sup id="cite_ref-90" class="reference"><a href="#cite_note-90" title=""><span>[</span>91<span>]</span></a></sup><sup id="cite_ref-91" class="reference"><a href="#cite_note-91" title=""><span>[</span>92<span>]</span></a></sup></p>
<p><a name="Treatment" id="Treatment"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=26" title="Edit section: Treatment">edit</a>]</span> <span class="mw-headline">Treatment</span></h2>
<p>Treatment for prostate cancer may involve <a href="/w/index.php?title=Active_surveillance&amp;action=edit&amp;redlink=1" class="new" title="Active surveillance (page does not exist)">active surveillance</a>, <a href="/wiki/Surgery" title="Surgery">surgery</a>, <a href="/wiki/Radiation_therapy" title="Radiation therapy">radiation therapy</a> including <a href="/wiki/Brachytherapy" title="Brachytherapy">brachytherapy</a> (<a href="/wiki/Prostate_brachytherapy" title="Prostate brachytherapy">prostate brachytherapy</a>) and external beam radiation, <a href="/wiki/High_Intensity_Focused_Ultrasound_(HIFU)" title="High Intensity Focused Ultrasound (HIFU)" class="mw-redirect">High Intensity Focused Ultrasound (HIFU)</a>, <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a>, <a href="/wiki/Cryosurgery" title="Cryosurgery">cryosurgery</a>, hormonal therapy, or some combination. Which option is best depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors are the man's age, his general health, and his feelings about potential treatments and their possible side effects. Because all treatments can have significant <a href="/wiki/Adverse_effect_(medicine)" title="Adverse effect (medicine)" class="mw-redirect">side effects</a>, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations.</p>
<p>The selection of treatment options may be a complex decision involving many factors. For example, radical prostatectomy after primary radiation failure is a very technically challenging surgery and may not be an option.<sup id="cite_ref-pmid16314889_92-0" class="reference"><a href="#cite_note-pmid16314889-92" title=""><span>[</span>93<span>]</span></a></sup> This may enter into the treatment decision.</p>
<p>If the cancer has spread beyond the prostate, treatment options significantly change, so most doctors who treat prostate cancer use a variety of <a href="/wiki/Nomogram" title="Nomogram">nomograms</a> to predict the probability of spread. Treatment by watchful waiting, HIFU, radiation therapy, cryosurgery, and surgery are generally offered to men whose cancer remains within the prostate. Hormonal therapy and chemotherapy are often reserved for disease which has spread beyond the prostate. However, there are exceptions: radiation therapy may be used for some advanced tumors, and hormonal therapy is used for some early stage tumors. <a href="/wiki/Cryotherapy" title="Cryotherapy">Cryotherapy</a> (the process of freezing the tumor), hormonal therapy, and chemotherapy may also be offered if initial treatment fails and the cancer progresses.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93" title=""><span>[</span>94<span>]</span></a></sup></p>
<p><a name="Active_surveillance" id="Active_surveillance"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=27" title="Edit section: Active surveillance">edit</a>]</span> <span class="mw-headline">Active surveillance</span></h3>
<p><a href="/w/index.php?title=Active_surveillance&amp;action=edit&amp;redlink=1" class="new" title="Active surveillance (page does not exist)">Active surveillance</a> refers to observation and regular monitoring without invasive treatment. Active surveillance is often used when an early stage, slow-growing prostate cancer is suspected. Conversely <a href="/wiki/Watchful_waiting" title="Watchful waiting">watchful waiting</a> may also be suggested when the risks of surgery, radiation therapy, or hormonal therapy outweigh the possible benefits. Other treatments can be started if symptoms develop, or if there are signs that the cancer growth is accelerating (e.g., rapidly rising PSA, increase in Gleason score on repeat biopsy, etc.). Approximately one-third of men who choose active surveillance for early stage tumors eventually have signs of tumor progression, and they may need to begin treatment within three years.<sup id="cite_ref-94" class="reference"><a href="#cite_note-94" title=""><span>[</span>95<span>]</span></a></sup> Men who choose active surveillance avoid the risks of surgery, radiation, and other treatments. The risk of disease progression and metastasis (spread of the cancer) may be increased, but this increase risk appears to be small if the program of surveillance is followed closely, generally including serial PSA assessments and repeat prostate biopsies every 1-2 years depending on the PSA trends.</p>
<p>For younger men, a trial of active surveillance may not mean avoiding treatment altogether, but may reasonably allow a delay of a few years or more, during which time the quality of life impact of active treatment can be avoided. Published data to date suggest that carefully selected men will not miss a window for cure with this approach. Additional health problems that develop with advancing age during the observation period can also make it harder to undergo surgery and radiation therapy.</p>
<p><a name="Hormonal_therapy" id="Hormonal_therapy"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=28" title="Edit section: Hormonal therapy">edit</a>]</span> <span class="mw-headline">Hormonal therapy</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Prostatehormone.jpg" class="image" title="Hormonal therapy in prostate cancer. Diagram shows the different organs (purple text), hormones (black text and arrows), and treatments (red text and arrows) important in hormonal therapy."><img alt="" src="http://upload.wikimedia.org/wikipedia/en/thumb/5/5f/Prostatehormone.jpg/180px-Prostatehormone.jpg" width="180" height="480" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Prostatehormone.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<b>Hormonal therapy in prostate cancer.</b> Diagram shows the different organs (<i>purple text</i>), hormones (<i>black text and arrows</i>), and treatments (<i>red text and arrows</i>) important in hormonal therapy.</div>
</div>
</div>
<p><a href="/wiki/Hormonal_therapy_(oncology)" title="Hormonal therapy (oncology)">Hormonal therapy</a> uses medications or surgery to block prostate cancer cells from getting <a href="/wiki/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT), a hormone produced in the prostate and required for the growth and spread of most prostate cancer cells. Blocking DHT often causes prostate cancer to stop growing and even shrink. However, hormonal therapy rarely cures prostate cancer because cancers which initially respond to hormonal therapy typically become resistant after one to two years. Hormonal therapy is therefore usually used when cancer has spread from the prostate. It may also be given to certain men undergoing radiation therapy or surgery to help prevent return of their cancer.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95" title=""><span>[</span>96<span>]</span></a></sup></p>
<p>Hormonal therapy for prostate cancer targets the pathways the body uses to produce DHT. A <a href="/wiki/Feedback_loop" title="Feedback loop" class="mw-redirect">feedback loop</a> involving the testicles, the hypothalamus, and the pituitary, adrenal, and prostate glands controls the blood levels of DHT. First, low blood levels of DHT stimulate the <a href="/wiki/Hypothalamus" title="Hypothalamus">hypothalamus</a> to produce <a href="/wiki/Gonadotropin_releasing_hormone" title="Gonadotropin releasing hormone" class="mw-redirect">gonadotropin releasing hormone</a> (GnRH). GnRH then stimulates the <a href="/wiki/Pituitary_gland" title="Pituitary gland">pituitary gland</a> to produce <a href="/wiki/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH), and LH stimulates the <a href="/wiki/Testicles" title="Testicles" class="mw-redirect">testicles</a> to produce testosterone. Finally, testosterone from the testicles and dehydroepiandrosterone from the <a href="/wiki/Adrenal_gland" title="Adrenal gland">adrenal glands</a> stimulate the prostate to produce more DHT. Hormonal therapy can decrease levels of DHT by interrupting this pathway at any point. There are several forms of hormonal therapy:</p>
<ul>
<li><a href="/wiki/Castration" title="Castration">Orchiectomy</a> is surgery to remove the testicles. Because the testicles make most of the body's testosterone, after orchiectomy testosterone levels drop. Now the prostate not only lacks the testosterone stimulus to produce DHT, but also it does not have enough testosterone to transform into DHT.</li>
<li><a href="/wiki/Antiandrogens" title="Antiandrogens" class="mw-redirect">Antiandrogens</a> are medications such as <a href="/wiki/Flutamide" title="Flutamide">flutamide</a>, <a href="/wiki/Bicalutamide" title="Bicalutamide">bicalutamide</a>, <a href="/wiki/Nilutamide" title="Nilutamide">nilutamide</a>, and <a href="/wiki/Cyproterone_acetate" title="Cyproterone acetate" class="mw-redirect">cyproterone acetate</a> which directly block the actions of testosterone and DHT within prostate cancer cells.</li>
<li>Medications which block the production of adrenal androgens such as DHEA include <a href="/wiki/Ketoconazole" title="Ketoconazole">ketoconazole</a> and <a href="/wiki/Aminoglutethimide" title="Aminoglutethimide">aminoglutethimide</a>. Because the adrenal glands only make about 5% of the body's androgens, these medications are generally used only in combination with other methods that can block the 95% of androgens made by the testicles. These combined methods are called total androgen blockade (TAB). TAB can also be achieved using antiandrogens.</li>
<li>GnRH action can be interrupted in one of two ways. <a href="/wiki/Gonadotropin-releasing_hormone_analog" title="Gonadotropin-releasing hormone analog" class="mw-redirect">GnRH antagonists</a> suppress the production of LH directly, while <a href="/wiki/Gonadotropin-releasing_hormone_analog" title="Gonadotropin-releasing hormone analog" class="mw-redirect">GnRH agonists</a> suppress LH through the process of <a href="/wiki/Downregulation" title="Downregulation" class="mw-redirect">downregulation</a> after an initial stimulation effect. <a href="/wiki/Abarelix" title="Abarelix">Abarelix</a> is an example of a GnRH antagonist, while the GnRH agonists include <a href="/wiki/Leuprolide" title="Leuprolide">leuprolide</a>, <a href="/wiki/Goserelin" title="Goserelin">goserelin</a>, <a href="/wiki/Triptorelin" title="Triptorelin">triptorelin</a>, and <a href="/wiki/Buserelin" title="Buserelin">buserelin</a>. Initially, GnRH agonists <i>increase</i> the production of LH. However, because the constant supply of the medication does not match the body's natural production rhythm, production of both LH and GnRH decreases after a few weeks.<sup id="cite_ref-96" class="reference"><a href="#cite_note-96" title=""><span>[</span>97<span>]</span></a></sup></li>
<li>A very recent Trial I study (N=21) found that <a href="/wiki/Abiraterone" title="Abiraterone">Abiraterone Acetate</a> caused dramatic reduction in <a href="/wiki/PSA" title="PSA">PSA</a> levels and <a href="/wiki/Tumor" title="Tumor">Tumor</a> sizes in aggressive end-stage prostate cancer for 70% of patients. This is prostate cancer that resists all other treatments (e.g., castration, other hormones, etc.). Officially the impacts on life-span are not yet known because subjects have not been taking the drug very long. Larger Trial III Clinical Studies are in the works. If successful an approved treatment is hoped for around 2011.<sup id="cite_ref-97" class="reference"><a href="#cite_note-97" title=""><span>[</span>98<span>]</span></a></sup><sup id="cite_ref-98" class="reference"><a href="#cite_note-98" title=""><span>[</span>99<span>]</span></a></sup></li>
</ul>
<p>The most successful hormonal treatments are orchiectomy and GnRH agonists. Despite their higher cost, GnRH agonists are often chosen over orchiectomy for cosmetic and emotional reasons. Eventually, total androgen blockade may prove to be better than orchiectomy or GnRH agonists used alone.</p>
<p>Each treatment has disadvantages which limit its use in certain circumstances. Although orchiectomy is a low-risk surgery, the psychological impact of removing the testicles can be significant. The loss of testosterone also causes <a href="/wiki/Hot_flush" title="Hot flush" class="mw-redirect">hot flashes</a>, weight gain, loss of <a href="/wiki/Libido" title="Libido">libido</a>, enlargement of the <a href="/wiki/Breast" title="Breast">breasts</a> (<a href="/wiki/Gynecomastia" title="Gynecomastia">gynecomastia</a>), impotence and <a href="/wiki/Osteoporosis" title="Osteoporosis">osteoporosis</a>. GnRH agonists eventually cause the same side effects as orchiectomy but may cause worse symptoms at the beginning of treatment. When GnRH agonists are first used, testosterone surges can lead to increased bone pain from metastatic cancer, so antiandrogens or abarelix are often added to blunt these side effects. Estrogens are not commonly used because they increase the risk for <a href="/wiki/Cardiovascular_disease" title="Cardiovascular disease">cardiovascular disease</a> and <a href="/wiki/Thrombosis" title="Thrombosis">blood clots</a>. The antiandrogens do not generally cause impotence and usually cause less loss of bone and muscle mass. Ketoconazole can cause <a href="/wiki/Hepatotoxicity" title="Hepatotoxicity">liver damage</a> with prolonged use, and aminoglutethimide can cause skin <a href="/wiki/Rash" title="Rash">rashes</a>.</p>
<p><a name="Surgery" id="Surgery"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=29" title="Edit section: Surgery">edit</a>]</span> <span class="mw-headline">Surgery</span></h3>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Prostatectomy" title="Prostatectomy">Prostatectomy</a></div>
<p>Surgical removal of the prostate, or <a href="/wiki/Prostatectomy" title="Prostatectomy">prostatectomy</a>, is a common treatment either for early stage prostate cancer, or for cancer which has failed to respond to radiation therapy. The most common type is <a href="/wiki/Radical_retropubic_prostatectomy" title="Radical retropubic prostatectomy">radical retropubic prostatectomy</a>, when the surgeon removes the prostate through an abdominal incision. Another type is <a href="/wiki/Radical_perineal_prostatectomy" title="Radical perineal prostatectomy">radical perineal prostatectomy</a>, when the surgeon removes the prostate through an incision in the <a href="/wiki/Perineum" title="Perineum">perineum</a>, the skin between the <a href="/wiki/Scrotum" title="Scrotum">scrotum</a> and <a href="/wiki/Anus" title="Anus">anus</a>. Radical prostatectomy can also be performed laparoscopically, through a series of small (1cm) incisions in the abdomen, with or without the assistance of a surgical robot.</p>
<p><a name="Radical_prostatectomy" id="Radical_prostatectomy"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=30" title="Edit section: Radical prostatectomy">edit</a>]</span> <span class="mw-headline">Radical prostatectomy</span></h4>
<p><a href="/wiki/Radical_prostatectomy" title="Radical prostatectomy" class="mw-redirect">Radical prostatectomy</a> is effective for tumors which have not spread beyond the prostate;<sup id="cite_ref-pmid15888698_99-0" class="reference"><a href="#cite_note-pmid15888698-99" title=""><span>[</span>100<span>]</span></a></sup> cure rates depend on risk factors such as PSA level and Gleason grade. However, it may cause <a href="/wiki/Nerve" title="Nerve">nerve</a> damage that significantly alters the quality of life of the prostate cancer survivor.</p>
<p>Radical prostatectomy has traditionally been used alone when the cancer is small. In the event of positive margins or locally advanced disease found on pathology, adjuvant radiation therapy may offer improved survival. Surgery may also be offered when a cancer is not responding to radiation therapy. However, because radiation therapy causes tissue changes, prostatectomy after radiation has a higher risk of complications.</p>
<p>Laparoscopic radical prostatectomy, LRP, is a new way to approach the prostate surgically with intent to cure. Contrasted with the open surgical form of prostate cancer surgery, laparoscopic radical prostatectomy does not require a large incision. Relying on modern technology, such as miniaturization, fiber optics, and the like, laparoscopic radical prostatectomy is a minimally invasive prostate cancer treatment.</p>
<p>In the hands of an experienced surgeon, robotic assisted laparoscopic prostatectomy (RALP) may reduce positive surgical margins when compared to <a href="/wiki/Radical_retropubic_prostatectomy" title="Radical retropubic prostatectomy">radical retropubic prostatectomy</a> (RRP) among patients with <strong class="selflink">prostate cancer</strong> according to a retrospective study.<sup id="cite_ref-pmid17936849_4-1" class="reference"><a href="#cite_note-pmid17936849-4" title=""><span>[</span>5<span>]</span></a></sup> The <a href="/wiki/Relative_risk_reduction" title="Relative risk reduction">relative risk reduction</a> was 57.7%. For patients at similar risk to those in this study (35.5% of patients had positive surgical margins following RRP), this leads to an <a href="/wiki/Absolute_risk_reduction" title="Absolute risk reduction">absolute risk reduction</a> of 20.5%. 4.9 patients must be treated for one to benefit (<a href="/wiki/Number_needed_to_treat" title="Number needed to treat">number needed to treat</a> = 4.9). The relative merits of RALP and benefits over open radical prostatectomy are an area of intense research currently in urology and no definitive data, that has been widely accepted by the broader urological community, exists to say it is superior to a open radical retropubic prostatectomy.</p>
<p><a name="Transurethral_resection_of_the_prostate" id="Transurethral_resection_of_the_prostate"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=31" title="Edit section: Transurethral resection of the prostate">edit</a>]</span> <span class="mw-headline">Transurethral resection of the prostate</span></h4>
<p><a href="/wiki/Transurethral_resection_of_the_prostate" title="Transurethral resection of the prostate">Transurethral resection of the prostate</a>, commonly called a "TURP," is a surgical procedure performed when the tube from the bladder to the penis (<a href="/wiki/Urethra" title="Urethra">urethra</a>) is blocked by prostate enlargement. TURP is generally for benign disease and is not meant as definitive treatment for prostate cancer. During a TURP, a small instrument (<a href="/wiki/Cystoscope" title="Cystoscope" class="mw-redirect">cystoscope</a>) is placed into the penis and the blocking prostate is cut away.</p>
<p><a name="Orchiectomy" id="Orchiectomy"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=32" title="Edit section: Orchiectomy">edit</a>]</span> <span class="mw-headline">Orchiectomy</span></h4>
<p>In metastatic disease, where cancer has spread beyond the prostate, removal of the <a href="/wiki/Testicle" title="Testicle">testicles</a> (called <a href="/wiki/Orchiectomy" title="Orchiectomy" class="mw-redirect">orchiectomy</a>) may be done to decrease testosterone levels and control cancer growth. (See hormonal therapy, below).</p>
<p><a name="Cryosurgery" id="Cryosurgery"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=33" title="Edit section: Cryosurgery">edit</a>]</span> <span class="mw-headline">Cryosurgery</span></h4>
<p><a href="/wiki/Cryosurgery" title="Cryosurgery">Cryosurgery</a> is another method of treating prostate cancer in which the prostate gland is exposed to freezing temperatures.<sup id="cite_ref-100" class="reference"><a href="#cite_note-100" title=""><span>[</span>101<span>]</span></a></sup> It is less invasive than radical prostatectomy, and <a href="/wiki/General_anesthesia" title="General anesthesia" class="mw-redirect">general anesthesia</a> is less commonly used. Under ultrasound guidance, a method invented by Dr. <a href="/wiki/Gary_Onik" title="Gary Onik">Gary Onik</a>,<sup id="cite_ref-101" class="reference"><a href="#cite_note-101" title=""><span>[</span>102<span>]</span></a></sup> metal rods are inserted through the skin of the <a href="/wiki/Perineum" title="Perineum">perineum</a> into the prostate. Highly purified Argon gas is used to cool the rods, freezing the surrounding tissue at −186 °<a href="/wiki/Celsius" title="Celsius">C</a> (−302 °<a href="/wiki/Fahrenheit" title="Fahrenheit">F</a>). As the water within the prostate cells freeze, the cells die. The <a href="/wiki/Urethra" title="Urethra">urethra</a> is protected from freezing by a <a href="/wiki/Foley_catheter" title="Foley catheter">catheter</a> filled with warm liquid. Cryosurgery generally causes fewer problems with urinary control than other treatments, but impotence occurs up to ninety percent of the time. When used as the initial treatment for prostate cancer and in the hands of an experienced cryosurgeon, cryosurgery has a 10 year biochemical disease free rate superior to all other treatments including radical prostatectomy and any form of radiation.<sup id="cite_ref-102" class="reference"><a href="#cite_note-102" title=""><span>[</span>103<span>]</span></a></sup> Cryosurgery has also been demonstrated to be superior to radical prostatectomy for recurrent cancer following radiation therapy.</p>
<p><a name="Complications_of_surgery" id="Complications_of_surgery"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=34" title="Edit section: Complications of surgery">edit</a>]</span> <span class="mw-headline">Complications of surgery</span></h4>
<p>The most common serious complications of surgery are loss of <a href="/wiki/Urinary_incontinence" title="Urinary incontinence">urinary control</a> and <a href="/wiki/Impotence" title="Impotence" class="mw-redirect">impotence</a>. Reported rates of both complications vary widely depending on how they are assessed, by whom, and how long after surgery, as well as the setting (e.g., academic series vs. community-based or population-based data). Although penile sensation and the ability to achieve <a href="/wiki/Orgasm" title="Orgasm">orgasm</a> usually remain intact, erection and ejaculation are often impaired. Medications such as <a href="/wiki/Sildenafil" title="Sildenafil">sildenafil</a> (Viagra), <a href="/wiki/Tadalafil" title="Tadalafil">tadalafil</a> (Cialis), or <a href="/wiki/Vardenafil" title="Vardenafil">vardenafil</a> (Levitra) may restore some degree of potency. For most men with organ-confined disease, a more limited "nerve-sparing" technique may help reduce urinary incontinence and impotence.<sup id="cite_ref-103" class="reference"><a href="#cite_note-103" title=""><span>[</span>104<span>]</span></a></sup></p>
<p><a name="Radiation_therapy" id="Radiation_therapy"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=35" title="Edit section: Radiation therapy">edit</a>]</span> <span class="mw-headline">Radiation therapy</span></h3>
<p><a name="Overview" id="Overview"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=36" title="Edit section: Overview">edit</a>]</span> <span class="mw-headline">Overview</span></h4>
<div class="thumb tleft">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Brachytherapy.jpg" class="image" title="Brachytherapy for prostate cancer is administered using &quot;seeds,&quot; small radioactive rods implanted directly into the tumor."><img alt="" src="http://upload.wikimedia.org/wikipedia/en/thumb/e/e3/Brachytherapy.jpg/180px-Brachytherapy.jpg" width="180" height="146" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Brachytherapy.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<b><a href="/wiki/Brachytherapy" title="Brachytherapy">Brachytherapy</a></b> for prostate cancer is administered using "seeds," small radioactive rods implanted directly into the tumor.</div>
</div>
</div>
<p><a href="/wiki/Radiation_therapy" title="Radiation therapy">Radiation therapy</a>, also known as radiotherapy, is often used to treat all stages of prostate cancer, or when surgery fails. Radiotherapy uses <a href="/wiki/Ionizing_radiation" title="Ionizing radiation">ionizing radiation</a> to kill prostate cancer cells. When absorbed in tissue, <a href="/wiki/Ionizing_radiation" title="Ionizing radiation">Ionizing radiation</a> such as Gamma and x-rays damage the <a href="/wiki/DNA" title="DNA">DNA</a> in cancer cells, which increases the probability of apoptosis (cell death). Normal cells are able to repair radiation damage, while cancer cells are not. Radiation therapy exploits this fact to treat cancer. Two different kinds of radiation therapy are used in prostate cancer treatment: <a href="/wiki/External_beam_radiotherapy" title="External beam radiotherapy">external beam radiation therapy</a> and <a href="/wiki/Brachytherapy" title="Brachytherapy">brachytherapy</a> (specifically <a href="/wiki/Prostate_brachytherapy" title="Prostate brachytherapy">prostate brachytherapy</a>).</p>
<p>External beam radiation therapy uses a <a href="/wiki/Linear_accelerator" title="Linear accelerator" class="mw-redirect">linear accelerator</a> to produce high-energy x-rays which are directed in a beam towards the prostate. A technique called Intensity Modulated Radiation Therapy (<a href="/wiki/IMRT" title="IMRT" class="mw-redirect">IMRT</a>) may be used to adjust the radiation beam to conform with the shape of the tumor, allowing higher doses to be given to the prostate and seminal vesicles with less damage to the bladder and rectum. External beam radiation therapy is generally given over several weeks, with daily visits to a radiation therapy center. New types of radiation therapy such as IMRT have fewer side effects than traditional treatment.</p>
<div class="thumb tright">
<div class="thumbinner" style="width:182px;"><a href="/wiki/File:Linacprostate.jpg" class="image" title="External beam radiation therapy for prostate cancer is delivered by a linear accelerator, such as this one."><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/c/c4/Linacprostate.jpg/180px-Linacprostate.jpg" width="180" height="214" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Linacprostate.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<a href="/wiki/External_beam_radiotherapy" title="External beam radiotherapy">External beam radiation therapy</a> for prostate cancer is delivered by a linear accelerator, such as this one.</div>
</div>
</div>
<p>Permanent implant brachytherapy is a popular treatment choice for patients with low to intermediate risk features, can be performed on an outpatient basis, and is associated with good 10-year outcomes with relatively low morbidity<sup id="cite_ref-104" class="reference"><a href="#cite_note-104" title=""><span>[</span>105<span>]</span></a></sup> It involves the placement of about 100 small "seeds" containing radioactive material (such as <a href="/wiki/Iodine-125" title="Iodine-125">iodine-125</a> or <a href="/wiki/Palladium-103" title="Palladium-103">palladium-103</a>) with a needle through the skin of the <a href="/wiki/Perineum" title="Perineum">perineum</a> directly into the tumor while under spinal or general anesthetic. These seeds emit <a href="/wiki/Superficial_X-ray" title="Superficial X-ray" class="mw-redirect">lower-energy X-rays</a> which are only able to travel a short distance. Although the seeds eventually become inert, they remain in the prostate permanently. The risk of exposure to others from men with implanted seeds is generally accepted to be insignificant.<sup id="cite_ref-105" class="reference"><a href="#cite_note-105" title=""><span>[</span>106<span>]</span></a></sup></p>
<p><a name="Uses" id="Uses"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=37" title="Edit section: Uses">edit</a>]</span> <span class="mw-headline">Uses</span></h4>
<p>Radiation therapy is commonly used in prostate cancer treatment. It may be used instead of surgery or after surgery in early stage prostate cancer (adjuvant radiotherapy). Radiation treatments also can be combined with hormonal therapy for intermediate risk disease, when surgery or radiation therapy alone is less likely to cure the cancer. Some radiation oncologists combine external beam radiation and brachytherapy for intermediate to high risk situations. Radiation therapy is often used in conjuntion with hormone therapy for high risk patients.<sup id="cite_ref-106" class="reference"><a href="#cite_note-106" title=""><span>[</span>107<span>]</span></a></sup> Others use a "triple modality" combination of external beam radiation therapy, brachytherapy, and hormonal therapy. In advanced stages of prostate cancer, radiation is used to treat painful bone metastases or reduce spinal cord compression.</p>
<p>Radiation therapy is also used after radical prostatectomy for either cancer recurrence or if multiple risk factors are found during surgery. Radiation therapy delivered immediately after surgery when risk factors are present (positive surgical margin, extracapsular extension, seminal vessicle involvement) has been demonstrated to reduce cancer recurrence, decrease distant metastasis, and increase overall survival in two separate randomized trials.<sup id="cite_ref-107" class="reference"><a href="#cite_note-107" title=""><span>[</span>108<span>]</span></a></sup></p>
<p><a name="Side_Effects" id="Side_Effects"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=38" title="Edit section: Side Effects">edit</a>]</span> <span class="mw-headline">Side Effects</span></h4>
<p>Side effects of radiation therapy might occur after a few weeks into treatment. Both types of radiation therapy may cause <a href="/wiki/Diarrhea" title="Diarrhea">diarrhea</a> and mild <a href="/wiki/Gastrointestinal_bleeding" title="Gastrointestinal bleeding">rectal bleeding</a> due to <a href="/wiki/Radiation_proctitis" title="Radiation proctitis">radiation proctitis</a>, as well as potential urinary incontinence and impotence. Symptoms tend to improve over time.</p>
<p><a name="Comparison_to_surgery" id="Comparison_to_surgery"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=39" title="Edit section: Comparison to surgery">edit</a>]</span> <span class="mw-headline">Comparison to surgery</span></h4>
<p>Multiple retrospective analyses have demonstrated that overall survival and disease free survival outcomes are similar between radical prostatectomy, external beam radiation therapy, and brachytherapy.<sup id="cite_ref-108" class="reference"><a href="#cite_note-108" title=""><span>[</span>109<span>]</span></a></sup> Rates for impotence when comparing radiation to nerve-sparing surgery are similar. Radiation has lower rates of incontinence compared with surgery, but has higher rates of occasional mild rectal bleeding.<sup id="cite_ref-109" class="reference"><a href="#cite_note-109" title=""><span>[</span>110<span>]</span></a></sup> Men who have undergone external beam radiation therapy may have a slightly higher risk of later developing <a href="/wiki/Colon_cancer" title="Colon cancer" class="mw-redirect">colon cancer</a> and <a href="/wiki/Bladder_cancer" title="Bladder cancer">bladder cancer</a>.<sup id="cite_ref-110" class="reference"><a href="#cite_note-110" title=""><span>[</span>111<span>]</span></a></sup></p>
<p><a name="High_intensity_focused_ultrasound_.28HIFU.29" id="High_intensity_focused_ultrasound_.28HIFU.29"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=40" title="Edit section: High intensity focused ultrasound (HIFU)">edit</a>]</span> <span class="mw-headline">High intensity focused ultrasound (HIFU)</span></h3>
<p><a href="/wiki/HIFU" title="HIFU" class="mw-redirect">HIFU</a> for prostate cancer utilizes <a href="/wiki/High_intensity_focused_ultrasound" title="High intensity focused ultrasound">high intensity focused ultrasound</a> to ablate/destroy the tissue of the prostate. During the HIFU procedure, sound waves are used to heat the prostate tissue thus destroying the cancerous cells. Essentially, ultrasonic waves are precisely focused on specific areas of the prostate to eliminate the prostate cancer with minimal risks of affecting other tissue or organs. Temperatures at the focal point of the sound waves can exceed 100 °<a href="/wiki/Celsius" title="Celsius">C</a> (212 °<a href="/wiki/Fahrenheit" title="Fahrenheit">F</a>).<sup id="cite_ref-Thomas-A_111-0" class="reference"><a href="#cite_note-Thomas-A-111" title=""><span>[</span>112<span>]</span></a></sup> The ability to focus the ultrasonic waves leads to a relatively low occurrence of both <a href="/wiki/Incontinence" title="Incontinence">incontinence</a> and <a href="/wiki/Impotence" title="Impotence" class="mw-redirect">impotence</a>. (0.6% and 0-20%, respectively)<sup id="cite_ref-Toyoaki-Uchida_112-0" class="reference"><a href="#cite_note-Toyoaki-Uchida-112" title=""><span>[</span>113<span>]</span></a></sup> According to preliminary international studies, HIFU has a high success rate with a reduced risk of side effects. Studies using HIFU machine have shown that 94% of patients with a pretreatment PSA (<a href="/wiki/Prostate_Specific_Antigen" title="Prostate Specific Antigen" class="mw-redirect">Prostate Specific Antigen</a>) of less than 10 ng/mL were cancer-free after three years.<sup id="cite_ref-Toyoaki-Uchida_112-1" class="reference"><a href="#cite_note-Toyoaki-Uchida-112" title=""><span>[</span>113<span>]</span></a></sup> However, many studies of HIFU were performed by manufacturers of HIFU devices, or members of manufacturers' advisory panels.<sup id="cite_ref-113" class="reference"><a href="#cite_note-113" title=""><span>[</span>114<span>]</span></a></sup></p>
<p>HIFU was first used in the 1940s and 1950s in efforts to destroy tumors in the central nervous system. Since then, HIFU has been shown to be effective at destroying malignant tissue in the brain, prostate, spleen, liver, kidney, breast, and bone.<sup id="cite_ref-Thomas-A_111-1" class="reference"><a href="#cite_note-Thomas-A-111" title=""><span>[</span>112<span>]</span></a></sup> Today, the HIF procedure for prostate cancer is performed using a transrectal probe. This procedure has been performed for over ten years and is currently approved for use in Japan, Europe, Canada, and parts of Central and South America.</p>
<p>HIFU is currently not approved for medical use in the United States. Current NCCN guidelines for the treatment of prostate cancer do not include HIFU as part of standard of care, though many promising clinical trials exist. Many patients have received the HIFU procedure at facilities in Canada, and Central and South America.</p>
<p><a name="Palliative_care" id="Palliative_care"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=41" title="Edit section: Palliative care">edit</a>]</span> <span class="mw-headline">Palliative care</span></h3>
<p><a href="/wiki/Palliative_care" title="Palliative care">Palliative care</a> for advanced stage prostate cancer focuses on extending life and relieving the symptoms of metastatic disease. As noted above <a href="/wiki/Abiraterone" title="Abiraterone">Abiraterone Acetate</a> is showing some promise in treating advance stage prostate cancer. It causes a dramatic reduction in <a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">PSA</a> levels and <a href="/wiki/Tumor" title="Tumor">Tumor</a> sizes in aggressive advanced-stage prostate cancer for 70% of patients. <a href="/wiki/Chemotherapy" title="Chemotherapy">Chemotherapy</a> may be offered to slow disease progression and postpone symptoms. The most commonly used regimen combines the chemotherapeutic drug <a href="/wiki/Docetaxel" title="Docetaxel">docetaxel</a> with a <a href="/wiki/Corticosteroid" title="Corticosteroid">corticosteroid</a> such as <a href="/wiki/Prednisone" title="Prednisone">prednisone</a>.<sup id="cite_ref-114" class="reference"><a href="#cite_note-114" title=""><span>[</span>115<span>]</span></a></sup> <a href="/wiki/Bisphosphonates" title="Bisphosphonates" class="mw-redirect">Bisphosphonates</a> such as <a href="/wiki/Zoledronic_acid" title="Zoledronic acid">zoledronic acid</a> have been shown to delay skeletal complications such as <a href="/wiki/Fracture" title="Fracture">fractures</a> or the need for radiation therapy in patients with hormone-refractory metastatic prostate cancer.<sup id="cite_ref-115" class="reference"><a href="#cite_note-115" title=""><span>[</span>116<span>]</span></a></sup></p>
<p><a href="/wiki/Bone_pain" title="Bone pain">Bone pain</a> due to metastatic disease is treated with <a href="/wiki/Opioid" title="Opioid">opioid</a> <a href="/wiki/Analgesic" title="Analgesic">pain relievers</a> such as <a href="/wiki/Morphine" title="Morphine">morphine</a> and <a href="/wiki/Oxycodone" title="Oxycodone">oxycodone</a>. External beam radiation therapy directed at bone metastases may provide <a href="/wiki/Pain" title="Pain">pain</a> relief. Injections of certain <a href="/wiki/Radioisotope" title="Radioisotope" class="mw-redirect">radioisotopes</a>, such as <a href="/wiki/Strontium-89" title="Strontium-89" class="mw-redirect">strontium-89</a>, <a href="/wiki/Phosphorus-32" title="Phosphorus-32" class="mw-redirect">phosphorus-32</a>, or <a href="/wiki/Samarium-153-ethylene_diamine_tetramethylene_phosphonate" title="Samarium-153-ethylene diamine tetramethylene phosphonate" class="mw-redirect">samarium-153</a>, also target bone metastases and may help relieve pain.</p>
<p><a name="Alternative_therapies" id="Alternative_therapies"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=42" title="Edit section: Alternative therapies">edit</a>]</span> <span class="mw-headline">Alternative therapies</span></h3>
<p>As an alternative to active surveillance or definitive treatments, alternative therapies are also under investigation for the management of prostate cancer. PSA has been shown to be lowered in men with apparent localized prostate cancer using a vegan diet (fish allowed), regular exercise, and stress reduction.<sup id="cite_ref-116" class="reference"><a href="#cite_note-116" title=""><span>[</span>117<span>]</span></a></sup> These results have so far proven durable after two-years' treatment. However, this study did not compare the vegan diet to either active surveillance or definitive treatment, and thus cannot comment on the comparative efficacy of the vegan diet in treating prostate cancer.<sup id="cite_ref-117" class="reference"><a href="#cite_note-117" title=""><span>[</span>118<span>]</span></a></sup></p>
<p>Many other single agents have been shown to reduce PSA, slow PSA doubling times, or have similar effects on secondary markers in men with localized cancer in short term trials, such as pomegranate juice or genistein, an isoflavone found in various legumes.<sup id="cite_ref-118" class="reference"><a href="#cite_note-118" title=""><span>[</span>119<span>]</span></a></sup><sup id="cite_ref-119" class="reference"><a href="#cite_note-119" title=""><span>[</span>120<span>]</span></a></sup></p>
<p>The potential of using multiple such agents in concert, let alone combining them with lifestyle changes, has not yet been studied. A more thorough review of natural approaches to prostate cancer has been published.<sup id="cite_ref-120" class="reference"><a href="#cite_note-120" title=""><span>[</span>121<span>]</span></a></sup></p>
<p><a name="Prognosis" id="Prognosis"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=43" title="Edit section: Prognosis">edit</a>]</span> <span class="mw-headline">Prognosis</span></h2>
<p>Prostate cancer rates are higher and prognosis poorer in developed countries than the rest of the world. Many of the risk factors for prostate cancer are more prevalent in the <a href="/wiki/Developed_world" title="Developed world" class="mw-redirect">developed world</a>, including longer life expectancy and diets high in red meat and reduced-fat dairy products to which <a href="/wiki/Vitamin_A_palmitate" title="Vitamin A palmitate" class="mw-redirect">vitamin A palmitate</a> has been added<sup id="cite_ref-121" class="reference"><a href="#cite_note-121" title=""><span>[</span>122<span>]</span></a></sup> (although it must be noted, that people who consume larger amounts of meat and dairy also tend to consume fewer portions of fruits and vegetables. It is not currently clear whether both of these factors, or just one of them, contributes to the occurrence of prostate cancer).<sup id="cite_ref-122" class="reference"><a href="#cite_note-122" title=""><span>[</span>123<span>]</span></a></sup> Also, where there is more access to screening programs, there is a higher detection rate. Prostate cancer is the ninth most common cancer in the world, but is the number one non-skin cancer in United States men. Prostate cancer affected eighteen percent of American men and caused death in three percent in 2005.<sup id="cite_ref-123" class="reference"><a href="#cite_note-123" title=""><span>[</span>124<span>]</span></a></sup> In <a href="/wiki/Japan" title="Japan">Japan</a>, death from prostate cancer was one-fifth to one-half the rates in the United States and <a href="/wiki/Europe" title="Europe">Europe</a> in the 1990s.<sup id="cite_ref-124" class="reference"><a href="#cite_note-124" title=""><span>[</span>125<span>]</span></a></sup> In <a href="/wiki/India" title="India">India</a> in the 1990s, half of the people with prostate cancer confined to the prostate died within ten years.<sup id="cite_ref-125" class="reference"><a href="#cite_note-125" title=""><span>[</span>126<span>]</span></a></sup> African-American men have 50–60 times more prostate cancer and prostate cancer deaths than men in <a href="/wiki/Shanghai" title="Shanghai">Shanghai</a>, <a href="/wiki/China" title="China">China</a>.<sup id="cite_ref-126" class="reference"><a href="#cite_note-126" title=""><span>[</span>127<span>]</span></a></sup> In <a href="/wiki/Nigeria" title="Nigeria">Nigeria</a>, two percent of men develop prostate cancer and 64% of them are dead after two years.<sup id="cite_ref-127" class="reference"><a href="#cite_note-127" title=""><span>[</span>128<span>]</span></a></sup></p>
<p>In patients who undergo treatment, the most important clinical prognostic indicators of disease outcome are stage, pre-therapy PSA level and Gleason score. In general, the higher the grade and the stage, the poorer the prognosis. <a href="/wiki/Nomogram" title="Nomogram">Nomograms</a> can be used to calculate the estimated risk of the individual patient. The predictions are based on the experience of large groups of patients suffering from cancers at various stages.<sup id="cite_ref-128" class="reference"><a href="#cite_note-128" title=""><span>[</span>129<span>]</span></a></sup></p>
<p>In 1941, <a href="/wiki/Charles_Huggins" title="Charles Huggins" class="mw-redirect">Charles Huggins</a> reported that <a href="/wiki/Androgen" title="Androgen">androgen</a> ablation therapy causes regression of primary and metastatic androgen-dependent prostate cancer.<sup id="cite_ref-129" class="reference"><a href="#cite_note-129" title=""><span>[</span>130<span>]</span></a></sup> <a href="/wiki/Androgen" title="Androgen">Androgen</a> ablation therapy causes remission in 80-90% of patients undergoing therapy, resulting in a median progression-free survival of 12 to 33 months. After remission an androgen-independent phenotype typically emerges, where the median overall survival is 23–37 months from the time of initiation of <a href="/wiki/Androgen" title="Androgen">androgen</a> ablation therapy.<sup id="cite_ref-130" class="reference"><a href="#cite_note-130" title=""><span>[</span>131<span>]</span></a></sup> The actual mechanism contributes to the progression of prostate cancer is not clear and may vary between individual patient. A few possible mechanisms have been proposed.<sup id="cite_ref-131" class="reference"><a href="#cite_note-131" title=""><span>[</span>132<span>]</span></a></sup> <a href="/wiki/Androgen" title="Androgen">Androgen</a> at a concentration of 10-fold higher than the physiological concentration has also been shown to cause growth suppression and reversion of androgen-independent prostate cancer xenografts or androgen-independent prostate tumors derived <a href="/wiki/In_vivo" title="In vivo">in vivo</a> model to an <a href="/wiki/Androgen" title="Androgen">androgen</a>-stimulated phenotype in athymic mice.<sup id="cite_ref-132" class="reference"><a href="#cite_note-132" title=""><span>[</span>133<span>]</span></a></sup><sup id="cite_ref-133" class="reference"><a href="#cite_note-133" title=""><span>[</span>134<span>]</span></a></sup> These observation suggest the possibility to use androgen to treat the development of relapsed androgen-independent prostate tumors in patients. Oral infusion of <a href="/wiki/Green_tea" title="Green tea">green tea</a> <a href="/wiki/Polyphenols" title="Polyphenols" class="mw-redirect">polyphenols</a>, a potential alternative therapy for prostate cancer by natural compounds, has been shown to inhibit the development, progression, and <a href="/wiki/Metastasis" title="Metastasis">metastasis</a> as well in autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) model, which spontaneously develops prostate cancer.<sup id="cite_ref-134" class="reference"><a href="#cite_note-134" title=""><span>[</span>135<span>]</span></a></sup></p>
<p>Many prostate cancers are not destined to be lethal, and most men will ultimately die from causes other than of the disease. Decisions about treatment type and timing may therefore be informed by an estimation of the <b>risk</b> that the tumor will ultimately recur after treatment and/or progress to metastases and mortality. Several tools are available to help predict outcomes such as pathologic stage and recurrence after surgery or radiation therapy. Most combine stage, grade, and PSA level, and some also add the number or percent of biopsy cores positive, age, and/or other information.</p>
<p>The D’Amico classification stratifies men to low, intermediate, or high risk based on stage, grade, and PSA. It is used widely in clinical practice and research settings. The major downside to the 3-level system is that it does not account for multiple adverse parameters (e.g., high Gleason score <i>and</i> high PSA) in stratifying patients.</p>
<p>The Partin tables predict pathologic outcomes (margin status, extraprostatic extension, and seminal vesicle invasion) based on the same 3 variables, and are published as lookup tables.</p>
<p>The Kattan nomograms predict recurrence after surgery and/or radiation therapy, based on data available either at time of diagnosis or after surgery. The nomograms can be calculated using paper graphs, or using software available on a website or for handheld computers. The Kattan score represents the likelihood of remaining free of disease at a given time interval following treatment.</p>
<p>The <a href="http://urology.ucsf.edu" class="external text" title="http://urology.ucsf.edu" rel="nofollow">UCSF</a> Cancer of the Prostate Risk Assessment (CAPRA) score predicts both pathologic status and recurrence after surgery. It offers comparable accuracy as the Kattan preoperative nomogram, and can be calculated without paper tables or a calculator. Points are assigned based on PSA, Grade, stage, age, and percent of cores positive; the sum yields a 0–10 score, with every 2 points representing roughly a doubling of risk of recurrence. The CAPRA score was derived from community-based data in the <a href="http://www.capsure.net" class="external text" title="http://www.capsure.net" rel="nofollow">CaPSURE</a> database. It has been validated among over 10,000 prostatectomy patients, including patients from CaPSURE<sup id="cite_ref-135" class="reference"><a href="#cite_note-135" title=""><span>[</span>136<span>]</span></a></sup>; the SEARCH registry, representing data from several Veterans Administration and active military medical centers<sup id="cite_ref-136" class="reference"><a href="#cite_note-136" title=""><span>[</span>137<span>]</span></a></sup>; a multi-institutional cohort in Germany<sup id="cite_ref-137" class="reference"><a href="#cite_note-137" title=""><span>[</span>138<span>]</span></a></sup>; and the prostatectomy cohort at Johns Hopkins University.<sup id="cite_ref-138" class="reference"><a href="#cite_note-138" title=""><span>[</span>139<span>]</span></a></sup></p>
<p><a name="Epidemiology" id="Epidemiology"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=44" title="Edit section: Epidemiology">edit</a>]</span> <span class="mw-headline">Epidemiology</span></h2>
<p>Rates of prostate cancer vary widely across the world. Although the rates vary widely between countries, it is least common in South and East Asia, more common in Europe, and most common in the United States.<sup id="cite_ref-web.archive.org_0-1" class="reference"><a href="#cite_note-web.archive.org-0" title=""><span>[</span>1<span>]</span></a></sup> According to the <a href="/wiki/American_Cancer_Society" title="American Cancer Society">American Cancer Society</a>, prostate cancer is least common among Asian men and most common among black men, with figures for white men in-between.<sup id="cite_ref-139" class="reference"><a href="#cite_note-139" title=""><span>[</span>140<span>]</span></a></sup><sup id="cite_ref-140" class="reference"><a href="#cite_note-140" title=""><span>[</span>141<span>]</span></a></sup> However, these high rates may be affected by increasing rates of detection.<sup id="cite_ref-141" class="reference"><a href="#cite_note-141" title=""><span>[</span>142<span>]</span></a></sup></p>
<p>Prostate cancer develops most frequently in men over fifty. This cancer can occur only in men, as the prostate is exclusively of the male reproductive tract. It is the most common type of cancer in men in the United States, where it is responsible for more male deaths than any other cancer, except <a href="/wiki/Lung_cancer" title="Lung cancer">lung cancer</a>. In the United Kingdom it is also the second most common cause of cancer death after lung cancer, where around 35,000 cases are diagnosed every year and of which around 10,000 die of it. However, many men who develop prostate cancer never have symptoms, undergo no therapy, and eventually die of other causes. That is because malignant <a href="/wiki/Neoplasm" title="Neoplasm">neoplasms</a> of the prostate are, in most cases, slow-growing, and because most of those affected are over 60. Hence they often die of causes unrelated to the prostate cancer, such as heart/circulatory disease, pneumonia, other unconnected cancers or old age. Many factors, including <a href="/wiki/Genetics" title="Genetics">genetics</a> and <a href="/wiki/Diet_(nutrition)" title="Diet (nutrition)">diet</a>, have been implicated in the development of prostate cancer. The Prostate Cancer Prevention Trial found that <a href="/wiki/Finasteride" title="Finasteride">finasteride</a> reduces the incidence of prostate cancer rate by 30%. There had been a controversy about this also increasing the risk of more aggressive cancers, but more recent research showed this was not the case.<sup id="cite_ref-142" class="reference"><a href="#cite_note-142" title=""><span>[</span>143<span>]</span></a></sup><sup id="cite_ref-cancerpreventionresearch.aacrjournals.org_44-1" class="reference"><a href="#cite_note-cancerpreventionresearch.aacrjournals.org-44" title=""><span>[</span>45<span>]</span></a></sup></p>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=45" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:152px;"><a href="/wiki/File:Andrzej_W._Schally.jpg" class="image" title="Andrzej W. Schally was awarded the 1977 Nobel Prize in Medicine for his research relating to prostate cancer."><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Andrzej_W._Schally.jpg/150px-Andrzej_W._Schally.jpg" width="150" height="196" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Andrzej_W._Schally.jpg" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<b><a href="/wiki/Andrzej_W._Schally" title="Andrzej W. Schally" class="mw-redirect">Andrzej W. Schally</a></b> was awarded the 1977 Nobel Prize in Medicine for his research relating to prostate cancer.</div>
</div>
</div>
<p>Although the prostate was first described by <a href="/wiki/Venice" title="Venice">Venetian</a> anatomist <a href="/wiki/Niccol%C3%B2_Massa" title="Niccolò Massa">Niccolò Massa</a> in 1536, and illustrated by <a href="/wiki/Flanders" title="Flanders">Flemish</a> anatomist <a href="/wiki/Vesalius" title="Vesalius" class="mw-redirect">Andreas Vesalius</a> in 1538, prostate cancer was not identified until 1853.<sup id="cite_ref-143" class="reference"><a href="#cite_note-143" title=""><span>[</span>144<span>]</span></a></sup> Prostate cancer was initially considered a rare disease, probably because of shorter <a href="/wiki/Life_expectancy" title="Life expectancy">life expectancies</a> and poorer detection methods in the 19th century. The first treatments of prostate cancer were surgeries to relieve urinary obstruction.<sup id="cite_ref-144" class="reference"><a href="#cite_note-144" title=""><span>[</span>145<span>]</span></a></sup> Removal of the entire gland (radical perineal <a href="/wiki/Prostatectomy" title="Prostatectomy">prostatectomy</a>) was first performed in 1904 by <a href="/wiki/Hugh_H._Young" title="Hugh H. Young">Hugh H. Young</a> at <a href="/wiki/Johns_Hopkins_Hospital" title="Johns Hopkins Hospital">Johns Hopkins Hospital</a>.<sup id="cite_ref-145" class="reference"><a href="#cite_note-145" title=""><span>[</span>146<span>]</span></a></sup> Surgical removal of the testes (<a href="/wiki/Orchiectomy" title="Orchiectomy" class="mw-redirect">orchiectomy</a>) to treat prostate cancer was first performed in the 1890s, but with limited success. <a href="/wiki/Transurethral_resection_of_the_prostate" title="Transurethral resection of the prostate">Transurethral resection of the prostate</a> (TURP) replaced radical prostatectomy for symptomatic relief of obstruction in the middle of the 20th century because it could better preserve penile erectile function. Radical retropubic prostatectomy was developed in 1983 by Patrick Walsh.<sup id="cite_ref-146" class="reference"><a href="#cite_note-146" title=""><span>[</span>147<span>]</span></a></sup> This surgical approach allowed for removal of the prostate and lymph nodes with maintenance of penile function.</p>
<p>In 1941 <a href="/wiki/Charles_B._Huggins" title="Charles B. Huggins" class="mw-redirect">Charles B. Huggins</a> published studies in which he used <a href="/wiki/Estrogen" title="Estrogen">estrogen</a> to oppose testosterone production in men with metastatic prostate cancer. This discovery of "chemical <a href="/wiki/Castration" title="Castration">castration</a>" won Huggins the 1966 <a href="/wiki/Nobel_Prize_in_Physiology_or_Medicine" title="Nobel Prize in Physiology or Medicine">Nobel Prize in Physiology or Medicine</a>.<sup id="cite_ref-147" class="reference"><a href="#cite_note-147" title=""><span>[</span>148<span>]</span></a></sup> The role of the hormone <a href="/wiki/GnRH" title="GnRH" class="mw-redirect">GnRH</a> in reproduction was determined by <a href="/wiki/Andrzej_W._Schally" title="Andrzej W. Schally" class="mw-redirect">Andrzej W. Schally</a> and <a href="/wiki/Roger_Guillemin" title="Roger Guillemin">Roger Guillemin</a>, who both won the 1977 Nobel Prize in Physiology or Medicine for this work. Receptor agonists, such as <a href="/wiki/Leuprolide" title="Leuprolide">leuprolide</a> and <a href="/wiki/Goserelin" title="Goserelin">goserelin</a>, were subsequently developed and used to treat prostate cancer.<sup id="cite_ref-148" class="reference"><a href="#cite_note-148" title=""><span>[</span>149<span>]</span></a></sup><sup id="cite_ref-149" class="reference"><a href="#cite_note-149" title=""><span>[</span>150<span>]</span></a></sup></p>
<p><a href="/wiki/Radiation_therapy" title="Radiation therapy">Radiation therapy</a> for prostate cancer was first developed in the early 20th century and initially consisted of intraprostatic <a href="/wiki/Radium" title="Radium">radium</a> implants. External beam radiation became more popular as stronger radiation sources became available in the middle of the 20th century. Brachytherapy with implanted seeds was first described in 1983.<sup id="cite_ref-150" class="reference"><a href="#cite_note-150" title=""><span>[</span>151<span>]</span></a></sup> Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a> and <a href="/wiki/5-fluorouracil" title="5-fluorouracil" class="mw-redirect">5-fluorouracil</a> was quickly joined by multiple regimens using a host of other systemic chemotherapy drugs.<sup id="cite_ref-151" class="reference"><a href="#cite_note-151" title=""><span>[</span>152<span>]</span></a></sup></p>
<p><a name="Prostate_cancer_models" id="Prostate_cancer_models"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=46" title="Edit section: Prostate cancer models">edit</a>]</span> <span class="mw-headline">Prostate cancer models</span></h2>
<p>Scientists have established a few prostate cancer <a href="/wiki/Cell_lines" title="Cell lines" class="mw-redirect">cell lines</a> to investigate the mechanism involved in the progression of prostate cancer. <a href="/wiki/LNCaP" title="LNCaP">LNCaP</a>, PC-3(<a href="/wiki/PC3" title="PC3">PC3</a>), and DU-145(<a href="/wiki/DU145" title="DU145">DU145</a>) are commonly used prostate cancer cell lines. The LNCaP cancer cell line was established from a human lymph node metastatic lesion of prostatic adenocarcinoma. PC-3 and DU-145 cells were established from human prostatic adenocarcinoma metastatic to bone and to brain, respectively. LNCaP cells express <a href="/wiki/Androgen_receptor" title="Androgen receptor">androgen receptor</a> (AR), however, PC-3 and DU-145 cells express very little or no AR. AR, an androgen-activated <a href="/wiki/Transcription_factor" title="Transcription factor">transcription factor</a>, belongs to the steroid <a href="/wiki/Nuclear_receptor" title="Nuclear receptor">nuclear receptor</a> family. Development of the prostate is dependent on androgen signaling mediated through AR, and AR is also important during the development of prostate cancer. The proliferation of LNCaP cells is <a href="/wiki/Androgen" title="Androgen">androgen</a>-dependent but the proliferation of PC-3 and DU-145 cells is <a href="/wiki/Androgen" title="Androgen">androgen</a>-insensitive.Elevation of AR expression is often observed in advanced prostate <a href="/wiki/Tumor" title="Tumor">tumors</a> in patients.<sup id="cite_ref-152" class="reference"><a href="#cite_note-152" title=""><span>[</span>153<span>]</span></a></sup><sup id="cite_ref-153" class="reference"><a href="#cite_note-153" title=""><span>[</span>154<span>]</span></a></sup> Some androgen-independent LNCaP sublines have been developed from the ATCC androgen-dependent LNCaP cells after androgen deprivation for study of prostate cancer progression. These <a href="/wiki/Androgen" title="Androgen">androgen</a>-independent LNCaP cells have elevated <a href="/wiki/AR" title="AR">AR</a> expression and express <a href="/wiki/Prostate_specific_antigen" title="Prostate specific antigen">prostate specific antigen</a> upon <a href="/wiki/Androgen" title="Androgen">androgen</a> treatment. <a href="/wiki/Androgen" title="Androgen">Androgens</a> paradoxically inhibit the proliferation of these <a href="/wiki/Androgen" title="Androgen">androgen</a>-independent prostate <a href="/wiki/Cancer" title="Cancer">cancer</a> cells.<sup id="cite_ref-154" class="reference"><a href="#cite_note-154" title=""><span>[</span>155<span>]</span></a></sup><sup id="cite_ref-155" class="reference"><a href="#cite_note-155" title=""><span>[</span>156<span>]</span></a></sup><sup id="cite_ref-156" class="reference"><a href="#cite_note-156" title=""><span>[</span>157<span>]</span></a></sup></p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=47" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small references-column-width" style="-moz-column-width:30em; column-width:30em;">
<ol class="references">
<li id="cite_note-web.archive.org-0">^ <a href="#cite_ref-web.archive.org_0-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-web.archive.org_0-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="web"><a href="http://web.archive.org/web/20060205235509/http://www.jncicancerspectrum.oxfordjournals.org/cgi/statContent/cspectfstat;99" class="external text" title="http://web.archive.org/web/20060205235509/http://www.jncicancerspectrum.oxfordjournals.org/cgi/statContent/cspectfstat;99" rel="nofollow">"IARC Worldwide Cancer Incidence Statistics—Prostate"</a>. <i>JNCI Cancer Spectrum</i>. <a href="/wiki/Oxford_University_Press" title="Oxford University Press">Oxford University Press</a>. December 19, 2001<span class="printonly">. <a href="http://web.archive.org/web/20060205235509/http://www.jncicancerspectrum.oxfordjournals.org/cgi/statContent/cspectfstat;99" class="external free" title="http://web.archive.org/web/20060205235509/http://www.jncicancerspectrum.oxfordjournals.org/cgi/statContent/cspectfstat;99" rel="nofollow">http://web.archive.org/web/20060205235509/http://www.jncicancerspectrum.oxfordjournals.org/cgi/statContent/cspectfstat;99</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=IARC+Worldwide+Cancer+Incidence+Statistics%E2%80%94Prostate&amp;rft.atitle=JNCI+Cancer+Spectrum&amp;rft.date=December+19%2C+2001&amp;rft.pub=%5B%5BOxford+University+Press%5D%5D&amp;rft_id=http%3A%2F%2Fweb.archive.org%2Fweb%2F20060205235509%2Fhttp%3A%2F%2Fwww.jncicancerspectrum.oxfordjournals.org%2Fcgi%2FstatContent%2Fcspectfstat%3B99&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Retrieved on <span class="mw-formatted-date" title="2007-04-05"><a href="/wiki/2007" title="2007">2007</a>-<a href="/wiki/April_5" title="April 5">04-05</a></span> through the <a href="/wiki/Internet_Archive" title="Internet Archive">Internet Archive</a></li>
<li id="cite_note-1"><b><a href="#cite_ref-1" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFAum.C3.BCller1979">Aumüller, G. (1979). <i>Prostate Gland and Seminal Vesicles</i>. Berlin-Heidecool.lberg: Springer-Verlag.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Prostate+Gland+and+Seminal+Vesicles&amp;rft.aulast=Aum%C3%BCller&amp;rft.aufirst=G.&amp;rft.au=Aum%C3%BCller%2C+G.&amp;rft.date=1979&amp;rft.place=Berlin-Heidecool.lberg&amp;rft.pub=Springer-Verlag&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-2"><b><a href="#cite_ref-2" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFMooreDalley.2C_A.1999">Moore, K.; Dalley, A. (1999). <i>Clinically Oriented Anatomy</i>. Baltimore, Maryland: Lippincott Williams &amp; Wilkins.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Clinically+Oriented+Anatomy&amp;rft.aulast=Moore&amp;rft.aufirst=K.&amp;rft.au=Moore%2C+K.&amp;rft.au=Dalley%2C+A.&amp;rft.date=1999&amp;rft.place=Baltimore%2C+Maryland&amp;rft.pub=Lippincott+Williams+%26+Wilkins&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-3"><b><a href="#cite_ref-3" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFSteive1930">Steive, H. (1930). "Männliche Genitalorgane". <i>Handbuch der mikroskopischen Anatomie des Menschen. Vol. VII Part 2</i>. Berlin: Springer. pp.&#160;1–399.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=M%C3%A4nnliche+Genitalorgane&amp;rft.atitle=Handbuch+der+mikroskopischen+Anatomie+des+Menschen.+Vol.+VII+Part+2&amp;rft.aulast=Steive&amp;rft.aufirst=H.&amp;rft.au=Steive%2C+H.&amp;rft.date=1930&amp;rft.pages=pp.%26nbsp%3B1%E2%80%93399&amp;rft.place=Berlin&amp;rft.pub=Springer&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17936849-4">^ <a href="#cite_ref-pmid17936849_4-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17936849_4-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFSmith_JA.2C_Chan_RC.2C_Chang_SS.2C_.27.27et_al.27.272007">Smith JA, Chan RC, Chang SS, <i>et al</i> (2007). "<a href="http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(07)01979-9" class="external text" title="http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(07)01979-9" rel="nofollow">A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy</a>". <i>J. Urol.</i> <b>178</b> (6): 2385–9; discussion 2389–90. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.juro.2007.08.008" class="external text" title="http://dx.doi.org/10.1016%2Fj.juro.2007.08.008" rel="nofollow">10.1016/j.juro.2007.08.008</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17936849" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17936849">PMID 17936849</a><span class="printonly">. <a href="http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(07)01979-9" class="external free" title="http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(07)01979-9" rel="nofollow">http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(07)01979-9</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+comparison+of+the+incidence+and+location+of+positive+surgical+margins+in+robotic+assisted+laparoscopic+radical+prostatectomy+and+open+retropubic+radical+prostatectomy&amp;rft.jtitle=J.+Urol.&amp;rft.aulast=Smith+JA%2C+Chan+RC%2C+Chang+SS%2C+%27%27et+al%27%27&amp;rft.au=Smith+JA%2C+Chan+RC%2C+Chang+SS%2C+%27%27et+al%27%27&amp;rft.date=2007&amp;rft.volume=178&amp;rft.issue=6&amp;rft.pages=2385%E2%80%939%3B+discussion+2389%E2%80%9390&amp;rft_id=info:doi/10.1016%2Fj.juro.2007.08.008&amp;rft_id=info:pmid/17936849&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0022-5347%2807%2901979-9&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-5"><b><a href="#cite_ref-5" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMillerHafez.2C_KS.2C_Stewart.2C_A.2C_et_al2003">Miller, DC; Hafez, KS, Stewart, A, et al (2003). "Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base". <i>Cancer</i> <b>98</b>: 1169. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fcncr.11635" class="external text" title="http://dx.doi.org/10.1002%2Fcncr.11635" rel="nofollow">10.1002/cncr.11635</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12973840" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12973840">PMID 12973840</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate+carcinoma+presentation%2C+diagnosis%2C+and+staging%3A+an+update+from+the+National+Cancer+Data+Base&amp;rft.jtitle=Cancer&amp;rft.aulast=Miller&amp;rft.aufirst=DC&amp;rft.au=Miller%2C+DC&amp;rft.au=Hafez%2C+KS%2C+Stewart%2C+A%2C+et+al&amp;rft.date=2003&amp;rft.volume=98&amp;rft.pages=1169&amp;rft_id=info:doi/10.1002%2Fcncr.11635&amp;rft_id=info:pmid/12973840&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-6"><b><a href="#cite_ref-6" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFvan_der_Cruijsen-KoeterVis_AN.2C_Roobol_MJ.2C_Wildhagen_MF.2C_de_Koning_HJ.2C_van_der_Kwast_TH.2C_Schroder_FH2005">van der Cruijsen-Koeter, IW; Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schroder FH (July 2005). "Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam". <i>Urol</i> <b>174</b> (1): 121–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.ju.0000162061.40533.0f" class="external text" title="http://dx.doi.org/10.1097%2F01.ju.0000162061.40533.0f" rel="nofollow">10.1097/01.ju.0000162061.40533.0f</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15947595" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15947595">PMID 15947595</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Comparison+of+screen+detected+and+clinically+diagnosed+prostate+cancer+in+the+European+randomized+study+of+screening+for+prostate+cancer%2C+section+rotterdam&amp;rft.jtitle=Urol&amp;rft.aulast=van+der+Cruijsen-Koeter&amp;rft.aufirst=IW&amp;rft.au=van+der+Cruijsen-Koeter%2C+IW&amp;rft.au=Vis+AN%2C+Roobol+MJ%2C+Wildhagen+MF%2C+de+Koning+HJ%2C+van+der+Kwast+TH%2C+Schroder+FH&amp;rft.date=July+2005&amp;rft.volume=174&amp;rft.issue=1&amp;rft.pages=121%E2%80%935&amp;rft_id=info:doi/10.1097%2F01.ju.0000162061.40533.0f&amp;rft_id=info:pmid/15947595&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-7"><b><a href="#cite_ref-7" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHsingAnand_P._Chokkalingam2006">Hsing, Ann W.; Anand P. Chokkalingam (May 1 2006). "<a href="http://www.bioscience.org/2006/v11/af/1891/fulltext.htm" class="external text" title="http://www.bioscience.org/2006/v11/af/1891/fulltext.htm" rel="nofollow">Prostate cancer epidemiology</a>". <i>Frontiers in Bioscience</i> <b>11</b>: 1388–1413. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.2741%2F1891" class="external text" title="http://dx.doi.org/10.2741%2F1891" rel="nofollow">10.2741/1891</a></span><span class="printonly">. <a href="http://www.bioscience.org/2006/v11/af/1891/fulltext.htm" class="external free" title="http://www.bioscience.org/2006/v11/af/1891/fulltext.htm" rel="nofollow">http://www.bioscience.org/2006/v11/af/1891/fulltext.htm</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate+cancer+epidemiology&amp;rft.jtitle=Frontiers+in+Bioscience&amp;rft.aulast=Hsing&amp;rft.aufirst=Ann+W.&amp;rft.au=Hsing%2C+Ann+W.&amp;rft.au=Anand+P.+Chokkalingam&amp;rft.date=May+1+2006&amp;rft.volume=11&amp;rft.pages=1388%E2%80%931413&amp;rft_id=info:doi/10.2741%2F1891&amp;rft_id=http%3A%2F%2Fwww.bioscience.org%2F2006%2Fv11%2Faf%2F1891%2Ffulltext.htm&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-8"><b><a href="#cite_ref-8" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHankeyFeuer_EJ.2C_Clegg_LX.2C_Hayes_RB.2C_Legler_JM.2C_Prorok_PC.2C_Ries_LA.2C_Merrill_RM.2C_Kaplan_RS1999">Hankey, BF; Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS (June 16 1999). "Cancer surveillance series: interpreting trends in prostate cancer—part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates". <i>J Natl Cancer Inst</i> <b>91</b> (12): 1017–24. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fjnci%2F91.12.1017" class="external text" title="http://dx.doi.org/10.1093%2Fjnci%2F91.12.1017" rel="nofollow">10.1093/jnci/91.12.1017</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10379964" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10379964">PMID 10379964</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cancer+surveillance+series%3A+interpreting+trends+in+prostate+cancer%E2%80%94part+I%3A+Evidence+of+the+effects+of+screening+in+recent+prostate+cancer+incidence%2C+mortality%2C+and+survival+rates&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.aulast=Hankey&amp;rft.aufirst=BF&amp;rft.au=Hankey%2C+BF&amp;rft.au=Feuer+EJ%2C+Clegg+LX%2C+Hayes+RB%2C+Legler+JM%2C+Prorok+PC%2C+Ries+LA%2C+Merrill+RM%2C+Kaplan+RS&amp;rft.date=June+16+1999&amp;rft.volume=91&amp;rft.issue=12&amp;rft.pages=1017%E2%80%9324&amp;rft_id=info:doi/10.1093%2Fjnci%2F91.12.1017&amp;rft_id=info:pmid/10379964&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-9"><b><a href="#cite_ref-9" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBreslowChan_CW.2C_Dhom_G.2C_Drury_RA.2C_Franks_LM.2C_Gellei_B.2C_Lee_YS.2C_Lundberg_S.2C_Sparke_B.2C_Sternby_NH.2C_Tulinius_H.1977">Breslow, N; Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. (November 15 1977). "Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France". <i>Int J Cancer</i> <b>20</b> (5): 680–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fijc.2910200506" class="external text" title="http://dx.doi.org/10.1002%2Fijc.2910200506" rel="nofollow">10.1002/ijc.2910200506</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/924691" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/924691">PMID 924691</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Latent+carcinoma+of+prostate+at+autopsy+in+seven+areas.+The+International+Agency+for+Research+on+Cancer%2C+Lyons%2C+France&amp;rft.jtitle=Int+J+Cancer&amp;rft.aulast=Breslow&amp;rft.aufirst=N&amp;rft.au=Breslow%2C+N&amp;rft.au=Chan+CW%2C+Dhom+G%2C+Drury+RA%2C+Franks+LM%2C+Gellei+B%2C+Lee+YS%2C+Lundberg+S%2C+Sparke+B%2C+Sternby+NH%2C+Tulinius+H.&amp;rft.date=November+15+1977&amp;rft.volume=20&amp;rft.issue=5&amp;rft.pages=680%E2%80%938&amp;rft_id=info:doi/10.1002%2Fijc.2910200506&amp;rft_id=info:pmid/924691&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-10"><b><a href="#cite_ref-10" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFJemal_AMurray_T.2C_Ward_E.2C_Samuels_A.2C_Tiwari_RC.2C_Ghafoor_A.2C_Feuer_EJ.2C_Thun_MJ2005">Jemal A; Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (Jan-February 2005). "Cancer statistics, 2005". <i>CA Cancer J Clin</i> <b>55</b> (1): 10–30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15661684" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15661684">PMID 15661684</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cancer+statistics%2C+2005&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.aulast=Jemal+A&amp;rft.au=Jemal+A&amp;rft.au=Murray+T%2C+Ward+E%2C+Samuels+A%2C+Tiwari+RC%2C+Ghafoor+A%2C+Feuer+EJ%2C+Thun+MJ&amp;rft.date=Jan-February+2005&amp;rft.volume=55&amp;rft.issue=1&amp;rft.pages=10%E2%80%9330&amp;rft_id=info:pmid/15661684&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Erratum in: CA Cancer J Clin. 2005 Jul-Aug;55(4):259</li>
<li id="cite_note-11"><b><a href="#cite_ref-11" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHoffmanGilliland_FD.3B_Eley_JW.3B_Harlan_LC.3B_Stephenson_RA.3B_Stanford_JL.3B_Albertson_PC.3B_Hamilton_AS.3B_Hunt_WC.3B_Potosky_AL2001">Hoffman, RM; Gilliland FD; Eley JW; Harlan LC; Stephenson RA; Stanford JL; Albertson PC; Hamilton AS; Hunt WC; Potosky AL (March 7 2001). "Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study". <i>J Natl Cancer Inst</i> <b>93</b> (5): 388–95. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fjnci%2F93.5.388" class="external text" title="http://dx.doi.org/10.1093%2Fjnci%2F93.5.388" rel="nofollow">10.1093/jnci/93.5.388</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11238701" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11238701">PMID 11238701</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Racial+and+ethnic+differences+in+advanced-stage+prostate+cancer%3A+the+Prostate+Cancer+Outcomes+Study&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.aulast=Hoffman&amp;rft.aufirst=RM&amp;rft.au=Hoffman%2C+RM&amp;rft.au=Gilliland+FD%3B+Eley+JW%3B+Harlan+LC%3B+Stephenson+RA%3B+Stanford+JL%3B+Albertson+PC%3B+Hamilton+AS%3B+Hunt+WC%3B+Potosky+AL&amp;rft.date=March+7+2001&amp;rft.volume=93&amp;rft.issue=5&amp;rft.pages=388%E2%80%9395&amp;rft_id=info:doi/10.1093%2Fjnci%2F93.5.388&amp;rft_id=info:pmid/11238701&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-12"><b><a href="#cite_ref-12" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSteinbergCarter_BS.3B_Beaty_TH.3B_Childs_B.3B_Walsh_PC1990">Steinberg, GD; Carter BS; Beaty TH; Childs B; Walsh PC (1990). "Family history and the risk of prostate cancer". <i>Prostate</i> <b>17</b> (4): 337–47. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fpros.2990170409" class="external text" title="http://dx.doi.org/10.1002%2Fpros.2990170409" rel="nofollow">10.1002/pros.2990170409</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2251225" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2251225">PMID 2251225</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Family+history+and+the+risk+of+prostate+cancer&amp;rft.jtitle=Prostate&amp;rft.aulast=Steinberg&amp;rft.aufirst=GD&amp;rft.au=Steinberg%2C+GD&amp;rft.au=Carter+BS%3B+Beaty+TH%3B+Childs+B%3B+Walsh+PC&amp;rft.date=1990&amp;rft.volume=17&amp;rft.issue=4&amp;rft.pages=337%E2%80%9347&amp;rft_id=info:doi/10.1002%2Fpros.2990170409&amp;rft_id=info:pmid/2251225&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-13"><b><a href="#cite_ref-13" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLichtensteinHolm_NV.3B_Verkasalo_PK.3B_Iliadou_A.3B_Kaprio_J.3B_Koskenvuo_M.3B_Pukkala_E.3B_Skytthe_A.3B_Hemminki_K2000">Lichtenstein, P; Holm NV; Verkasalo PK; Iliadou A; Kaprio J; Koskenvuo M; Pukkala E; Skytthe A; Hemminki K (July 13 2000). "Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland". <i>N Engl J Med</i> <b>343</b> (2): 78–85. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJM200007133430201" class="external text" title="http://dx.doi.org/10.1056%2FNEJM200007133430201" rel="nofollow">10.1056/NEJM200007133430201</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10891514" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10891514">PMID 10891514</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Environmental+and+heritable+factors+in+the+causation+of+cancer%E2%80%94analyses+of+cohorts+of+twins+from+Sweden%2C+Denmark%2C+and+Finland&amp;rft.jtitle=N+Engl+J+Med&amp;rft.aulast=Lichtenstein&amp;rft.aufirst=P&amp;rft.au=Lichtenstein%2C+P&amp;rft.au=Holm+NV%3B+Verkasalo+PK%3B+Iliadou+A%3B+Kaprio+J%3B+Koskenvuo+M%3B+Pukkala+E%3B+Skytthe+A%3B+Hemminki+K&amp;rft.date=July+13+2000&amp;rft.volume=343&amp;rft.issue=2&amp;rft.pages=78%E2%80%9385&amp;rft_id=info:doi/10.1056%2FNEJM200007133430201&amp;rft_id=info:pmid/10891514&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-14"><b><a href="#cite_ref-14" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFStruewingHartge_P.3B_Wacholder_S.3B_Baker_SM.3B_Berlin_M.3B_McAdams_M.3B_Timmerman_MM.3B_Brody_LC.3B_Tucker_MA1997">Struewing, JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA (May 15 1997). "The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews". <i>N Engl J Med</i> <b>336</b> (20): 1401–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJM199705153362001" class="external text" title="http://dx.doi.org/10.1056%2FNEJM199705153362001" rel="nofollow">10.1056/NEJM199705153362001</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9145676" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9145676">PMID 9145676</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+risk+of+cancer+associated+with+specific+mutations+of+BRCA1+and+BRCA2+among+Ashkenazi+Jews&amp;rft.jtitle=N+Engl+J+Med&amp;rft.aulast=Struewing&amp;rft.aufirst=JP&amp;rft.au=Struewing%2C+JP&amp;rft.au=Hartge+P%3B+Wacholder+S%3B+Baker+SM%3B+Berlin+M%3B+McAdams+M%3B+Timmerman+MM%3B+Brody+LC%3B+Tucker+MA&amp;rft.date=May+15+1997&amp;rft.volume=336&amp;rft.issue=20&amp;rft.pages=1401%E2%80%938&amp;rft_id=info:doi/10.1056%2FNEJM199705153362001&amp;rft_id=info:pmid/9145676&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-15"><b><a href="#cite_ref-15" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFGann.2C_PH_and_Giovannucci2005">Gann, PH and Giovannucci (2005). <a href="http://www.prostatecancerfoundation.org/atf/cf/%7B705B3273-F2EF-4EF6-A653-E15C5D8BB6B1%7D/Nutrition_Guide.pdf" class="external text" title="http://www.prostatecancerfoundation.org/atf/cf/%7B705B3273-F2EF-4EF6-A653-E15C5D8BB6B1%7D/Nutrition_Guide.pdf" rel="nofollow">"Prostate Cancer and Nutrition"</a> (PDF)<span class="printonly">. <a href="http://www.prostatecancerfoundation.org/atf/cf/%7B705B3273-F2EF-4EF6-A653-E15C5D8BB6B1%7D/Nutrition_Guide.pdf" class="external free" title="http://www.prostatecancerfoundation.org/atf/cf/%7B705B3273-F2EF-4EF6-A653-E15C5D8BB6B1%7D/Nutrition_Guide.pdf" rel="nofollow">http://www.prostatecancerfoundation.org/atf/cf/%7B705B3273-F2EF-4EF6-A653-E15C5D8BB6B1%7D/Nutrition_Guide.pdf</a></span><span class="reference-accessdate">. Retrieved on February 20 2006</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Prostate+Cancer+and+Nutrition&amp;rft.atitle=&amp;rft.aulast=Gann%2C+PH+and+Giovannucci&amp;rft.au=Gann%2C+PH+and+Giovannucci&amp;rft.date=2005&amp;rft_id=http%3A%2F%2Fwww.prostatecancerfoundation.org%2Fatf%2Fcf%2F%257B705B3273-F2EF-4EF6-A653-E15C5D8BB6B1%257D%2FNutrition_Guide.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> in .pdf format.</li>
<li id="cite_note-16"><b><a href="#cite_ref-16" title="">^</a></b> Chavarro et al., "A prospective study of blood trans fatty acid levels and risk of prostate cancer," Proc. Amer. Assoc. Cancer Res., Volume 47, 2006 <a href="http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/943" class="external autonumber" title="http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/943" rel="nofollow">[1]</a>. See also <a href="http://www.cancersupportivecare.com/nutritionprostate.pdf" class="external text" title="http://www.cancersupportivecare.com/nutritionprostate.pdf" rel="nofollow">Ledesma 2004 Nutrition &amp; prostate cancer</a>.</li>
<li id="cite_note-pmid17507623-17"><b><a href="#cite_ref-pmid17507623_17-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPeters_U.2C_Leitzmann_MF.2C_Chatterjee_N.2C_Wang_Y.2C_Albanes_D.2C_Gelmann_EP.2C_Friesen_MD.2C_Riboli_E.2C_Hayes_RB2007">Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, Friesen MD, Riboli E, Hayes RB (2007). "<a href="http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=17507623" class="external text" title="http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=17507623" rel="nofollow">Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial</a>". <i>Cancer Epidemiol. Biomarkers Prev.</i> <b>16</b> (5): 962–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1158%2F1055-9965.EPI-06-0861" class="external text" title="http://dx.doi.org/10.1158%2F1055-9965.EPI-06-0861" rel="nofollow">10.1158/1055-9965.EPI-06-0861</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17507623" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17507623">PMID 17507623</a><span class="printonly">. <a href="http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=17507623" class="external free" title="http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=17507623" rel="nofollow">http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=17507623</a></span><span class="reference-accessdate">. Retrieved on 2007-12-17</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serum+lycopene%2C+other+carotenoids%2C+and+prostate+cancer+risk%3A+a+nested+case-control+study+in+the+prostate%2C+lung%2C+colorectal%2C+and+ovarian+cancer+screening+trial&amp;rft.jtitle=Cancer+Epidemiol.+Biomarkers+Prev.&amp;rft.aulast=Peters+U%2C+Leitzmann+MF%2C+Chatterjee+N%2C+Wang+Y%2C+Albanes+D%2C+Gelmann+EP%2C+Friesen+MD%2C+Riboli+E%2C+Hayes+RB&amp;rft.au=Peters+U%2C+Leitzmann+MF%2C+Chatterjee+N%2C+Wang+Y%2C+Albanes+D%2C+Gelmann+EP%2C+Friesen+MD%2C+Riboli+E%2C+Hayes+RB&amp;rft.date=2007&amp;rft.volume=16&amp;rft.issue=5&amp;rft.pages=962%E2%80%938&amp;rft_id=info:doi/10.1158%2F1055-9965.EPI-06-0861&amp;rft_id=info:pmid/17507623&amp;rft_id=http%3A%2F%2Fcebp.aacrjournals.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D17507623&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-18"><b><a href="#cite_ref-18" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSchulmanEkane_S.3B_Zlotta_AR2001">Schulman, CC; Ekane S; Zlotta AR (September 2001). "Nutrition and prostate cancer: evidence or suspicion?". <i>Urology</i> <b>58</b> (3): 318–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0090-4295%2801%2901262-6" class="external text" title="http://dx.doi.org/10.1016%2FS0090-4295%2801%2901262-6" rel="nofollow">10.1016/S0090-4295(01)01262-6</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11549473" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11549473">PMID 11549473</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Nutrition+and+prostate+cancer%3A+evidence+or+suspicion%3F&amp;rft.jtitle=Urology&amp;rft.aulast=Schulman&amp;rft.aufirst=CC&amp;rft.au=Schulman%2C+CC&amp;rft.au=Ekane+S%3B+Zlotta+AR&amp;rft.date=September+2001&amp;rft.volume=58&amp;rft.issue=3&amp;rft.pages=318%E2%80%9334&amp;rft_id=info:doi/10.1016%2FS0090-4295%2801%2901262-6&amp;rft_id=info:pmid/11549473&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-19"><b><a href="#cite_ref-19" title="">^</a></b> <a href="http://yedda.com/questions/Low_fat_milk_causes_prostate_cancer_7351021963170/" class="external free" title="http://yedda.com/questions/Low_fat_milk_causes_prostate_cancer_7351021963170/" rel="nofollow">http://yedda.com/questions/Low_fat_milk_causes_prostate_cancer_7351021963170/</a></li>
<li id="cite_note-20"><b><a href="#cite_ref-20" title="">^</a></b> <cite style="font-style:normal" class="">"Position of the American Dietetic Association and Dietitians of Canada: Vegetarian diets". <i>J Am Diet Assoc</i> <b>103</b> (6): 748–65. 2003. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1053%2Fjada.2003.50142" class="external text" title="http://dx.doi.org/10.1053%2Fjada.2003.50142" rel="nofollow">10.1053/jada.2003.50142</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12778049" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12778049">PMID 12778049</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Position+of+the+American+Dietetic+Association+and+Dietitians+of+Canada%3A+Vegetarian+diets&amp;rft.jtitle=J+Am+Diet+Assoc&amp;rft.date=2003&amp;rft.volume=103&amp;rft.issue=6&amp;rft.pages=748%E2%80%9365&amp;rft_id=info:doi/10.1053%2Fjada.2003.50142&amp;rft_id=info:pmid/12778049&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-21"><b><a href="#cite_ref-21" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFJacobsRodriguez_C.2C_Mondul_AM.2C_Connell_CJ.2C_Henley_SJ.2C_Calle_EE.2C_Thun_MJ2005">Jacobs, EJ; Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ (July 6 2005). "A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence". <i>J Natl Cancer Inst</i> <b>97</b> (13): 975–80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15998950" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15998950">PMID 15998950</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+large+cohort+study+of+aspirin+and+other+nonsteroidal+anti-inflammatory+drugs+and+prostate+cancer+incidence&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.aulast=Jacobs&amp;rft.aufirst=EJ&amp;rft.au=Jacobs%2C+EJ&amp;rft.au=Rodriguez+C%2C+Mondul+AM%2C+Connell+CJ%2C+Henley+SJ%2C+Calle+EE%2C+Thun+MJ&amp;rft.date=July+6+2005&amp;rft.volume=97&amp;rft.issue=13&amp;rft.pages=975%E2%80%9380&amp;rft_id=info:pmid/15998950&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-22"><b><a href="#cite_ref-22" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFShannonTewoderos_S.2C_Garzotto_M.2C_Beer_TM.2C_Derenick_R.2C_Palma_A.2C_Farris_PE2005">Shannon, J; Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE (August 15 2005). "Statins and prostate cancer risk: a case-control study". <i>Am J Epidemiol</i> <b>162</b> (4): 318–25. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Faje%2Fkwi203" class="external text" title="http://dx.doi.org/10.1093%2Faje%2Fkwi203" rel="nofollow">10.1093/aje/kwi203</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16014776" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16014776">PMID 16014776</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Statins+and+prostate+cancer+risk%3A+a+case-control+study&amp;rft.jtitle=Am+J+Epidemiol&amp;rft.aulast=Shannon&amp;rft.aufirst=J&amp;rft.au=Shannon%2C+J&amp;rft.au=Tewoderos+S%2C+Garzotto+M%2C+Beer+TM%2C+Derenick+R%2C+Palma+A%2C+Farris+PE&amp;rft.date=August+15+2005&amp;rft.volume=162&amp;rft.issue=4&amp;rft.pages=318%E2%80%9325&amp;rft_id=info:doi/10.1093%2Faje%2Fkwi203&amp;rft_id=info:pmid/16014776&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Epub 2005 July 13</li>
<li id="cite_note-pmid12887469-23">^ <a href="#cite_ref-pmid12887469_23-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12887469_23-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid12887469_23-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFGiles_GG.2C_Severi_G.2C_English_DR.2C_McCredie_MR.2C_Borland_R.2C_Boyle_P.2C_Hopper_JL2003">Giles GG, Severi G, English DR, McCredie MR, Borland R, Boyle P, Hopper JL (August 2003). "Sexual factors and prostate cancer". <i>BJU Int.</i> <b>92</b> (3): 211–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1046%2Fj.1464-410X.2003.04319.x" class="external text" title="http://dx.doi.org/10.1046%2Fj.1464-410X.2003.04319.x" rel="nofollow">10.1046/j.1464-410X.2003.04319.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12887469" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12887469">PMID 12887469</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Sexual+factors+and+prostate+cancer&amp;rft.jtitle=BJU+Int.&amp;rft.aulast=Giles+GG%2C+Severi+G%2C+English+DR%2C+McCredie+MR%2C+Borland+R%2C+Boyle+P%2C+Hopper+JL&amp;rft.au=Giles+GG%2C+Severi+G%2C+English+DR%2C+McCredie+MR%2C+Borland+R%2C+Boyle+P%2C+Hopper+JL&amp;rft.date=August+2003&amp;rft.volume=92&amp;rft.issue=3&amp;rft.pages=211%E2%80%936&amp;rft_id=info:doi/10.1046%2Fj.1464-410X.2003.04319.x&amp;rft_id=info:pmid/12887469&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-24"><b><a href="#cite_ref-24" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLeitzmann2004">Leitzmann, Michael F. (April 7 2004). "Ejaculation Frequency and Subsequent Risk of Prostate Cancer". <i>JAMA</i> <b>291</b> (13): 1578–86. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.291.13.1578" class="external text" title="http://dx.doi.org/10.1001%2Fjama.291.13.1578" rel="nofollow">10.1001/jama.291.13.1578</a></span>. 2004;291:1578-1586. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15069045" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15069045">PMID 15069045</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Ejaculation+Frequency+and+Subsequent+Risk+of+Prostate+Cancer&amp;rft.jtitle=JAMA&amp;rft.aulast=Leitzmann&amp;rft.aufirst=Michael+F.&amp;rft.au=Leitzmann%2C+Michael+F.&amp;rft.date=April+7+2004&amp;rft.volume=291&amp;rft.issue=13&amp;rft.pages=1578%E2%80%9386&amp;rft_id=info:doi/10.1001%2Fjama.291.13.1578&amp;rft_id=info:pmid/15069045&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=15069045&amp;query_hl=2&amp;itool=pubmed_docsum|" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=15069045&amp;query_hl=2&amp;itool=pubmed_docsum|" rel="nofollow">PMID: 15069045</a></li>
<li id="cite_note-25"><b><a href="#cite_ref-25" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDennisLynch_CF.3B_Torner_JC2002">Dennis, LK; Lynch CF; Torner JC (July 2002). "Epidemiologic association between prostatitis and prostate cancer". <i>Urology</i> <b>60</b> (1): 78–83. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0090-4295%2802%2901637-0" class="external text" title="http://dx.doi.org/10.1016%2FS0090-4295%2802%2901637-0" rel="nofollow">10.1016/S0090-4295(02)01637-0</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12100928" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12100928">PMID 12100928</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Epidemiologic+association+between+prostatitis+and+prostate+cancer&amp;rft.jtitle=Urology&amp;rft.aulast=Dennis&amp;rft.aufirst=LK&amp;rft.au=Dennis%2C+LK&amp;rft.au=Lynch+CF%3B+Torner+JC&amp;rft.date=July+2002&amp;rft.volume=60&amp;rft.issue=1&amp;rft.pages=78%E2%80%9383&amp;rft_id=info:doi/10.1016%2FS0090-4295%2802%2901637-0&amp;rft_id=info:pmid/12100928&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-26"><b><a href="#cite_ref-26" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCalleRodriguez_C.2C_Walker-Thurmond_K.2C_Thun_MJ2003">Calle, EE; Rodriguez C, Walker-Thurmond K, Thun MJ (April 24 2003). "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults". <i>N Engl J Med</i> <b>348</b> (17): 1625–38. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa021423" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa021423" rel="nofollow">10.1056/NEJMoa021423</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12711737" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12711737">PMID 12711737</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Overweight%2C+obesity%2C+and+mortality+from+cancer+in+a+prospectively+studied+cohort+of+U.S.+adults&amp;rft.jtitle=N+Engl+J+Med&amp;rft.aulast=Calle&amp;rft.aufirst=EE&amp;rft.au=Calle%2C+EE&amp;rft.au=Rodriguez+C%2C+Walker-Thurmond+K%2C+Thun+MJ&amp;rft.date=April+24+2003&amp;rft.volume=348&amp;rft.issue=17&amp;rft.pages=1625%E2%80%9338&amp;rft_id=info:doi/10.1056%2FNEJMoa021423&amp;rft_id=info:pmid/12711737&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-27"><b><a href="#cite_ref-27" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGannHennekens_CH.2C_Ma_J.2C_Longcope_C.2C_Stampfer_MJ1996">Gann, PH; Hennekens CH, Ma J, Longcope C, Stampfer MJ (August 21 1996). "Prospective study of sex hormone levels and risk of prostate cancer". <i>J Natl Cancer Inst</i> <b>88</b> (16): 1118–26. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fjnci%2F88.16.1118" class="external text" title="http://dx.doi.org/10.1093%2Fjnci%2F88.16.1118" rel="nofollow">10.1093/jnci/88.16.1118</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8757191" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8757191">PMID 8757191</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prospective+study+of+sex+hormone+levels+and+risk+of+prostate+cancer&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.aulast=Gann&amp;rft.aufirst=PH&amp;rft.au=Gann%2C+PH&amp;rft.au=Hennekens+CH%2C+Ma+J%2C+Longcope+C%2C+Stampfer+MJ&amp;rft.date=August+21+1996&amp;rft.volume=88&amp;rft.issue=16&amp;rft.pages=1118%E2%80%9326&amp;rft_id=info:doi/10.1093%2Fjnci%2F88.16.1118&amp;rft_id=info:pmid/8757191&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-aorange-28"><b><a href="#cite_ref-aorange_28-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="https://my.mcg.edu/portal/page/portal/News/archive/2007/Veterans%20exposed%20to%20Agent%20%20Orange%20have%20higher%20rates%20of%20prost" class="external text" title="https://my.mcg.edu/portal/page/portal/News/archive/2007/Veterans%20exposed%20to%20Agent%20%20Orange%20have%20higher%20rates%20of%20prost" rel="nofollow">"Veterans exposed to Agent Orange have higher rates of prostate cancer recurrence"</a>. <i>Medical College of Georgia News</i>. May 20, 2007<span class="printonly">. <a href="https://my.mcg.edu/portal/page/portal/News/archive/2007/Veterans%20exposed%20to%20Agent%20%20Orange%20have%20higher%20rates%20of%20prost" class="external free" title="https://my.mcg.edu/portal/page/portal/News/archive/2007/Veterans%20exposed%20to%20Agent%20%20Orange%20have%20higher%20rates%20of%20prost" rel="nofollow">https://my.mcg.edu/portal/page/portal/News/archive/2007/Veterans%20exposed%20to%20Agent%20%20Orange%20have%20higher%20rates%20of%20prost</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Veterans+exposed+to+Agent+Orange+have+higher+rates+of+prostate+cancer+recurrence&amp;rft.atitle=Medical+College+of+Georgia+News&amp;rft.date=May+20%2C+2007&amp;rft_id=https%3A%2F%2Fmy.mcg.edu%2Fportal%2Fpage%2Fportal%2FNews%2Farchive%2F2007%2FVeterans%2520exposed%2520to%2520Agent%2520%2520Orange%2520have%2520higher%2520rates%2520of%2520prost&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-BBC_NEWS_Masturbation-29">^ <a href="#cite_ref-BBC_NEWS_Masturbation_29-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-BBC_NEWS_Masturbation_29-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-BBC_NEWS_Masturbation_29-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="web"><a href="http://news.bbc.co.uk/1/hi/health/3072021.stm" class="external text" title="http://news.bbc.co.uk/1/hi/health/3072021.stm" rel="nofollow">"Masturbation 'cuts cancer risk'"</a>. <i>Health</i>. BBC NEWS. 2003-07-16<span class="printonly">. <a href="http://news.bbc.co.uk/1/hi/health/3072021.stm" class="external free" title="http://news.bbc.co.uk/1/hi/health/3072021.stm" rel="nofollow">http://news.bbc.co.uk/1/hi/health/3072021.stm</a></span><span class="reference-accessdate">. Retrieved on 2008-04-24</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Masturbation+%27cuts+cancer+risk%27&amp;rft.atitle=Health&amp;rft.date=2003-07-16&amp;rft.pub=BBC+NEWS&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fhealth%2F3072021.stm&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-30"><b><a href="#cite_ref-30" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFEssink-Botde_Koning_HJ.2C_Nijs_HG.2C_Kirkels_WJ.2C_van_der_Maas_PJ.2C_Schroder_FH1998">Essink-Bot, ML; de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schroder FH (June 17 1998). "Short-term effects of population-based screening for prostate cancer on health-related quality of life". <i>J Natl Cancer Inst</i> <b>90</b> (12): 925–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fjnci%2F90.12.925" class="external text" title="http://dx.doi.org/10.1093%2Fjnci%2F90.12.925" rel="nofollow">10.1093/jnci/90.12.925</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9637143" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9637143">PMID 9637143</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Short-term+effects+of+population-based+screening+for+prostate+cancer+on+health-related+quality+of+life&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.aulast=Essink-Bot&amp;rft.aufirst=ML&amp;rft.au=Essink-Bot%2C+ML&amp;rft.au=de+Koning+HJ%2C+Nijs+HG%2C+Kirkels+WJ%2C+van+der+Maas+PJ%2C+Schroder+FH&amp;rft.date=June+17+1998&amp;rft.volume=90&amp;rft.issue=12&amp;rft.pages=925%E2%80%9331&amp;rft_id=info:doi/10.1093%2Fjnci%2F90.12.925&amp;rft_id=info:pmid/9637143&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17667550-31"><b><a href="#cite_ref-pmid17667550_31-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFChuang_AY.2C_Demarzo_AM.2C_Veltri_RW.2C_Sharma_RB.2C_Bieberich_CJ.2C_Epstein_JI2007">Chuang AY, Demarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007). "Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma". <i>The American Journal of Surgical Pathology</i> <b>31</b> (8): 1246–1255. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2FPAS.0b013e31802f5d33" class="external text" title="http://dx.doi.org/10.1097%2FPAS.0b013e31802f5d33" rel="nofollow">10.1097/PAS.0b013e31802f5d33</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17667550" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17667550">PMID 17667550</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Immunohistochemical+Differentiation+of+High-grade+Prostate+Carcinoma+From+Urothelial+Carcinoma&amp;rft.jtitle=The+American+Journal+of+Surgical+Pathology&amp;rft.aulast=Chuang+AY%2C+Demarzo+AM%2C+Veltri+RW%2C+Sharma+RB%2C+Bieberich+CJ%2C+Epstein+JI&amp;rft.au=Chuang+AY%2C+Demarzo+AM%2C+Veltri+RW%2C+Sharma+RB%2C+Bieberich+CJ%2C+Epstein+JI&amp;rft.date=2007&amp;rft.volume=31&amp;rft.issue=8&amp;rft.pages=1246%E2%80%931255&amp;rft_id=info:doi/10.1097%2FPAS.0b013e31802f5d33&amp;rft_id=info:pmid/17667550&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-32"><b><a href="#cite_ref-32" title="">^</a></b> Iyer M, Salazar FB, Lewis X, Zhang L, Wu L, Carey M and Gambhir SS. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transg Res.2005; 14(1): 47–55</li>
<li id="cite_note-33"><b><a href="#cite_ref-33" title="">^</a></b> <a href="http://www.msnbc.msn.com/id/18328032/site/newsweek/" class="external text" title="http://www.msnbc.msn.com/id/18328032/site/newsweek/" rel="nofollow">A Prostate Cancer Revolution</a>. Newsweek, April 26, 2007.</li>
<li id="cite_note-pmid17437801-34"><b><a href="#cite_ref-pmid17437801_34-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHansel_DE.2C_DeMarzo_AM.2C_Platz_EA.2C_.27.27et_al.27.272007">Hansel DE, DeMarzo AM, Platz EA, <i>et al</i> (2007). "Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies". <i>J. Urol.</i> <b>177</b> (5): 1736–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.juro.2007.01.013" class="external text" title="http://dx.doi.org/10.1016%2Fj.juro.2007.01.013" rel="nofollow">10.1016/j.juro.2007.01.013</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17437801" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17437801">PMID 17437801</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Early+prostate+cancer+antigen+expression+in+predicting+presence+of+prostate+cancer+in+men+with+histologically+negative+biopsies&amp;rft.jtitle=J.+Urol.&amp;rft.aulast=Hansel+DE%2C+DeMarzo+AM%2C+Platz+EA%2C+%27%27et+al%27%27&amp;rft.au=Hansel+DE%2C+DeMarzo+AM%2C+Platz+EA%2C+%27%27et+al%27%27&amp;rft.date=2007&amp;rft.volume=177&amp;rft.issue=5&amp;rft.pages=1736%E2%80%9340&amp;rft_id=info:doi/10.1016%2Fj.juro.2007.01.013&amp;rft_id=info:pmid/17437801&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-35"><b><a href="#cite_ref-35" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSartor_AO.2C_Hricak_H.2C_Wheeler_TM.2C_.27.27et_al.27.272008">Sartor AO, Hricak H, Wheeler TM, <i>et al</i> (December 2008). "Evaluating localized prostate cancer and identifying candidates for focal therapy". <i>Urology</i> <b>72</b> (6 Suppl): S12–24. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.urology.2008.10.004" class="external text" title="http://dx.doi.org/10.1016%2Fj.urology.2008.10.004" rel="nofollow">10.1016/j.urology.2008.10.004</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19095124" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/19095124">PMID 19095124</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Evaluating+localized+prostate+cancer+and+identifying+candidates+for+focal+therapy&amp;rft.jtitle=Urology&amp;rft.aulast=Sartor+AO%2C+Hricak+H%2C+Wheeler+TM%2C+%27%27et+al%27%27&amp;rft.au=Sartor+AO%2C+Hricak+H%2C+Wheeler+TM%2C+%27%27et+al%27%27&amp;rft.date=December+2008&amp;rft.volume=72&amp;rft.issue=6+Suppl&amp;rft.pages=S12%E2%80%9324&amp;rft_id=info:doi/10.1016%2Fj.urology.2008.10.004&amp;rft_id=info:pmid/19095124&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-36"><b><a href="#cite_ref-36" title="">^</a></b> Ronquist G, Carlsson L, Larsson A, Nilsson BO: "Prostasomes: Proceedings from a symposium held at the Wenner-Gren Centre, Stockholm, June 2001" pp. 1-9. Portland Press , London</li>
<li id="cite_note-37"><b><a href="#cite_ref-37" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWigle_DT.2C_Turner_MC.2C_Gomes_J.2C_Parent_ME2008">Wigle DT, Turner MC, Gomes J, Parent ME (March 2008). "Role of hormonal and other factors in human prostate cancer". <i>J Toxicol Environ Health B Crit Rev</i> <b>11</b> (3-4): 242–59. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1080%2F10937400701873548" class="external text" title="http://dx.doi.org/10.1080%2F10937400701873548" rel="nofollow">10.1080/10937400701873548</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18368555" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18368555">PMID 18368555</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Role+of+hormonal+and+other+factors+in+human+prostate+cancer&amp;rft.jtitle=J+Toxicol+Environ+Health+B+Crit+Rev&amp;rft.aulast=Wigle+DT%2C+Turner+MC%2C+Gomes+J%2C+Parent+ME&amp;rft.au=Wigle+DT%2C+Turner+MC%2C+Gomes+J%2C+Parent+ME&amp;rft.date=March+2008&amp;rft.volume=11&amp;rft.issue=3-4&amp;rft.pages=242%E2%80%9359&amp;rft_id=info:doi/10.1080%2F10937400701873548&amp;rft_id=info:pmid/18368555&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-38"><b><a href="#cite_ref-38" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFStromYamamura_Y.2C_Duphorne_CM.2C_Spitz_MR.2C_Babaian_RJ.2C_Pillow_PC.2C_Hursting_SD1999">Strom, SS; Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC, Hursting SD (1999). "Phytoestrogen intake and prostate cancer: a case-control study using a new database". <i>Nutr Cancer</i> <b>33</b> (1): 20–5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10227039" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10227039">PMID 10227039</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Phytoestrogen+intake+and+prostate+cancer%3A+a+case-control+study+using+a+new+database&amp;rft.jtitle=Nutr+Cancer&amp;rft.aulast=Strom&amp;rft.aufirst=SS&amp;rft.au=Strom%2C+SS&amp;rft.au=Yamamura+Y%2C+Duphorne+CM%2C+Spitz+MR%2C+Babaian+RJ%2C+Pillow+PC%2C+Hursting+SD&amp;rft.date=1999&amp;rft.volume=33&amp;rft.issue=1&amp;rft.pages=20%E2%80%935&amp;rft_id=info:pmid/10227039&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Erratum in: Nutr Cancer 2000;36(2):243.</li>
<li id="cite_note-39"><b><a href="#cite_ref-39" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSteinerPound.2C_CR.2C_Gingrich.2C_JR.2C_et_al.2002">Steiner, MS; Pound, CR, Gingrich, JR, et al. (2002). "Acapodene (GTx-006) reduces high-grade prostatic intraepithelial neoplasia in phase II clinical trial (abstract)". <i>Proc Am Soc Clin Oncol</i> <b>21</b>: 180a.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Acapodene+%28GTx-006%29+reduces+high-grade+prostatic+intraepithelial+neoplasia+in+phase+II+clinical+trial+%28abstract%29&amp;rft.jtitle=Proc+Am+Soc+Clin+Oncol&amp;rft.aulast=Steiner&amp;rft.aufirst=MS&amp;rft.au=Steiner%2C+MS&amp;rft.au=Pound%2C+CR%2C+Gingrich%2C+JR%2C+et+al.&amp;rft.date=2002&amp;rft.volume=21&amp;rft.pages=180a&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-40"><b><a href="#cite_ref-40" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPriceStein.2C_B.2C_Goluboff.2C_E.2C_et_al.2005">Price, D; Stein, B, Goluboff, E, et al. (2005). "Double-blind, placebo-controlled trial of toremifene for the prevention of prostate cancer in men with high-grade prostatic intrapeithelial neoplasia (abstract)". <i>J Clin Oncol</i> <b>23</b>: 106s.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Double-blind%2C+placebo-controlled+trial+of+toremifene+for+the+prevention+of+prostate+cancer+in+men+with+high-grade+prostatic+intrapeithelial+neoplasia+%28abstract%29&amp;rft.jtitle=J+Clin+Oncol&amp;rft.aulast=Price&amp;rft.aufirst=D&amp;rft.au=Price%2C+D&amp;rft.au=Stein%2C+B%2C+Goluboff%2C+E%2C+et+al.&amp;rft.date=2005&amp;rft.volume=23&amp;rft.pages=106s&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-41"><b><a href="#cite_ref-41" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFThompsonGoodman_PJ.2C_Tangen_CM.2C_Lucia_MS.2C_Miller_GJ.2C_Ford_LG.2C_Lieber_MM.2C_Cespedes_RD.2C_Atkins_JN.2C_Lippman_SM.2C_Carlin_SM.2C_Ryan_A.2C_Szczepanek_CM.2C_Crowley_JJ.2C_Coltman_CA_Jr.2003">Thompson, IM; Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. (July 17 2003). "The influence of finasteride on the development of prostate cancer". <i>N Engl J Med</i> <b>349</b> (3): 215–24. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa030660" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa030660" rel="nofollow">10.1056/NEJMoa030660</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12824459" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12824459">PMID 12824459</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+influence+of+finasteride+on+the+development+of+prostate+cancer&amp;rft.jtitle=N+Engl+J+Med&amp;rft.aulast=Thompson&amp;rft.aufirst=IM&amp;rft.au=Thompson%2C+IM&amp;rft.au=Goodman+PJ%2C+Tangen+CM%2C+Lucia+MS%2C+Miller+GJ%2C+Ford+LG%2C+Lieber+MM%2C+Cespedes+RD%2C+Atkins+JN%2C+Lippman+SM%2C+Carlin+SM%2C+Ryan+A%2C+Szczepanek+CM%2C+Crowley+JJ%2C+Coltman+CA+Jr.&amp;rft.date=July+17+2003&amp;rft.volume=349&amp;rft.issue=3&amp;rft.pages=215%E2%80%9324&amp;rft_id=info:doi/10.1056%2FNEJMoa030660&amp;rft_id=info:pmid/12824459&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-42"><b><a href="#cite_ref-42" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFAndrioleRoehrborn_C.2C_Schulman_C.2C_Slawin_KM.2C_Somerville_M.2C_Rittmaster_RS2004">Andriole, GL; Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS (September 2004). "Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia". <i>Urology</i> <b>64</b> (3): 537–41; discussion 542–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.urology.2004.04.084" class="external text" title="http://dx.doi.org/10.1016%2Fj.urology.2004.04.084" rel="nofollow">10.1016/j.urology.2004.04.084</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15351586" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15351586">PMID 15351586</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Effect+of+dutasteride+on+the+detection+of+prostate+cancer+in+men+with+benign+prostatic+hyperplasia&amp;rft.jtitle=Urology&amp;rft.aulast=Andriole&amp;rft.aufirst=GL&amp;rft.au=Andriole%2C+GL&amp;rft.au=Roehrborn+C%2C+Schulman+C%2C+Slawin+KM%2C+Somerville+M%2C+Rittmaster+RS&amp;rft.date=September+2004&amp;rft.volume=64&amp;rft.issue=3&amp;rft.pages=537%E2%80%9341%3B+discussion+542%E2%80%933&amp;rft_id=info:doi/10.1016%2Fj.urology.2004.04.084&amp;rft_id=info:pmid/15351586&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-43"><b><a href="#cite_ref-43" title="">^</a></b> <cite style="font-style:normal" class="news" id="CITEREFGine_Kolata">Gine Kolata. <a href="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" class="external text" title="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" rel="nofollow">"New Take on a Prostate Drug, and a New Debate"</a>. <a href="/wiki/NY_Times" title="NY Times" class="mw-redirect">NY Times</a> date = June 15, 2008<span class="printonly">. <a href="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" class="external free" title="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" rel="nofollow">http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A</a></span><span class="reference-accessdate">. Retrieved on 2008-06-15</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=New+Take+on+a+Prostate+Drug%2C+and+a+New+Debate&amp;rft.atitle=&amp;rft.aulast=Gine+Kolata&amp;rft.au=Gine+Kolata&amp;rft.pub=%5B%5BNY+Times%5D%5D+date+%3D+June+15%2C+2008&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2008%2F06%2F15%2Fhealth%2F15prostate.html%3Fei%3D5087%26em%3D%26en%3D813eaa4e10f57756%26ex%3D1213675200%26adxnnl%3D1%26adxnnlx%3D1213503418-GD4DbGjYsDxqV%2FxuGWnE1A&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-cancerpreventionresearch.aacrjournals.org-44">^ <a href="#cite_ref-cancerpreventionresearch.aacrjournals.org_44-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cancerpreventionresearch.aacrjournals.org_44-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFPotosky_A.2C_Miller_B.2C_Albertsen_P.2C_Kramer_B2008">Potosky A, Miller B, Albertsen P, Kramer B (2008). "<a href="http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0092v1" class="external text" title="http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0092v1" rel="nofollow">Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach</a>". <i>Cancer Prevention Research</i> <b>Published Online First on May 18, 2008 as 10.1158/1940-6207.CAPR-08-0092</b>: 174. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1158%2F1940-6207.CAPR-08-0092" class="external text" title="http://dx.doi.org/10.1158%2F1940-6207.CAPR-08-0092" rel="nofollow">10.1158/1940-6207.CAPR-08-0092</a></span><span class="printonly">. <a href="http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0092v1" class="external free" title="http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0092v1" rel="nofollow">http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0092v1</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Finasteride+Does+Not+Increase+the+Risk+of+High-Grade+Prostate+Cancer%3A+A+Bias-Adjusted+Modeling+Approach&amp;rft.jtitle=Cancer+Prevention+Research&amp;rft.aulast=Potosky+A%2C+Miller+B%2C+Albertsen+P%2C+Kramer+B&amp;rft.au=Potosky+A%2C+Miller+B%2C+Albertsen+P%2C+Kramer+B&amp;rft.date=2008&amp;rft.volume=Published+Online+First+on+May+18%2C+2008+as+10.1158%2F1940-6207.CAPR-08-0092&amp;rft.pages=174&amp;rft_id=info:doi/10.1158%2F1940-6207.CAPR-08-0092&amp;rft_id=http%3A%2F%2Fcancerpreventionresearch.aacrjournals.org%2Fcgi%2Frapidpdf%2F1940-6207.CAPR-08-0092v1&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-45"><b><a href="#cite_ref-45" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLee_AH.2C_Fraser_ML.2C_Meng_X.2C_Binns_CW2006">Lee AH, Fraser ML, Meng X, Binns CW (April 2006). "Protective effects of green tea against prostate cancer". <i>Expert Rev Anticancer Ther</i> <b>6</b> (4): 507–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1586%2F14737140.6.4.507" class="external text" title="http://dx.doi.org/10.1586%2F14737140.6.4.507" rel="nofollow">10.1586/14737140.6.4.507</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16613539" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16613539">PMID 16613539</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Protective+effects+of+green+tea+against+prostate+cancer&amp;rft.jtitle=Expert+Rev+Anticancer+Ther&amp;rft.aulast=Lee+AH%2C+Fraser+ML%2C+Meng+X%2C+Binns+CW&amp;rft.au=Lee+AH%2C+Fraser+ML%2C+Meng+X%2C+Binns+CW&amp;rft.date=April+2006&amp;rft.volume=6&amp;rft.issue=4&amp;rft.pages=507%E2%80%9313&amp;rft_id=info:doi/10.1586%2F14737140.6.4.507&amp;rft_id=info:pmid/16613539&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-46"><b><a href="#cite_ref-46" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKikuchi_N.2C_Ohmori_K.2C_Shimazu_T.2C_.27.27et_al.27.272006">Kikuchi N, Ohmori K, Shimazu T, <i>et al</i> (August 2006). "No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study". <i>Br. J. Cancer</i> <b>95</b> (3): 371–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1038%2Fsj.bjc.6603230" class="external text" title="http://dx.doi.org/10.1038%2Fsj.bjc.6603230" rel="nofollow">10.1038/sj.bjc.6603230</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16804523" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16804523">PMID 16804523</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=No+association+between+green+tea+and+prostate+cancer+risk+in+Japanese+men%3A+the+Ohsaki+Cohort+Study&amp;rft.jtitle=Br.+J.+Cancer&amp;rft.aulast=Kikuchi+N%2C+Ohmori+K%2C+Shimazu+T%2C+%27%27et+al%27%27&amp;rft.au=Kikuchi+N%2C+Ohmori+K%2C+Shimazu+T%2C+%27%27et+al%27%27&amp;rft.date=August+2006&amp;rft.volume=95&amp;rft.issue=3&amp;rft.pages=371%E2%80%933&amp;rft_id=info:doi/10.1038%2Fsj.bjc.6603230&amp;rft_id=info:pmid/16804523&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-47"><b><a href="#cite_ref-47" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBettuzzi_S.2C_Brausi_M.2C_Rizzi_F.2C_Castagnetti_G.2C_Peracchia_G.2C_Corti_A2006">Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A (2006). "Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study". <i>Cancer Res</i> <b>66</b> (2): 1234–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1158%2F0008-5472.CAN-05-1145" class="external text" title="http://dx.doi.org/10.1158%2F0008-5472.CAN-05-1145" rel="nofollow">10.1158/0008-5472.CAN-05-1145</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16424063" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16424063">PMID 16424063</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Chemoprevention+of+human+prostate+cancer+by+oral+administration+of+green+tea+catechins+in+volunteers+with+high-grade+prostate+intraepithelial+neoplasia%3A+a+preliminary+report+from+a+one-year+proof-of-principle+study&amp;rft.jtitle=Cancer+Res&amp;rft.aulast=Bettuzzi+S%2C+Brausi+M%2C+Rizzi+F%2C+Castagnetti+G%2C+Peracchia+G%2C+Corti+A&amp;rft.au=Bettuzzi+S%2C+Brausi+M%2C+Rizzi+F%2C+Castagnetti+G%2C+Peracchia+G%2C+Corti+A&amp;rft.date=2006&amp;rft.volume=66&amp;rft.issue=2&amp;rft.pages=1234%E2%80%9340&amp;rft_id=info:doi/10.1158%2F0008-5472.CAN-05-1145&amp;rft_id=info:pmid/16424063&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-BBC_NEWS_Multivitamin-48"><b><a href="#cite_ref-BBC_NEWS_Multivitamin_48-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://news.bbc.co.uk/1/hi/health/6657795.stm" class="external text" title="http://news.bbc.co.uk/1/hi/health/6657795.stm" rel="nofollow">"Multivitamin prostate warning"</a>. <i>Health</i>. BBC NEWS. 2007-05-16<span class="printonly">. <a href="http://news.bbc.co.uk/1/hi/health/6657795.stm" class="external free" title="http://news.bbc.co.uk/1/hi/health/6657795.stm" rel="nofollow">http://news.bbc.co.uk/1/hi/health/6657795.stm</a></span><span class="reference-accessdate">. Retrieved on 2008-04-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Multivitamin+prostate+warning&amp;rft.atitle=Health&amp;rft.date=2007-05-16&amp;rft.pub=BBC+NEWS&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fhealth%2F6657795.stm&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17505071-49"><b><a href="#cite_ref-pmid17505071_49-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLawson_KA.2C_Wright_ME.2C_Subar_A.2C_Mouw_T.2C_Hollenbeck_A.2C_Schatzkin_A.2C_Leitzmann_MF2007">Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, Leitzmann MF (May 2007). "Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study". <i>J. Natl. Cancer Inst.</i> <b>99</b> (10): 754–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fjnci%2Fdjk177" class="external text" title="http://dx.doi.org/10.1093%2Fjnci%2Fdjk177" rel="nofollow">10.1093/jnci/djk177</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17505071" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17505071">PMID 17505071</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Multivitamin+use+and+risk+of+prostate+cancer+in+the+National+Institutes+of+Health-AARP+Diet+and+Health+Study&amp;rft.jtitle=J.+Natl.+Cancer+Inst.&amp;rft.aulast=Lawson+KA%2C+Wright+ME%2C+Subar+A%2C+Mouw+T%2C+Hollenbeck+A%2C+Schatzkin+A%2C+Leitzmann+MF&amp;rft.au=Lawson+KA%2C+Wright+ME%2C+Subar+A%2C+Mouw+T%2C+Hollenbeck+A%2C+Schatzkin+A%2C+Leitzmann+MF&amp;rft.date=May+2007&amp;rft.volume=99&amp;rft.issue=10&amp;rft.pages=754%E2%80%9364&amp;rft_id=info:doi/10.1093%2Fjnci%2Fdjk177&amp;rft_id=info:pmid/17505071&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-CBS_News_Broccoli-50"><b><a href="#cite_ref-CBS_News_Broccoli_50-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.cbsnews.com/stories/2007/07/24/health/webmd/main3094509.shtml" class="external text" title="http://www.cbsnews.com/stories/2007/07/24/health/webmd/main3094509.shtml" rel="nofollow">"Broccoli May Help Cut Prostate Cancer, Broccoli, Cauliflower May Make Aggressive Prostate Cancer Less Likely"</a>. CBS News. 2007-07-24<span class="printonly">. <a href="http://www.cbsnews.com/stories/2007/07/24/health/webmd/main3094509.shtml" class="external free" title="http://www.cbsnews.com/stories/2007/07/24/health/webmd/main3094509.shtml" rel="nofollow">http://www.cbsnews.com/stories/2007/07/24/health/webmd/main3094509.shtml</a></span><span class="reference-accessdate">. Retrieved on 2008-04-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Broccoli+May+Help+Cut+Prostate+Cancer%2C+Broccoli%2C+Cauliflower+May+Make+Aggressive+Prostate+Cancer+Less+Likely&amp;rft.atitle=&amp;rft.date=2007-07-24&amp;rft.pub=CBS+News&amp;rft_id=http%3A%2F%2Fwww.cbsnews.com%2Fstories%2F2007%2F07%2F24%2Fhealth%2Fwebmd%2Fmain3094509.shtml&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17652276-51"><b><a href="#cite_ref-pmid17652276_51-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKirsh_VA.2C_Peters_U.2C_Mayne_ST.2C_Subar_AF.2C_Chatterjee_N.2C_Johnson_CC.2C_Hayes_RB2007">Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB (August 2007). "Prospective study of fruit and vegetable intake and risk of prostate cancer". <i>J. Natl. Cancer Inst.</i> <b>99</b> (15): 1200–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fjnci%2Fdjm065" class="external text" title="http://dx.doi.org/10.1093%2Fjnci%2Fdjm065" rel="nofollow">10.1093/jnci/djm065</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17652276" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17652276">PMID 17652276</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prospective+study+of+fruit+and+vegetable+intake+and+risk+of+prostate+cancer&amp;rft.jtitle=J.+Natl.+Cancer+Inst.&amp;rft.aulast=Kirsh+VA%2C+Peters+U%2C+Mayne+ST%2C+Subar+AF%2C+Chatterjee+N%2C+Johnson+CC%2C+Hayes+RB&amp;rft.au=Kirsh+VA%2C+Peters+U%2C+Mayne+ST%2C+Subar+AF%2C+Chatterjee+N%2C+Johnson+CC%2C+Hayes+RB&amp;rft.date=August+2007&amp;rft.volume=99&amp;rft.issue=15&amp;rft.pages=1200%E2%80%939&amp;rft_id=info:doi/10.1093%2Fjnci%2Fdjm065&amp;rft_id=info:pmid/17652276&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-52"><b><a href="#cite_ref-52" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSarkar_FH.2C_Li_Y2004">Sarkar FH, Li Y (December 2004). "Indole-3-carbinol and prostate cancer". <i>J. Nutr.</i> <b>134</b> (12 Suppl): 3493S–3498S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15570059" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15570059">PMID 15570059</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Indole-3-carbinol+and+prostate+cancer&amp;rft.jtitle=J.+Nutr.&amp;rft.aulast=Sarkar+FH%2C+Li+Y&amp;rft.au=Sarkar+FH%2C+Li+Y&amp;rft.date=December+2004&amp;rft.volume=134&amp;rft.issue=12+Suppl&amp;rft.pages=3493S%E2%80%933498S&amp;rft_id=info:pmid/15570059&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-53"><b><a href="#cite_ref-53" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHsu_JC.2C_Zhang_J.2C_Dev_A.2C_Wing_A.2C_Bjeldanes_LF.2C_Firestone_GL2005">Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF, Firestone GL (November 2005). "<a href="http://carcin.oxfordjournals.org/cgi/content/full/26/11/1896" class="external text" title="http://carcin.oxfordjournals.org/cgi/content/full/26/11/1896" rel="nofollow">Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells</a>". <i>Carcinogenesis</i> <b>26</b> (11): 1896–904. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fcarcin%2Fbgi155" class="external text" title="http://dx.doi.org/10.1093%2Fcarcin%2Fbgi155" rel="nofollow">10.1093/carcin/bgi155</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15958518" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15958518">PMID 15958518</a><span class="printonly">. <a href="http://carcin.oxfordjournals.org/cgi/content/full/26/11/1896" class="external free" title="http://carcin.oxfordjournals.org/cgi/content/full/26/11/1896" rel="nofollow">http://carcin.oxfordjournals.org/cgi/content/full/26/11/1896</a></span><span class="reference-accessdate">. Retrieved on 2008-09-12</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Indole-3-carbinol+inhibition+of+androgen+receptor+expression+and+downregulation+of+androgen+responsiveness+in+human+prostate+cancer+cells&amp;rft.jtitle=Carcinogenesis&amp;rft.aulast=Hsu+JC%2C+Zhang+J%2C+Dev+A%2C+Wing+A%2C+Bjeldanes+LF%2C+Firestone+GL&amp;rft.au=Hsu+JC%2C+Zhang+J%2C+Dev+A%2C+Wing+A%2C+Bjeldanes+LF%2C+Firestone+GL&amp;rft.date=November+2005&amp;rft.volume=26&amp;rft.issue=11&amp;rft.pages=1896%E2%80%93904&amp;rft_id=info:doi/10.1093%2Fcarcin%2Fbgi155&amp;rft_id=info:pmid/15958518&amp;rft_id=http%3A%2F%2Fcarcin.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2F26%2F11%2F1896&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-54"><b><a href="#cite_ref-54" title="">^</a></b> <a href="http://www.blackwell-synergy.com/links/doi/10.1046%2Fj.1464-410X.2003.04319.x" class="external autonumber" title="http://www.blackwell-synergy.com/links/doi/10.1046%2Fj.1464-410X.2003.04319.x" rel="nofollow">[2]</a>Giles, et al., Sexual factors and prostate cancer, BJU International, Volume 92 Issue 3, Ausust 2003, pp. 211-216</li>
<li id="cite_note-New_Scientist-55"><b><a href="#cite_ref-New_Scientist_55-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFDouglas_Fox2003">Douglas Fox (2003-07-16). <a href="http://www.newscientist.com/article/dn3942-masturbating-may-protect-against-prostate-cancer.html" class="external text" title="http://www.newscientist.com/article/dn3942-masturbating-may-protect-against-prostate-cancer.html" rel="nofollow">"Masturbating may protect against prostate cancer"</a>. New Scientist<span class="printonly">. <a href="http://www.newscientist.com/article/dn3942-masturbating-may-protect-against-prostate-cancer.html" class="external free" title="http://www.newscientist.com/article/dn3942-masturbating-may-protect-against-prostate-cancer.html" rel="nofollow">http://www.newscientist.com/article/dn3942-masturbating-may-protect-against-prostate-cancer.html</a></span><span class="reference-accessdate">. Retrieved on 2008-04-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Masturbating+may+protect+against+prostate+cancer&amp;rft.atitle=&amp;rft.aulast=Douglas+Fox&amp;rft.au=Douglas+Fox&amp;rft.date=2003-07-16&amp;rft.pub=New+Scientist&amp;rft_id=http%3A%2F%2Fwww.newscientist.com%2Farticle%2Fdn3942-masturbating-may-protect-against-prostate-cancer.html&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-56"><b><a href="#cite_ref-56" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLeitzmann_MF.2C_Platz_EA.2C_Stampfer_MJ.2C_Willett_WC.2C_Giovannucci_E2004">Leitzmann MF, Platz EA, Stampfer MJ, Willett WC, Giovannucci E (April 2004). "Ejaculation frequency and subsequent risk of prostate cancer". <i>JAMA</i> <b>291</b> (13): 1578–86. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.291.13.1578" class="external text" title="http://dx.doi.org/10.1001%2Fjama.291.13.1578" rel="nofollow">10.1001/jama.291.13.1578</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15069045" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15069045">PMID 15069045</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Ejaculation+frequency+and+subsequent+risk+of+prostate+cancer&amp;rft.jtitle=JAMA&amp;rft.aulast=Leitzmann+MF%2C+Platz+EA%2C+Stampfer+MJ%2C+Willett+WC%2C+Giovannucci+E&amp;rft.au=Leitzmann+MF%2C+Platz+EA%2C+Stampfer+MJ%2C+Willett+WC%2C+Giovannucci+E&amp;rft.date=April+2004&amp;rft.volume=291&amp;rft.issue=13&amp;rft.pages=1578%E2%80%9386&amp;rft_id=info:doi/10.1001%2Fjama.291.13.1578&amp;rft_id=info:pmid/15069045&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-57"><b><a href="#cite_ref-57" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDimitropoulouArtitaya_Lophatananon.2C_Douglas_Easton.2C_Richard_Pocock.2C_David_P._Dearnaley.2C_Michelle_Guy.2C_Steven_Edwards.2C_Lynne_O.27Brien.2C_Amanda_Hall.2C_Rosemary_Wilkinson.2C_Rosalind_Eeles.2C_Kenneth_R._Muir2008">Dimitropoulou, Polyxeni; Artitaya Lophatananon, Douglas Easton, Richard Pocock, David P. Dearnaley, Michelle Guy, Steven Edwards, Lynne O'Brien, Amanda Hall, Rosemary Wilkinson, Rosalind Eeles, Kenneth R. Muir (Nov 11 2008). "<a href="http://dx.doi.org/10.1111/j.1464-410X.2008.08030.x" class="external text" title="http://dx.doi.org/10.1111/j.1464-410X.2008.08030.x" rel="nofollow">Sexual activity and prostate cancer risk in men diagnosed at a younger age</a>" (in english). <i>BJU International</i> <b>103</b> (2): 178-185. <a href="/wiki/Online_Computer_Library_Center" title="Online Computer Library Center">OCLC</a> <a href="http://worldcat.org/oclc/10.1111%2Fj.1464-410X.2008.08030.x" class="external text" title="http://worldcat.org/oclc/10.1111%2Fj.1464-410X.2008.08030.x" rel="nofollow">10.1111/j.1464-410X.2008.08030.x</a><span class="printonly">. <a href="http://dx.doi.org/10.1111/j.1464-410X.2008.08030.x" class="external free" title="http://dx.doi.org/10.1111/j.1464-410X.2008.08030.x" rel="nofollow">http://dx.doi.org/10.1111/j.1464-410X.2008.08030.x</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Sexual+activity+and+prostate+cancer+risk+in+men+diagnosed+at+a+younger+age&amp;rft.jtitle=BJU+International&amp;rft.aulast=Dimitropoulou&amp;rft.aufirst=Polyxeni&amp;rft.au=Dimitropoulou%2C+Polyxeni&amp;rft.au=Artitaya+Lophatananon%2C+Douglas+Easton%2C+Richard+Pocock%2C+David+P.+Dearnaley%2C+Michelle+Guy%2C+Steven+Edwards%2C+Lynne+O%27Brien%2C+Amanda+Hall%2C+Rosemary+Wilkinson%2C+Rosalind+Eeles%2C+Kenneth+R.+Muir&amp;rft.date=Nov+11+2008&amp;rft.volume=103&amp;rft.issue=2&amp;rft.pages=178-185&amp;rft_id=info:oclcnum/10.1111%2Fj.1464-410X.2008.08030.x&amp;rft_id=http%3A%2F%2Fdx.doi.org%2F10.1111%2Fj.1464-410X.2008.08030.x&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-58"><b><a href="#cite_ref-58" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBerquin_IM.2C_Min_Y.2C_Wu_R.2C_.27.27et_al.27.272007">Berquin IM, Min Y, Wu R, <i>et al</i> (July 2007). "<a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1890998" class="external text" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&amp;artid=1890998" rel="nofollow">Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids</a>". <i>J. Clin. Invest.</i> <b>117</b> (7): 1866–75. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1172%2FJCI31494" class="external text" title="http://dx.doi.org/10.1172%2FJCI31494" rel="nofollow">10.1172/JCI31494</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17607361" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17607361">PMID 17607361</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Modulation+of+prostate+cancer+genetic+risk+by+omega-3+and+omega-6+fatty+acids&amp;rft.jtitle=J.+Clin.+Invest.&amp;rft.aulast=Berquin+IM%2C+Min+Y%2C+Wu+R%2C+%27%27et+al%27%27&amp;rft.au=Berquin+IM%2C+Min+Y%2C+Wu+R%2C+%27%27et+al%27%27&amp;rft.date=July+2007&amp;rft.volume=117&amp;rft.issue=7&amp;rft.pages=1866%E2%80%9375&amp;rft_id=info:doi/10.1172%2FJCI31494&amp;rft_id=info:pmid/17607361&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid14693732-59"><b><a href="#cite_ref-pmid14693732_59-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFM.C3.A4nnist.C3.B6_S.2C_Pietinen_P.2C_Virtanen_MJ.2C_Salminen_I.2C_Albanes_D.2C_Giovannucci_E.2C_Virtamo_J2003">Männistö S, Pietinen P, Virtanen MJ, Salminen I, Albanes D, Giovannucci E, Virtamo J (December 2003). "<a href="http://cebp.aacrjournals.org/cgi/reprint/12/12/1422.pdf" class="external text" title="http://cebp.aacrjournals.org/cgi/reprint/12/12/1422.pdf" rel="nofollow">Fatty acids and risk of prostate cancer in a nested case-control study in male smokers</a>" (PDF). <i>Cancer Epidemiol. Biomarkers Prev.</i> <b>12</b> (12): 1422–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14693732" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14693732">PMID 14693732</a><span class="printonly">. <a href="http://cebp.aacrjournals.org/cgi/reprint/12/12/1422.pdf" class="external free" title="http://cebp.aacrjournals.org/cgi/reprint/12/12/1422.pdf" rel="nofollow">http://cebp.aacrjournals.org/cgi/reprint/12/12/1422.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Fatty+acids+and+risk+of+prostate+cancer+in+a+nested+case-control+study+in+male+smokers&amp;rft.jtitle=Cancer+Epidemiol.+Biomarkers+Prev.&amp;rft.aulast=M%C3%A4nnist%C3%B6+S%2C+Pietinen+P%2C+Virtanen+MJ%2C+Salminen+I%2C+Albanes+D%2C+Giovannucci+E%2C+Virtamo+J&amp;rft.au=M%C3%A4nnist%C3%B6+S%2C+Pietinen+P%2C+Virtanen+MJ%2C+Salminen+I%2C+Albanes+D%2C+Giovannucci+E%2C+Virtamo+J&amp;rft.date=December+2003&amp;rft.volume=12&amp;rft.issue=12&amp;rft.pages=1422%E2%80%938&amp;rft_id=info:pmid/14693732&amp;rft_id=http%3A%2F%2Fcebp.aacrjournals.org%2Fcgi%2Freprint%2F12%2F12%2F1422.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-palmiticmyristic-60">^ <a href="#cite_ref-palmiticmyristic_60-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-palmiticmyristic_60-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFKurahashi_N.2C_Inoue_M.2C_Iwasaki_M.2C_Sasazuki_S.2C_Tsugane_AS2008">Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS (April 2008). "Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men". <i>Cancer Epidemiol. Biomarkers Prev.</i> <b>17</b> (4): 930–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1158%2F1055-9965.EPI-07-2681" class="external text" title="http://dx.doi.org/10.1158%2F1055-9965.EPI-07-2681" rel="nofollow">10.1158/1055-9965.EPI-07-2681</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18398033" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18398033">PMID 18398033</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Dairy+product%2C+saturated+fatty+acid%2C+and+calcium+intake+and+prostate+cancer+in+a+prospective+cohort+of+Japanese+men&amp;rft.jtitle=Cancer+Epidemiol.+Biomarkers+Prev.&amp;rft.aulast=Kurahashi+N%2C+Inoue+M%2C+Iwasaki+M%2C+Sasazuki+S%2C+Tsugane+AS&amp;rft.au=Kurahashi+N%2C+Inoue+M%2C+Iwasaki+M%2C+Sasazuki+S%2C+Tsugane+AS&amp;rft.date=April+2008&amp;rft.volume=17&amp;rft.issue=4&amp;rft.pages=930%E2%80%937&amp;rft_id=info:doi/10.1158%2F1055-9965.EPI-07-2681&amp;rft_id=info:pmid/18398033&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-saturated-61">^ <a href="#cite_ref-saturated_61-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-saturated_61-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-saturated_61-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFCrowe_FL.2C_Allen_NE.2C_Appleby_PN.2C_Overvad_K.2C_Aardestrup_IV.2C_Johnsen_NF.2C_Tj.C3.B8nneland_A.2C_Linseisen_J.2C_Kaaks_R.2C_Boeing_H.2C_Kr.C3.B6ger_J.2C_Trichopoulou_A.2C_Zavitsanou_A.2C_Trichopoulos_D.2C_Sacerdote_C.2C_Palli_D.2C_Tumino_R.2C_Agnoli_C.2C_Kiemeney_LA.2C_Bueno-de-Mesquita_HB.2C_Chirlaque_MD.2C_Ardanaz_E.2C_Larra.C3.B1aga_N.2C_Quir.C3.B3s_JR.2C_S.C3.A1nchez_MJ.2C_Gonz.C3.A1lez_CA.2C_Stattin_P.2C_Hallmans_G.2C_Bingham_S.2C_Khaw_KT.2C_Rinaldi_S.2C_Slimani_N.2C_Jenab_M.2C_Riboli_E.2C_Key_TJ2008">Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, Johnsen NF, Tjønneland A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Zavitsanou A, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Agnoli C, Kiemeney LA, Bueno-de-Mesquita HB, Chirlaque MD, Ardanaz E, Larrañaga N, Quirós JR, Sánchez MJ, González CA, Stattin P, Hallmans G, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ (November 2008). "<a href="http://www.ajcn.org/cgi/content/abstract/88/5/1353" class="external text" title="http://www.ajcn.org/cgi/content/abstract/88/5/1353" rel="nofollow">Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition</a>". <i>Am. J. Clin. Nutr.</i> <b>88</b> (5): 1353–63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18996872" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18996872">PMID 18996872</a><span class="printonly">. <a href="http://www.ajcn.org/cgi/content/abstract/88/5/1353" class="external free" title="http://www.ajcn.org/cgi/content/abstract/88/5/1353" rel="nofollow">http://www.ajcn.org/cgi/content/abstract/88/5/1353</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Fatty+acid+composition+of+plasma+phospholipids+and+risk+of+prostate+cancer+in+a+case-control+analysis+nested+within+the+European+Prospective+Investigation+into+Cancer+and+Nutrition&amp;rft.jtitle=Am.+J.+Clin.+Nutr.&amp;rft.aulast=Crowe+FL%2C+Allen+NE%2C+Appleby+PN%2C+Overvad+K%2C+Aardestrup+IV%2C+Johnsen+NF%2C+Tj%C3%B8nneland+A%2C+Linseisen+J%2C+Kaaks+R%2C+Boeing+H%2C+Kr%C3%B6ger+J%2C+Trichopoulou+A%2C+Zavitsanou+A%2C+Trichopoulos+D%2C+Sacerdote+C%2C+Palli+D%2C+Tumino+R%2C+Agnoli+C%2C+Kiemeney+LA%2C+Bueno-de-Mesquita+HB%2C+Chirlaque+MD%2C+Ardanaz+E%2C+Larra%C3%B1aga+N%2C+Quir%C3%B3s+JR%2C+S%C3%A1nchez+MJ%2C+Gonz%C3%A1lez+CA%2C+Stattin+P%2C+Hallmans+G%2C+Bingham+S%2C+Khaw+KT%2C+Rinaldi+S%2C+Slimani+N%2C+Jenab+M%2C+Riboli+E%2C+Key+TJ&amp;rft.au=Crowe+FL%2C+Allen+NE%2C+Appleby+PN%2C+Overvad+K%2C+Aardestrup+IV%2C+Johnsen+NF%2C+Tj%C3%B8nneland+A%2C+Linseisen+J%2C+Kaaks+R%2C+Boeing+H%2C+Kr%C3%B6ger+J%2C+Trichopoulou+A%2C+Zavitsanou+A%2C+Trichopoulos+D%2C+Sacerdote+C%2C+Palli+D%2C+Tumino+R%2C+Agnoli+C%2C+Kiemeney+LA%2C+Bueno-de-Mesquita+HB%2C+Chirlaque+MD%2C+Ardanaz+E%2C+Larra%C3%B1aga+N%2C+Quir%C3%B3s+JR%2C+S%C3%A1nchez+MJ%2C+Gonz%C3%A1lez+CA%2C+Stattin+P%2C+Hallmans+G%2C+Bingham+S%2C+Khaw+KT%2C+Rinaldi+S%2C+Slimani+N%2C+Jenab+M%2C+Riboli+E%2C+Key+TJ&amp;rft.date=November+2008&amp;rft.volume=88&amp;rft.issue=5&amp;rft.pages=1353%E2%80%9363&amp;rft_id=info:pmid/18996872&amp;rft_id=http%3A%2F%2Fwww.ajcn.org%2Fcgi%2Fcontent%2Fabstract%2F88%2F5%2F1353&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-62"><b><a href="#cite_ref-62" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGerald_L._Andriole.2C_M.D..2C_Robert_L._Grubb.2C_III.2C_M.D..2C_Saundra_S._Buys.2C_M.D..2C_David_Chia.2C_Ph.D..2C_Timothy_R._Church.2C_Ph.D..2C_Mona_N._Fouad.2C_M.D..2C_Edward_P._Gelmann.2C_M.D..2C_et_al">Gerald L. Andriole, M.D., Robert L. Grubb, III, M.D., Saundra S. Buys, M.D., David Chia, Ph.D., Timothy R. Church, Ph.D., Mona N. Fouad, M.D., Edward P. Gelmann, M.D., et al (<span class="mw-formatted-date" title="2009-03-18"><a href="/wiki/2009" title="2009">2009</a>-<a href="/wiki/March_18" title="March 18">03-18</a></span>). "<a href="http://content.nejm.org/cgi/content/full/NEJMoa0810696" class="external text" title="http://content.nejm.org/cgi/content/full/NEJMoa0810696" rel="nofollow">Mortality Results from a Randomized Prostate-Cancer Screening Trial</a>". <i>The New England Journal of Medicine</i><span class="printonly">. <a href="http://content.nejm.org/cgi/content/full/NEJMoa0810696" class="external free" title="http://content.nejm.org/cgi/content/full/NEJMoa0810696" rel="nofollow">http://content.nejm.org/cgi/content/full/NEJMoa0810696</a></span><span class="reference-accessdate">. Retrieved on 2009-03-19</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mortality+Results+from+a+Randomized+Prostate-Cancer+Screening+Trial&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.aulast=Gerald+L.+Andriole%2C+M.D.%2C+Robert+L.+Grubb%2C+III%2C+M.D.%2C+Saundra+S.+Buys%2C+M.D.%2C+David+Chia%2C+Ph.D.%2C+Timothy+R.+Church%2C+Ph.D.%2C+Mona+N.+Fouad%2C+M.D.%2C+Edward+P.+Gelmann%2C+M.D.%2C+et+al&amp;rft.au=Gerald+L.+Andriole%2C+M.D.%2C+Robert+L.+Grubb%2C+III%2C+M.D.%2C+Saundra+S.+Buys%2C+M.D.%2C+David+Chia%2C+Ph.D.%2C+Timothy+R.+Church%2C+Ph.D.%2C+Mona+N.+Fouad%2C+M.D.%2C+Edward+P.+Gelmann%2C+M.D.%2C+et+al&amp;rft.date=%5B%5B2009-03-18%5D%5D&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2FNEJMoa0810696&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-63"><b><a href="#cite_ref-63" title="">^</a></b> <a href="http://www.nytimes.com/2009/03/19/health/19cancer.html?em" class="external free" title="http://www.nytimes.com/2009/03/19/health/19cancer.html?em" rel="nofollow">http://www.nytimes.com/2009/03/19/health/19cancer.html?em</a></li>
<li id="cite_note-64"><b><a href="#cite_ref-64" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSchr.C3.B6der.2Cet.al.2009">Schröder,, Fritz H.; et.al. (March 18, 2009). "<a href="http://content.nejm.org/cgi/content/full/NEJMoa0810084" class="external text" title="http://content.nejm.org/cgi/content/full/NEJMoa0810084" rel="nofollow">Screening and Prostate-Cancer Mortality in a Randomized European Study</a>". <i>NEJM</i><span class="printonly">. <a href="http://content.nejm.org/cgi/content/full/NEJMoa0810084" class="external free" title="http://content.nejm.org/cgi/content/full/NEJMoa0810084" rel="nofollow">http://content.nejm.org/cgi/content/full/NEJMoa0810084</a></span><span class="reference-accessdate">. Retrieved on 20090324</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Screening+and+Prostate-Cancer+Mortality+in+a+Randomized+European+Study&amp;rft.jtitle=NEJM&amp;rft.aulast=Schr%C3%B6der%2C&amp;rft.aufirst=Fritz+H.&amp;rft.au=Schr%C3%B6der%2C%2C+Fritz+H.&amp;rft.au=et.al.&amp;rft.date=March+18%2C+2009&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2FNEJMoa0810084&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-65"><b><a href="#cite_ref-65" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFAndrioleet.al.2009">Andriole, Gerald L.; et.al. (March 18, 2009). "<a href="http://content.nejm.org/cgi/content/full/NEJMoa0810696" class="external text" title="http://content.nejm.org/cgi/content/full/NEJMoa0810696" rel="nofollow">Mortality Results from a Randomized Prostate-Cancer Screening Trial</a>". <i>NEJM</i><span class="printonly">. <a href="http://content.nejm.org/cgi/content/full/NEJMoa0810696" class="external free" title="http://content.nejm.org/cgi/content/full/NEJMoa0810696" rel="nofollow">http://content.nejm.org/cgi/content/full/NEJMoa0810696</a></span><span class="reference-accessdate">. Retrieved on 20090324</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mortality+Results+from+a+Randomized+Prostate-Cancer+Screening+Trial&amp;rft.jtitle=NEJM&amp;rft.aulast=Andriole&amp;rft.aufirst=Gerald+L.&amp;rft.au=Andriole%2C+Gerald+L.&amp;rft.au=et.al.&amp;rft.date=March+18%2C+2009&amp;rft_id=http%3A%2F%2Fcontent.nejm.org%2Fcgi%2Fcontent%2Ffull%2FNEJMoa0810696&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-66"><b><a href="#cite_ref-66" title="">^</a></b> <a href="http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Prostate_Cancer_Screening_Weigh_Risks_Benefits_With_Your_Doctor.asp" class="external free" title="http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Prostate_Cancer_Screening_Weigh_Risks_Benefits_With_Your_Doctor.asp" rel="nofollow">http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Prostate_Cancer_Screening_Weigh_Risks_Benefits_With_Your_Doctor.asp</a></li>
<li id="cite_note-67"><b><a href="#cite_ref-67" title="">^</a></b> <a href="http://www.auanet.org/content/press/press_releases/article.cfm?articleNo=106" class="external free" title="http://www.auanet.org/content/press/press_releases/article.cfm?articleNo=106" rel="nofollow">http://www.auanet.org/content/press/press_releases/article.cfm?articleNo=106</a> AUA statement March 2009 following publication of U.S. and European large scale screening effectiveness trial results</li>
<li id="cite_note-USPSTF_2002-68"><b><a href="#cite_ref-USPSTF_2002_68-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREF.5B.5BUS_Preventive_Services_Task_Force.7CUSPSTF.5D.5D2002"><a href="/wiki/US_Preventive_Services_Task_Force" title="US Preventive Services Task Force" class="mw-redirect">USPSTF</a> (December 2002). <a href="http://www.ahrq.gov/clinic/uspstf/uspsprca.htm" class="external text" title="http://www.ahrq.gov/clinic/uspstf/uspsprca.htm" rel="nofollow">"Screening for Prostate Cancer"</a>. <a href="/wiki/Agency_for_Healthcare_Research_and_Quality" title="Agency for Healthcare Research and Quality">Agency for Healthcare Research and Quality</a><span class="printonly">. <a href="http://www.ahrq.gov/clinic/uspstf/uspsprca.htm" class="external free" title="http://www.ahrq.gov/clinic/uspstf/uspsprca.htm" rel="nofollow">http://www.ahrq.gov/clinic/uspstf/uspsprca.htm</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Screening+for+Prostate+Cancer&amp;rft.atitle=&amp;rft.aulast=%5B%5BUS+Preventive+Services+Task+Force%7CUSPSTF%5D%5D&amp;rft.au=%5B%5BUS+Preventive+Services+Task+Force%7CUSPSTF%5D%5D&amp;rft.date=December+2002&amp;rft.pub=%5B%5BAgency+for+Healthcare+Research+and+Quality%5D%5D&amp;rft_id=http%3A%2F%2Fwww.ahrq.gov%2Fclinic%2Fuspstf%2Fuspsprca.htm&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> <cite style="font-style:normal" class="" id="CITEREF.5B.5BUS_Preventive_Services_Task_Force.7CUSPSTF.5D.5D2002"><a href="/wiki/US_Preventive_Services_Task_Force" title="US Preventive Services Task Force" class="mw-redirect">USPSTF</a> (December 3, 2002). "<a href="http://www.annals.org/cgi/reprint/137/11/915.pdf" class="external text" title="http://www.annals.org/cgi/reprint/137/11/915.pdf" rel="nofollow">Screening for prostate cancer: recommendation and rationale</a>" (PDF). <i><a href="/wiki/Annals_of_Internal_Medicine" title="Annals of Internal Medicine">Ann Intern Med</a></i> <b>137</b> (11): 915–6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12458992" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12458992">PMID 12458992</a><span class="printonly">. <a href="http://www.annals.org/cgi/reprint/137/11/915.pdf" class="external free" title="http://www.annals.org/cgi/reprint/137/11/915.pdf" rel="nofollow">http://www.annals.org/cgi/reprint/137/11/915.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Screening+for+prostate+cancer%3A+recommendation+and+rationale&amp;rft.jtitle=%5B%5BAnnals+of+Internal+Medicine%7CAnn+Intern+Med%5D%5D&amp;rft.aulast=%5B%5BUS+Preventive+Services+Task+Force%7CUSPSTF%5D%5D&amp;rft.au=%5B%5BUS+Preventive+Services+Task+Force%7CUSPSTF%5D%5D&amp;rft.date=December+3%2C+2002&amp;rft.volume=137&amp;rft.issue=11&amp;rft.pages=915%E2%80%936&amp;rft_id=info:pmid/12458992&amp;rft_id=http%3A%2F%2Fwww.annals.org%2Fcgi%2Freprint%2F137%2F11%2F915.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="" id="CITEREFHarris_R.2C_Lohr_KN2002">Harris R, Lohr KN (December 3, 2002). "<a href="http://www.annals.org/cgi/reprint/137/11/917.pdf" class="external text" title="http://www.annals.org/cgi/reprint/137/11/917.pdf" rel="nofollow">Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force</a>" (PDF). <i><a href="/wiki/Annals_of_Internal_Medicine" title="Annals of Internal Medicine">Ann Intern Med</a></i> <b>137</b> (11): 917–29. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12458993" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12458993">PMID 12458993</a><span class="printonly">. <a href="http://www.annals.org/cgi/reprint/137/11/917.pdf" class="external free" title="http://www.annals.org/cgi/reprint/137/11/917.pdf" rel="nofollow">http://www.annals.org/cgi/reprint/137/11/917.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Screening+for+prostate+cancer%3A+an+update+of+the+evidence+for+the+U.S.+Preventive+Services+Task+Force&amp;rft.jtitle=%5B%5BAnnals+of+Internal+Medicine%7CAnn+Intern+Med%5D%5D&amp;rft.aulast=Harris+R%2C+Lohr+KN&amp;rft.au=Harris+R%2C+Lohr+KN&amp;rft.date=December+3%2C+2002&amp;rft.volume=137&amp;rft.issue=11&amp;rft.pages=917%E2%80%9329&amp;rft_id=info:pmid/12458993&amp;rft_id=http%3A%2F%2Fwww.annals.org%2Fcgi%2Freprint%2F137%2F11%2F917.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-US_life_table_2003-69"><b><a href="#cite_ref-US_life_table_2003_69-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFArias_E2006">Arias E (April 19, 2006). "<a href="http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf" class="external text" title="http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf" rel="nofollow">United States Life Tables, 2003</a>" (PDF). <i>Natl Vital Stat Rep</i> <b>54</b> (14): 1–40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16681183" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16681183">PMID 16681183</a><span class="printonly">. <a href="http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf" class="external free" title="http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf" rel="nofollow">http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=United+States+Life+Tables%2C+2003&amp;rft.jtitle=Natl+Vital+Stat+Rep&amp;rft.aulast=Arias+E&amp;rft.au=Arias+E&amp;rft.date=April+19%2C+2006&amp;rft.volume=54&amp;rft.issue=14&amp;rft.pages=1%E2%80%9340&amp;rft_id=info:pmid/16681183&amp;rft_id=http%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fdata%2Fnvsr%2Fnvsr54%2Fnvsr54_14.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-ACS_guidelines-70"><b><a href="#cite_ref-ACS_guidelines_70-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFvon_Eschenbach_A.2C_Ho_R.2C_Murphy_GP.2C_Cunningham_M.2C_Lins_N1997">von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N (September-October 1997). "<a href="http://caonline.amcancersoc.org/cgi/reprint/47/5/261.pdf" class="external text" title="http://caonline.amcancersoc.org/cgi/reprint/47/5/261.pdf" rel="nofollow">American Cancer Society guideline for the early detection of prostate cancer: update 1997</a>" (PDF). <i>CA Cancer J Clin</i> <b>47</b> (5): 261–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.3322%2Fcanjclin.47.5.261" class="external text" title="http://dx.doi.org/10.3322%2Fcanjclin.47.5.261" rel="nofollow">10.3322/canjclin.47.5.261</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9314820" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9314820">PMID 9314820</a><span class="printonly">. <a href="http://caonline.amcancersoc.org/cgi/reprint/47/5/261.pdf" class="external free" title="http://caonline.amcancersoc.org/cgi/reprint/47/5/261.pdf" rel="nofollow">http://caonline.amcancersoc.org/cgi/reprint/47/5/261.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=American+Cancer+Society+guideline+for+the+early+detection+of+prostate+cancer%3A+update+1997&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.aulast=von+Eschenbach+A%2C+Ho+R%2C+Murphy+GP%2C+Cunningham+M%2C+Lins+N&amp;rft.au=von+Eschenbach+A%2C+Ho+R%2C+Murphy+GP%2C+Cunningham+M%2C+Lins+N&amp;rft.date=September-October+1997&amp;rft.volume=47&amp;rft.issue=5&amp;rft.pages=261%E2%80%934&amp;rft_id=info:doi/10.3322%2Fcanjclin.47.5.261&amp;rft_id=info:pmid/9314820&amp;rft_id=http%3A%2F%2Fcaonline.amcancersoc.org%2Fcgi%2Freprint%2F47%2F5%2F261.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> <cite style="font-style:normal" class="web" id="CITEREF.5B.5BAmerican_Cancer_Society.7CACS.5D.5D2007"><a href="/wiki/American_Cancer_Society" title="American Cancer Society">ACS</a> (March 28, 2007). <a href="http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp" class="external text" title="http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp" rel="nofollow">"Prostate Cancer: Early Detection"</a><span class="printonly">. <a href="http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp" class="external free" title="http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp" rel="nofollow">http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp</a></span><span class="reference-accessdate">. Retrieved on 2007-11-19</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Prostate+Cancer%3A+Early+Detection&amp;rft.atitle=&amp;rft.aulast=%5B%5BAmerican+Cancer+Society%7CACS%5D%5D&amp;rft.au=%5B%5BAmerican+Cancer+Society%7CACS%5D%5D&amp;rft.date=March+28%2C+2007&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fdocroot%2FPED%2Fcontent%2FPED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="" id="CITEREFSmith_RA.2C_Cokkinides_V.2C_Eyre_HJ2007">Smith RA, Cokkinides V, Eyre HJ (March-April 2007). "<a href="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" class="external text" title="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" rel="nofollow">Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects</a>" (PDF). <i>CA Cancer J Clin</i> <b>57</b> (2): 90–104. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17392386" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17392386">PMID 17392386</a><span class="printonly">. <a href="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" class="external free" title="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" rel="nofollow">http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cancer+screening+in+the+United+States%2C+2007%3A+a+review+of+current+guidelines%2C+practices%2C+and+prospects&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.aulast=Smith+RA%2C+Cokkinides+V%2C+Eyre+HJ&amp;rft.au=Smith+RA%2C+Cokkinides+V%2C+Eyre+HJ&amp;rft.date=March-April+2007&amp;rft.volume=57&amp;rft.issue=2&amp;rft.pages=90%E2%80%93104&amp;rft_id=info:pmid/17392386&amp;rft_id=http%3A%2F%2Fcaonline.amcancersoc.org%2Fcgi%2Freprint%2F57%2F2%2F90.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="" id="CITEREFSmith_RA.2C_Cokkinides_V.2C_Eyre_HJ2006">Smith RA, Cokkinides V, Eyre HJ (January-February 2006). "<a href="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" class="external text" title="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" rel="nofollow">American Cancer Society guidelines for the early detection of cancer, 2006</a>" (PDF). <i>CA Cancer J Clin</i> <b>56</b> (1): 11–25. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16449183" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16449183">PMID 16449183</a><span class="printonly">. <a href="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" class="external free" title="http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf" rel="nofollow">http://caonline.amcancersoc.org/cgi/reprint/57/2/90.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=American+Cancer+Society+guidelines+for+the+early+detection+of+cancer%2C+2006&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.aulast=Smith+RA%2C+Cokkinides+V%2C+Eyre+HJ&amp;rft.au=Smith+RA%2C+Cokkinides+V%2C+Eyre+HJ&amp;rft.date=January-February+2006&amp;rft.volume=56&amp;rft.issue=1&amp;rft.pages=11%E2%80%9325&amp;rft_id=info:pmid/16449183&amp;rft_id=http%3A%2F%2Fcaonline.amcancersoc.org%2Fcgi%2Freprint%2F57%2F2%2F90.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-ACS_history-71"><b><a href="#cite_ref-ACS_history_71-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREF.5B.5BAmerican_Cancer_Society.7CACS.5D.5D2007"><a href="/wiki/American_Cancer_Society" title="American Cancer Society">ACS</a> (March 29, 2007). <a href="http://www.cancer.org/docroot/PED/content/PED_2_3X_Chronological_History_of_ACS_Recommendations_on_Early_Detection_of_Cancer.asp" class="external text" title="http://www.cancer.org/docroot/PED/content/PED_2_3X_Chronological_History_of_ACS_Recommendations_on_Early_Detection_of_Cancer.asp" rel="nofollow">"Chronological History of ACS Recommendations on Early Detection of Cancer"</a><span class="printonly">. <a href="http://www.cancer.org/docroot/PED/content/PED_2_3X_Chronological_History_of_ACS_Recommendations_on_Early_Detection_of_Cancer.asp" class="external free" title="http://www.cancer.org/docroot/PED/content/PED_2_3X_Chronological_History_of_ACS_Recommendations_on_Early_Detection_of_Cancer.asp" rel="nofollow">http://www.cancer.org/docroot/PED/content/PED_2_3X_Chronological_History_of_ACS_Recommendations_on_Early_Detection_of_Cancer.asp</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Chronological+History+of+ACS+Recommendations+on+Early+Detection+of+Cancer&amp;rft.atitle=&amp;rft.aulast=%5B%5BAmerican+Cancer+Society%7CACS%5D%5D&amp;rft.au=%5B%5BAmerican+Cancer+Society%7CACS%5D%5D&amp;rft.date=March+29%2C+2007&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fdocroot%2FPED%2Fcontent%2FPED_2_3X_Chronological_History_of_ACS_Recommendations_on_Early_Detection_of_Cancer.asp&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-NCCN_2007-72"><b><a href="#cite_ref-NCCN_2007_72-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREF.5B.5BNational_Comprehensive_Cancer_Network.7CNCCN.5D.5D2007"><a href="/wiki/National_Comprehensive_Cancer_Network" title="National Comprehensive Cancer Network">NCCN</a> (May 10, 2007). <a href="http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf" class="external text" title="http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf" rel="nofollow">"Prostate Cancer Early Detection V.2.2007"</a> (PDF). <i>NCCN Clinical Practice Guidelines in Oncology</i><span class="printonly">. <a href="http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf" class="external free" title="http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf" rel="nofollow">http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Prostate+Cancer+Early+Detection+V.2.2007&amp;rft.atitle=NCCN+Clinical+Practice+Guidelines+in+Oncology&amp;rft.aulast=%5B%5BNational+Comprehensive+Cancer+Network%7CNCCN%5D%5D&amp;rft.au=%5B%5BNational+Comprehensive+Cancer+Network%7CNCCN%5D%5D&amp;rft.date=May+10%2C+2007&amp;rft_id=http%3A%2F%2Fwww.nccn.org%2Fprofessionals%2Fphysician_gls%2FPDF%2Fprostate_detection.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-D.27Amico_2004-73"><b><a href="#cite_ref-D.27Amico_2004_73-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.hms.harvard.edu/news/pressreleases/df/0704prostate_test.html" class="external text" title="http://www.hms.harvard.edu/news/pressreleases/df/0704prostate_test.html" rel="nofollow">"Study suggests value of regular PSA tests for tracking prostate cancer"</a>. <a href="/wiki/Dana-Farber_Cancer_Institute" title="Dana-Farber Cancer Institute">Dana-Farber Cancer Institute</a>. July 2004<span class="printonly">. <a href="http://www.hms.harvard.edu/news/pressreleases/df/0704prostate_test.html" class="external free" title="http://www.hms.harvard.edu/news/pressreleases/df/0704prostate_test.html" rel="nofollow">http://www.hms.harvard.edu/news/pressreleases/df/0704prostate_test.html</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Study+suggests+value+of+regular+PSA+tests+for+tracking+prostate+cancer&amp;rft.atitle=&amp;rft.date=July+2004&amp;rft.pub=%5B%5BDana-Farber+Cancer+Institute%5D%5D&amp;rft_id=http%3A%2F%2Fwww.hms.harvard.edu%2Fnews%2Fpressreleases%2Fdf%2F0704prostate_test.html&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> <cite style="font-style:normal" class="" id="CITEREFKladko_B2005">Kladko B (August 15, 2005). "<a href="http://www.boston.com/yourlife/health/men/articles/2005/08/15/prostate_cancer_test_gets_another_look/?page=full" class="external text" title="http://www.boston.com/yourlife/health/men/articles/2005/08/15/prostate_cancer_test_gets_another_look/?page=full" rel="nofollow">Prostate cancer test gets another look</a>". <i><a href="/wiki/The_Boston_Globe" title="The Boston Globe">The Boston Globe</a></i><span class="printonly">. <a href="http://www.boston.com/yourlife/health/men/articles/2005/08/15/prostate_cancer_test_gets_another_look/?page=full" class="external free" title="http://www.boston.com/yourlife/health/men/articles/2005/08/15/prostate_cancer_test_gets_another_look/?page=full" rel="nofollow">http://www.boston.com/yourlife/health/men/articles/2005/08/15/prostate_cancer_test_gets_another_look/?page=full</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate+cancer+test+gets+another+look&amp;rft.jtitle=%5B%5BThe+Boston+Globe%5D%5D&amp;rft.aulast=Kladko+B&amp;rft.au=Kladko+B&amp;rft.date=August+15%2C+2005&amp;rft_id=http%3A%2F%2Fwww.boston.com%2Fyourlife%2Fhealth%2Fmen%2Farticles%2F2005%2F08%2F15%2Fprostate_cancer_test_gets_another_look%2F%3Fpage%3Dfull&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Strum_2005-74"><b><a href="#cite_ref-Strum_2005_74-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFStrum_SB.2C_Pogliano_D2005">Strum SB, Pogliano D (May 2005). "<a href="http://www.prostate-cancer.org/resource/pdf/Is8-2.pdf" class="external text" title="http://www.prostate-cancer.org/resource/pdf/Is8-2.pdf" rel="nofollow">What every doctor who treats male patients should know</a>" (PDF). <i>PCRI Insights</i> <b>8</b> (2): 4–5<span class="printonly">. <a href="http://www.prostate-cancer.org/resource/pdf/Is8-2.pdf" class="external free" title="http://www.prostate-cancer.org/resource/pdf/Is8-2.pdf" rel="nofollow">http://www.prostate-cancer.org/resource/pdf/Is8-2.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=What+every+doctor+who+treats+male+patients+should+know&amp;rft.jtitle=PCRI+Insights&amp;rft.aulast=Strum+SB%2C+Pogliano+D&amp;rft.au=Strum+SB%2C+Pogliano+D&amp;rft.date=May+2005&amp;rft.volume=8&amp;rft.issue=2&amp;rft.pages=4%E2%80%935&amp;rft_id=http%3A%2F%2Fwww.prostate-cancer.org%2Fresource%2Fpdf%2FIs8-2.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-AUA_Patient_Guide_2008-75"><b><a href="#cite_ref-AUA_Patient_Guide_2008_75-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREF.5B.5BAmerican_Urological_Association.7CAUA.5D.5D2008"><a href="/w/index.php?title=American_Urological_Association&amp;action=edit&amp;redlink=1" class="new" title="American Urological Association (page does not exist)">AUA</a> (2008). <a href="http://www.auanet.org/guidelines/patient_guides/pc08.pdf" class="external text" title="http://www.auanet.org/guidelines/patient_guides/pc08.pdf" rel="nofollow">"Prostate Cancer Patient Guide"</a> (PDF). <i>AUA Patient Guidelines</i><span class="printonly">. <a href="http://www.auanet.org/guidelines/patient_guides/pc08.pdf" class="external free" title="http://www.auanet.org/guidelines/patient_guides/pc08.pdf" rel="nofollow">http://www.auanet.org/guidelines/patient_guides/pc08.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Prostate+Cancer+Patient+Guide&amp;rft.atitle=AUA+Patient+Guidelines&amp;rft.aulast=%5B%5BAmerican+Urological+Association%7CAUA%5D%5D&amp;rft.au=%5B%5BAmerican+Urological+Association%7CAUA%5D%5D&amp;rft.date=2008&amp;rft_id=http%3A%2F%2Fwww.auanet.org%2Fguidelines%2Fpatient_guides%2Fpc08.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Ross_2004-76">^ <a href="#cite_ref-Ross_2004_76-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ross_2004_76-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFRoss_LE.2C_Coates_RJ.2C_Breen_N.2C_Uhler_RJ.2C_Potosky_AL.2C_Blackman_D2004">Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D (2004). "Prostate-specific antigen test use reported in the 2000 National Health Interview Survey". <i>Prev Med</i> <b>38</b> (6): 732–44. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.ypmed.2004.01.005" class="external text" title="http://dx.doi.org/10.1016%2Fj.ypmed.2004.01.005" rel="nofollow">10.1016/j.ypmed.2004.01.005</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15193893" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15193893">PMID 15193893</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate-specific+antigen+test+use+reported+in+the+2000+National+Health+Interview+Survey&amp;rft.jtitle=Prev+Med&amp;rft.aulast=Ross+LE%2C+Coates+RJ%2C+Breen+N%2C+Uhler+RJ%2C+Potosky+AL%2C+Blackman+D&amp;rft.au=Ross+LE%2C+Coates+RJ%2C+Breen+N%2C+Uhler+RJ%2C+Potosky+AL%2C+Blackman+D&amp;rft.date=2004&amp;rft.volume=38&amp;rft.issue=6&amp;rft.pages=732%E2%80%9344&amp;rft_id=info:doi/10.1016%2Fj.ypmed.2004.01.005&amp;rft_id=info:pmid/15193893&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Lewis_2007-77"><b><a href="#cite_ref-Lewis_2007_77-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLewis_MH.2C_Gohagan_JK.2C_Merenstein_DJ2007">Lewis MH, Gohagan JK, Merenstein DJ (2007). "The locality rule and the physician's dilemma: local medical practices vs the national standard of care". <i><a href="/wiki/Journal_of_the_American_Medical_Association" title="Journal of the American Medical Association">JAMA</a></i> <b>297</b> (23): 2633–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.297.23.2633" class="external text" title="http://dx.doi.org/10.1001%2Fjama.297.23.2633" rel="nofollow">10.1001/jama.297.23.2633</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17579232" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17579232">PMID 17579232</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+locality+rule+and+the+physician%27s+dilemma%3A+local+medical+practices+vs+the+national+standard+of+care&amp;rft.jtitle=%5B%5BJournal+of+the+American+Medical+Association%7CJAMA%5D%5D&amp;rft.aulast=Lewis+MH%2C+Gohagan+JK%2C+Merenstein+DJ&amp;rft.au=Lewis+MH%2C+Gohagan+JK%2C+Merenstein+DJ&amp;rft.date=2007&amp;rft.volume=297&amp;rft.issue=23&amp;rft.pages=2633%E2%80%937&amp;rft_id=info:doi/10.1001%2Fjama.297.23.2633&amp;rft_id=info:pmid/17579232&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Mernstein_2004-78"><b><a href="#cite_ref-Mernstein_2004_78-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMerenstein_D2004">Merenstein D (2004). "Winners and losers". <i><a href="/wiki/Journal_of_the_American_Medical_Association" title="Journal of the American Medical Association">JAMA</a></i> <b>291</b> (1): 15–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.291.1.15" class="external text" title="http://dx.doi.org/10.1001%2Fjama.291.1.15" rel="nofollow">10.1001/jama.291.1.15</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14709561" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14709561">PMID 14709561</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Winners+and+losers&amp;rft.jtitle=%5B%5BJournal+of+the+American+Medical+Association%7CJAMA%5D%5D&amp;rft.aulast=Merenstein+D&amp;rft.au=Merenstein+D&amp;rft.date=2004&amp;rft.volume=291&amp;rft.issue=1&amp;rft.pages=15%E2%80%936&amp;rft_id=info:doi/10.1001%2Fjama.291.1.15&amp;rft_id=info:pmid/14709561&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-De_Angelis_2007-79"><b><a href="#cite_ref-De_Angelis_2007_79-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDe_Angelis_G.2C_Rittenhouse_HG.2C_Mikolajczyk_SD.2C_Blair_Shamel_L.2C_Semjonow_A2007">De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A (2007). "<a href="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2002501&amp;blobtype=pdf" class="external text" title="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2002501&amp;blobtype=pdf" rel="nofollow">Twenty years of PSA: from prostate antigen to tumor marker</a>". <i>Rev Urol</i> <b>9</b> (3): 113–23. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17934568" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17934568">PMID 17934568</a><span class="printonly">. <a href="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2002501&amp;blobtype=pdf" class="external free" title="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2002501&amp;blobtype=pdf" rel="nofollow">http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2002501&amp;blobtype=pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Twenty+years+of+PSA%3A+from+prostate+antigen+to+tumor+marker&amp;rft.jtitle=Rev+Urol&amp;rft.aulast=De+Angelis+G%2C+Rittenhouse+HG%2C+Mikolajczyk+SD%2C+Blair+Shamel+L%2C+Semjonow+A&amp;rft.au=De+Angelis+G%2C+Rittenhouse+HG%2C+Mikolajczyk+SD%2C+Blair+Shamel+L%2C+Semjonow+A&amp;rft.date=2007&amp;rft.volume=9&amp;rft.issue=3&amp;rft.pages=113%E2%80%9323&amp;rft_id=info:pmid/17934568&amp;rft_id=http%3A%2F%2Fwww.pubmedcentral.nih.gov%2Fpicrender.fcgi%3Fartid%3D2002501%26blobtype%3Dpdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Swan_2003-80"><b><a href="#cite_ref-Swan_2003_80-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSwan_J.2C_Breen_N.2C_Coates_RJ.2C_Rimer_BK.2C_Lee_NC2003">Swan J, Breen N, Coates RJ, Rimer BK, Lee NC (2003). "<a href="http://www3.interscience.wiley.com/cgi-bin/fulltext/103521394/PDFSTART" class="external text" title="http://www3.interscience.wiley.com/cgi-bin/fulltext/103521394/PDFSTART" rel="nofollow">Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey</a>". <i>Cancer</i> <b>97</b> (6): 1528–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fcncr.11208" class="external text" title="http://dx.doi.org/10.1002%2Fcncr.11208" rel="nofollow">10.1002/cncr.11208</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12627518" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12627518">PMID 12627518</a><span class="printonly">. <a href="http://www3.interscience.wiley.com/cgi-bin/fulltext/103521394/PDFSTART" class="external free" title="http://www3.interscience.wiley.com/cgi-bin/fulltext/103521394/PDFSTART" rel="nofollow">http://www3.interscience.wiley.com/cgi-bin/fulltext/103521394/PDFSTART</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Progress+in+cancer+screening+practices+in+the+United+States%3A+results+from+the+2000+National+Health+Interview+Survey&amp;rft.jtitle=Cancer&amp;rft.aulast=Swan+J%2C+Breen+N%2C+Coates+RJ%2C+Rimer+BK%2C+Lee+NC&amp;rft.au=Swan+J%2C+Breen+N%2C+Coates+RJ%2C+Rimer+BK%2C+Lee+NC&amp;rft.date=2003&amp;rft.volume=97&amp;rft.issue=6&amp;rft.pages=1528%E2%80%9340&amp;rft_id=info:doi/10.1002%2Fcncr.11208&amp;rft_id=info:pmid/12627518&amp;rft_id=http%3A%2F%2Fwww3.interscience.wiley.com%2Fcgi-bin%2Ffulltext%2F103521394%2FPDFSTART&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Ward_2008-81"><b><a href="#cite_ref-Ward_2008_81-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWard_E.2C_Halpern_M.2C_Schrag_N.2C_Cokkinides_V.2C_DeSantis_C.2C_Bandi_P.2C_Siegel_R.2C_Stewart_A.2C_Jemal_A2008">Ward E, Halpern M, Schrag N, Cokkinides V, DeSantis C, Bandi P, Siegel R, Stewart A, Jemal A (Jan-February 2008). "<a href="http://caonline.amcancersoc.org/cgi/reprint/58/1/9.pdf" class="external text" title="http://caonline.amcancersoc.org/cgi/reprint/58/1/9.pdf" rel="nofollow">Association of insurance with cancer care utilization and outcomes</a>" (PDF). <i>CA Cancer J Clin</i> <b>58</b> (1): 9–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.3322%2FCA.2007.0011" class="external text" title="http://dx.doi.org/10.3322%2FCA.2007.0011" rel="nofollow">10.3322/CA.2007.0011</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18096863" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18096863">PMID 18096863</a><span class="printonly">. <a href="http://caonline.amcancersoc.org/cgi/reprint/58/1/9.pdf" class="external free" title="http://caonline.amcancersoc.org/cgi/reprint/58/1/9.pdf" rel="nofollow">http://caonline.amcancersoc.org/cgi/reprint/58/1/9.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Association+of+insurance+with+cancer+care+utilization+and+outcomes&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.aulast=Ward+E%2C+Halpern+M%2C+Schrag+N%2C+Cokkinides+V%2C+DeSantis+C%2C+Bandi+P%2C+Siegel+R%2C+Stewart+A%2C+Jemal+A&amp;rft.au=Ward+E%2C+Halpern+M%2C+Schrag+N%2C+Cokkinides+V%2C+DeSantis+C%2C+Bandi+P%2C+Siegel+R%2C+Stewart+A%2C+Jemal+A&amp;rft.date=Jan-February+2008&amp;rft.volume=58&amp;rft.issue=1&amp;rft.pages=9%E2%80%9331&amp;rft_id=info:doi/10.3322%2FCA.2007.0011&amp;rft_id=info:pmid/18096863&amp;rft_id=http%3A%2F%2Fcaonline.amcancersoc.org%2Fcgi%2Freprint%2F58%2F1%2F9.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Beaulac_2006-82"><b><a href="#cite_ref-Beaulac_2006_82-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBeaulac_JA.2C_Fry_RN.2C_Onysko_J2006">Beaulac JA, Fry RN, Onysko J (2006). "Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada". <i>Can J Public Health</i> <b>97</b> (3): 171–6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16827400" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16827400">PMID 16827400</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Lifetime+and+recent+prostate+specific+antigen+%28PSA%29+screening+of+men+for+prostate+cancer+in+Canada&amp;rft.jtitle=Can+J+Public+Health&amp;rft.aulast=Beaulac+JA%2C+Fry+RN%2C+Onysko+J&amp;rft.au=Beaulac+JA%2C+Fry+RN%2C+Onysko+J&amp;rft.date=2006&amp;rft.volume=97&amp;rft.issue=3&amp;rft.pages=171%E2%80%936&amp;rft_id=info:pmid/16827400&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Gibbons_2003-83"><b><a href="#cite_ref-Gibbons_2003_83-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGibbons_L.2C_Waters_C2003">Gibbons L, Waters C (May 2003). "<a href="http://www.statcan.ca/english/studies/82-003/archive/2003/14-3-a.pdf" class="external text" title="http://www.statcan.ca/english/studies/82-003/archive/2003/14-3-a.pdf" rel="nofollow">Prostate cancer--testing, incidence, surgery and mortality</a>" (PDF). <i>Health Rep</i> <b>14</b> (3): 9–20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12816012" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12816012">PMID 12816012</a><span class="printonly">. <a href="http://www.statcan.ca/english/studies/82-003/archive/2003/14-3-a.pdf" class="external free" title="http://www.statcan.ca/english/studies/82-003/archive/2003/14-3-a.pdf" rel="nofollow">http://www.statcan.ca/english/studies/82-003/archive/2003/14-3-a.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate+cancer--testing%2C+incidence%2C+surgery+and+mortality&amp;rft.jtitle=Health+Rep&amp;rft.aulast=Gibbons+L%2C+Waters+C&amp;rft.au=Gibbons+L%2C+Waters+C&amp;rft.date=May+2003&amp;rft.volume=14&amp;rft.issue=3&amp;rft.pages=9%E2%80%9320&amp;rft_id=info:pmid/12816012&amp;rft_id=http%3A%2F%2Fwww.statcan.ca%2Fenglish%2Fstudies%2F82-003%2Farchive%2F2003%2F14-3-a.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-84"><b><a href="#cite_ref-84" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFChodakKeller_P.2C_Schoenberg_HW1989">Chodak, GW; Keller P, Schoenberg HW (May 1989). "Assessment of screening for prostate cancer using the digital rectal examination". <i>J Urol</i> <b>141</b> (5): 1136–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2709500" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/2709500">PMID 2709500</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Assessment+of+screening+for+prostate+cancer+using+the+digital+rectal+examination&amp;rft.jtitle=J+Urol&amp;rft.aulast=Chodak&amp;rft.aufirst=GW&amp;rft.au=Chodak%2C+GW&amp;rft.au=Keller+P%2C+Schoenberg+HW&amp;rft.date=May+1989&amp;rft.volume=141&amp;rft.issue=5&amp;rft.pages=1136%E2%80%938&amp;rft_id=info:pmid/2709500&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-85"><b><a href="#cite_ref-85" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKrahnMahoney_JE.2C_Eckman_MH.2C_Trachtenberg_J.2C_Pauker_SG.2C_Detsky_AS1994">Krahn, MD; Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS (September 14 1994). "Screening for prostate cancer.. A decision analytic view". <i>JAMA</i> <b>272</b> (10): 773–80. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.272.10.773" class="external text" title="http://dx.doi.org/10.1001%2Fjama.272.10.773" rel="nofollow">10.1001/jama.272.10.773</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7521400" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7521400">PMID 7521400</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Screening+for+prostate+cancer..+A+decision+analytic+view&amp;rft.jtitle=JAMA&amp;rft.aulast=Krahn&amp;rft.aufirst=MD&amp;rft.au=Krahn%2C+MD&amp;rft.au=Mahoney+JE%2C+Eckman+MH%2C+Trachtenberg+J%2C+Pauker+SG%2C+Detsky+AS&amp;rft.date=September+14+1994&amp;rft.volume=272&amp;rft.issue=10&amp;rft.pages=773%E2%80%9380&amp;rft_id=info:doi/10.1001%2Fjama.272.10.773&amp;rft_id=info:pmid/7521400&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Catalona_2007-86"><b><a href="#cite_ref-Catalona_2007_86-0" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFCatalona_WJ2007">Catalona WJ (August 16, 2007). <a href="http://www.cdccancerconference.net/Presentations/ET2.0/ET2.0_Catalona.pdf" class="external text" title="http://www.cdccancerconference.net/Presentations/ET2.0/ET2.0_Catalona.pdf" rel="nofollow">"How I manage a patient with a newly elevated PSA"</a> (PDF). <i>2007 <a href="/wiki/Centers_for_Disease_Control_and_Prevention" title="Centers for Disease Control and Prevention">CDC</a> Cancer Conference</i><span class="printonly">. <a href="http://www.cdccancerconference.net/Presentations/ET2.0/ET2.0_Catalona.pdf" class="external free" title="http://www.cdccancerconference.net/Presentations/ET2.0/ET2.0_Catalona.pdf" rel="nofollow">http://www.cdccancerconference.net/Presentations/ET2.0/ET2.0_Catalona.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=How+I+manage+a+patient+with+a+newly+elevated+PSA&amp;rft.atitle=2007+%5B%5BCenters+for+Disease+Control+and+Prevention%7CCDC%5D%5D+Cancer+Conference&amp;rft.aulast=Catalona+WJ&amp;rft.au=Catalona+WJ&amp;rft.date=August+16%2C+2007&amp;rft_id=http%3A%2F%2Fwww.cdccancerconference.net%2FPresentations%2FET2.0%2FET2.0_Catalona.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Kolota_2004-87"><b><a href="#cite_ref-Kolota_2004_87-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKolota_G2004">Kolota G (May 30, 2004). "<a href="http://query.nytimes.com/gst/fullpage.html?res=9F05E5DD1E3EF933A05756C0A9629C8B63&amp;sec=&amp;spon=&amp;pagewanted=all" class="external text" title="http://query.nytimes.com/gst/fullpage.html?res=9F05E5DD1E3EF933A05756C0A9629C8B63&amp;sec=&amp;spon=&amp;pagewanted=all" rel="nofollow">It was medical gospel, but it wasn't true</a>". <i><a href="/wiki/The_New_York_Times" title="The New York Times">The New York Times</a></i>: 4.7<span class="printonly">. <a href="http://query.nytimes.com/gst/fullpage.html?res=9F05E5DD1E3EF933A05756C0A9629C8B63&amp;sec=&amp;spon=&amp;pagewanted=all" class="external free" title="http://query.nytimes.com/gst/fullpage.html?res=9F05E5DD1E3EF933A05756C0A9629C8B63&amp;sec=&amp;spon=&amp;pagewanted=all" rel="nofollow">http://query.nytimes.com/gst/fullpage.html?res=9F05E5DD1E3EF933A05756C0A9629C8B63&amp;sec=&amp;spon=&amp;pagewanted=all</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=It+was+medical+gospel%2C+but+it+wasn%27t+true&amp;rft.jtitle=%5B%5BThe+New+York+Times%5D%5D&amp;rft.aulast=Kolota+G&amp;rft.au=Kolota+G&amp;rft.date=May+30%2C+2004&amp;rft.pages=4.7&amp;rft_id=http%3A%2F%2Fquery.nytimes.com%2Fgst%2Ffullpage.html%3Fres%3D9F05E5DD1E3EF933A05756C0A9629C8B63%26sec%3D%26spon%3D%26pagewanted%3Dall&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="" id="CITEREFThompson_IM.2C_Pauler_DK.2C_Goodman_PJ.2C_Tangen_CM.2C_Lucia_MS.2C_Parnes_HL.2C_Minasian_LM.2C_Ford_LG.2C_Lippman_SM.2C_Crawford_ED.2C_Crowley_JJ.2C_Coltman_CA_Jr2004">Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (May 27, 2004). "Prevalence of prostate cancer among men with a prostate-specific antigen level &lt; or =4.0 ng per milliliter". <i><a href="/wiki/New_England_Journal_of_Medicine" title="New England Journal of Medicine">N Engl J Med</a></i> <b>350</b> (22): 2239–46. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15163773" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15163773">PMID 15163773</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prevalence+of+prostate+cancer+among+men+with+a+prostate-specific+antigen+level+%3C+or+%3D4.0+ng+per+milliliter&amp;rft.jtitle=%5B%5BNew+England+Journal+of+Medicine%7CN+Engl+J+Med%5D%5D&amp;rft.aulast=Thompson+IM%2C+Pauler+DK%2C+Goodman+PJ%2C+Tangen+CM%2C+Lucia+MS%2C+Parnes+HL%2C+Minasian+LM%2C+Ford+LG%2C+Lippman+SM%2C+Crawford+ED%2C+Crowley+JJ%2C+Coltman+CA+Jr&amp;rft.au=Thompson+IM%2C+Pauler+DK%2C+Goodman+PJ%2C+Tangen+CM%2C+Lucia+MS%2C+Parnes+HL%2C+Minasian+LM%2C+Ford+LG%2C+Lippman+SM%2C+Crawford+ED%2C+Crowley+JJ%2C+Coltman+CA+Jr&amp;rft.date=May+27%2C+2004&amp;rft.volume=350&amp;rft.issue=22&amp;rft.pages=2239%E2%80%9346&amp;rft_id=info:pmid/15163773&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="" id="CITEREFCarter_HB2004">Carter HB (May 27, 2004). "Prostate cancers in men with low PSA levels--must we find them?". <i><a href="/wiki/New_England_Journal_of_Medicine" title="New England Journal of Medicine">N Engl J Med</a></i> <b>350</b> (22): 2292–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMe048003" class="external text" title="http://dx.doi.org/10.1056%2FNEJMe048003" rel="nofollow">10.1056/NEJMe048003</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15163780" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15163780">PMID 15163780</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate+cancers+in+men+with+low+PSA+levels--must+we+find+them%3F&amp;rft.jtitle=%5B%5BNew+England+Journal+of+Medicine%7CN+Engl+J+Med%5D%5D&amp;rft.aulast=Carter+HB&amp;rft.au=Carter+HB&amp;rft.date=May+27%2C+2004&amp;rft.volume=350&amp;rft.issue=22&amp;rft.pages=2292%E2%80%934&amp;rft_id=info:doi/10.1056%2FNEJMe048003&amp;rft_id=info:pmid/15163780&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="" id="CITEREFCatalona_WJ.2C_Richie_JP.2C_Ahmann_FR.2C_Hudson_MA.2C_Scardino_PT.2C_Flanigan_RC.2C_deKernion_JB.2C_Ratliff_TL.2C_Kavoussi_LR.2C_Dalkin_BL.2C_et_al.1994">Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al. (May 1994). "Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men". <i>J Urol</i> <b>151</b> (5): 1283–90. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7512659" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7512659">PMID 7512659</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Comparison+of+digital+rectal+examination+and+serum+prostate+specific+antigen+in+the+early+detection+of+prostate+cancer%3A+results+of+a+multicenter+clinical+trial+of+6%2C630+men&amp;rft.jtitle=J+Urol&amp;rft.aulast=Catalona+WJ%2C+Richie+JP%2C+Ahmann+FR%2C+Hudson+MA%2C+Scardino+PT%2C+Flanigan+RC%2C+deKernion+JB%2C+Ratliff+TL%2C+Kavoussi+LR%2C+Dalkin+BL%2C+et+al.&amp;rft.au=Catalona+WJ%2C+Richie+JP%2C+Ahmann+FR%2C+Hudson+MA%2C+Scardino+PT%2C+Flanigan+RC%2C+deKernion+JB%2C+Ratliff+TL%2C+Kavoussi+LR%2C+Dalkin+BL%2C+et+al.&amp;rft.date=May+1994&amp;rft.volume=151&amp;rft.issue=5&amp;rft.pages=1283%E2%80%9390&amp;rft_id=info:pmid/7512659&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span><br />
<cite style="font-style:normal" class="web" id="CITEREF.5B.5BFood_and_Drug_Administration.7CFDA.5D.5D1994"><a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration" class="mw-redirect">FDA</a> (August 29, 1994). <a href="http://www.fda.gov/bbs/topics/ANSWERS/ANS00598.html" class="external text" title="http://www.fda.gov/bbs/topics/ANSWERS/ANS00598.html" rel="nofollow">"FDA approves test for prostate cancer"</a><span class="printonly">. <a href="http://www.fda.gov/bbs/topics/ANSWERS/ANS00598.html" class="external free" title="http://www.fda.gov/bbs/topics/ANSWERS/ANS00598.html" rel="nofollow">http://www.fda.gov/bbs/topics/ANSWERS/ANS00598.html</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=FDA+approves+test+for+prostate+cancer&amp;rft.atitle=&amp;rft.aulast=%5B%5BFood+and+Drug+Administration%7CFDA%5D%5D&amp;rft.au=%5B%5BFood+and+Drug+Administration%7CFDA%5D%5D&amp;rft.date=August+29%2C+1994&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fbbs%2Ftopics%2FANSWERS%2FANS00598.html&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-88"><b><a href="#cite_ref-88" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRoobolKranse_R.2C_de_Koning_HJ.2C_Schroder_FH2004">Roobol, MJ; Kranse R, de Koning HJ, Schroder FH (February 2004). "Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM)". <i>Urology</i> <b>63</b> (2): 309–13; discussion 313–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.urology.2003.09.083" class="external text" title="http://dx.doi.org/10.1016%2Fj.urology.2003.09.083" rel="nofollow">10.1016/j.urology.2003.09.083</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14972478" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14972478">PMID 14972478</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate-specific+antigen+velocity+at+low+prostate-specific+antigen+levels+as+screening+tool+for+prostate+cancer%3A+results+of+second+screening+round+of+ERSPC+%28ROTTERDAM%29&amp;rft.jtitle=Urology&amp;rft.aulast=Roobol&amp;rft.aufirst=MJ&amp;rft.au=Roobol%2C+MJ&amp;rft.au=Kranse+R%2C+de+Koning+HJ%2C+Schroder+FH&amp;rft.date=February+2004&amp;rft.volume=63&amp;rft.issue=2&amp;rft.pages=309%E2%80%9313%3B+discussion+313%E2%80%935&amp;rft_id=info:doi/10.1016%2Fj.urology.2003.09.083&amp;rft_id=info:pmid/14972478&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-89"><b><a href="#cite_ref-89" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCatalonaRichie_JP.2C_deKernion_JB.2C_Ahmann_FR.2C_Ratliff_TL.2C_Dalkin_BL.2C_Kavoussi_LR.2C_MacFarlane_MT.2C_Southwick_PC1994">Catalona, WJ; Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, Kavoussi LR, MacFarlane MT, Southwick PC (December 1994). "Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves". <i>J Urol</i> <b>152</b> (6 Pt 1): 2031–6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7525994" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7525994">PMID 7525994</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Comparison+of+prostate+specific+antigen+concentration+versus+prostate+specific+antigen+density+in+the+early+detection+of+prostate+cancer%3A+receiver+operating+characteristic+curves&amp;rft.jtitle=J+Urol&amp;rft.aulast=Catalona&amp;rft.aufirst=WJ&amp;rft.au=Catalona%2C+WJ&amp;rft.au=Richie+JP%2C+deKernion+JB%2C+Ahmann+FR%2C+Ratliff+TL%2C+Dalkin+BL%2C+Kavoussi+LR%2C+MacFarlane+MT%2C+Southwick+PC&amp;rft.date=December+1994&amp;rft.volume=152&amp;rft.issue=6+Pt+1&amp;rft.pages=2031%E2%80%936&amp;rft_id=info:pmid/7525994&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-90"><b><a href="#cite_ref-90" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHoffmanClanon_DL.2C_Littenberg_B.2C_Frank_JJ.2C_Peirce_JC2000">Hoffman, RM; Clanon DL, Littenberg B, Frank JJ, Peirce JC (October 2000). "Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels". <i>J Gen Intern Med</i> <b>15</b> (10): 739–48. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1046%2Fj.1525-1497.2000.90907.x" class="external text" title="http://dx.doi.org/10.1046%2Fj.1525-1497.2000.90907.x" rel="nofollow">10.1046/j.1525-1497.2000.90907.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11089718" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11089718">PMID 11089718</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Using+the+free-to-total+prostate-specific+antigen+ratio+to+detect+prostate+cancer+in+men+with+nonspecific+elevations+of+prostate-specific+antigen+levels&amp;rft.jtitle=J+Gen+Intern+Med&amp;rft.aulast=Hoffman&amp;rft.aufirst=RM&amp;rft.au=Hoffman%2C+RM&amp;rft.au=Clanon+DL%2C+Littenberg+B%2C+Frank+JJ%2C+Peirce+JC&amp;rft.date=October+2000&amp;rft.volume=15&amp;rft.issue=10&amp;rft.pages=739%E2%80%9348&amp;rft_id=info:doi/10.1046%2Fj.1525-1497.2000.90907.x&amp;rft_id=info:pmid/11089718&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-91"><b><a href="#cite_ref-91" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPartinBrawer_MK.3B_Bartsch_G.3B_Horninger_W.3B_Taneja_SS.3B_Lepor_H.3B_Babaian_R.3B_Childs_SJ.3B_Stamey_T.3B_Fritsche_HA.3B_Sokoll_L.3B_Chan_DW.3B_Thiel_RP.3B_Cheli_CD2003">Partin, AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD (November 2003). "Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial". <i>J Urol</i> <b>170</b> (5): 1787–91. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.ju.0000092695.55705.dd" class="external text" title="http://dx.doi.org/10.1097%2F01.ju.0000092695.55705.dd" rel="nofollow">10.1097/01.ju.0000092695.55705.dd</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14532777" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14532777">PMID 14532777</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Complexed+prostate+specific+antigen+improves+specificity+for+prostate+cancer+detection%3A+results+of+a+prospective+multicenter+clinical+trial&amp;rft.jtitle=J+Urol&amp;rft.aulast=Partin&amp;rft.aufirst=AW&amp;rft.au=Partin%2C+AW&amp;rft.au=Brawer+MK%3B+Bartsch+G%3B+Horninger+W%3B+Taneja+SS%3B+Lepor+H%3B+Babaian+R%3B+Childs+SJ%3B+Stamey+T%3B+Fritsche+HA%3B+Sokoll+L%3B+Chan+DW%3B+Thiel+RP%3B+Cheli+CD&amp;rft.date=November+2003&amp;rft.volume=170&amp;rft.issue=5&amp;rft.pages=1787%E2%80%9391&amp;rft_id=info:doi/10.1097%2F01.ju.0000092695.55705.dd&amp;rft_id=info:pmid/14532777&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid16314889-92"><b><a href="#cite_ref-pmid16314889_92-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMouraviev_V.2C_Evans_B.2C_Polascik_TJ2006">Mouraviev V, Evans B, Polascik TJ (2006). "Salvage prostate cryoablation after primary interstitial brachytherapy failure: a feasible approach". <i>Prostate Cancer Prostatic Dis.</i> <b>9</b> (1): 99–101. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1038%2Fsj.pcan.4500853" class="external text" title="http://dx.doi.org/10.1038%2Fsj.pcan.4500853" rel="nofollow">10.1038/sj.pcan.4500853</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16314889" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16314889">PMID 16314889</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Salvage+prostate+cryoablation+after+primary+interstitial+brachytherapy+failure%3A+a+feasible+approach&amp;rft.jtitle=Prostate+Cancer+Prostatic+Dis.&amp;rft.aulast=Mouraviev+V%2C+Evans+B%2C+Polascik+TJ&amp;rft.au=Mouraviev+V%2C+Evans+B%2C+Polascik+TJ&amp;rft.date=2006&amp;rft.volume=9&amp;rft.issue=1&amp;rft.pages=99%E2%80%93101&amp;rft_id=info:doi/10.1038%2Fsj.pcan.4500853&amp;rft_id=info:pmid/16314889&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-93"><b><a href="#cite_ref-93" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.shavemagazine.com/body/health/090401/2" class="external text" title="http://www.shavemagazine.com/body/health/090401/2" rel="nofollow">"Prostate Cancer At A Glance"</a>. <a href="http://www.shavemagazine.com/" class="external text" title="http://www.shavemagazine.com/" rel="nofollow">ShaveMagazine.com</a><span class="printonly">. <a href="http://www.shavemagazine.com/body/health/090401/2" class="external free" title="http://www.shavemagazine.com/body/health/090401/2" rel="nofollow">http://www.shavemagazine.com/body/health/090401/2</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Prostate+Cancer+At+A+Glance&amp;rft.atitle=&amp;rft.pub=%5Bhttp%3A%2F%2Fwww.shavemagazine.com%2F+ShaveMagazine.com%5D&amp;rft_id=http%3A%2F%2Fwww.shavemagazine.com%2Fbody%2Fhealth%2F090401%2F2&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-94"><b><a href="#cite_ref-94" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWuSun_L.2C_Moul_JW.2C_Wu_HY.2C_McLeod_DG.2C_Amling_C.2C_Lance_R.2C_Kusuda_L.2C_Donahue_T.2C_Foley_J.2C_Chung_A.2C_Sexton_W.2C_Soderdahl_D2004">Wu, H; Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D (March 2004). "Watchful waiting and factors predictive of secondary treatment of localized prostate cancer". <i>J Urol</i> <b>171</b> (3): 1111–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.ju.0000113300.74132.8b" class="external text" title="http://dx.doi.org/10.1097%2F01.ju.0000113300.74132.8b" rel="nofollow">10.1097/01.ju.0000113300.74132.8b</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14767282" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14767282">PMID 14767282</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Watchful+waiting+and+factors+predictive+of+secondary+treatment+of+localized+prostate+cancer&amp;rft.jtitle=J+Urol&amp;rft.aulast=Wu&amp;rft.aufirst=H&amp;rft.au=Wu%2C+H&amp;rft.au=Sun+L%2C+Moul+JW%2C+Wu+HY%2C+McLeod+DG%2C+Amling+C%2C+Lance+R%2C+Kusuda+L%2C+Donahue+T%2C+Foley+J%2C+Chung+A%2C+Sexton+W%2C+Soderdahl+D&amp;rft.date=March+2004&amp;rft.volume=171&amp;rft.issue=3&amp;rft.pages=1111%E2%80%936&amp;rft_id=info:doi/10.1097%2F01.ju.0000113300.74132.8b&amp;rft_id=info:pmid/14767282&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-95"><b><a href="#cite_ref-95" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRobsonDawson_N1996">Robson, M; Dawson N (June 1996). "How is androgen-dependent metastatic prostate cancer best treated?". <i>Hematol Oncol Clin North Am</i> <b>10</b> (3): 727–47. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0889-8588%2805%2970364-6" class="external text" title="http://dx.doi.org/10.1016%2FS0889-8588%2805%2970364-6" rel="nofollow">10.1016/S0889-8588(05)70364-6</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8773508" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8773508">PMID 8773508</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=How+is+androgen-dependent+metastatic+prostate+cancer+best+treated%3F&amp;rft.jtitle=Hematol+Oncol+Clin+North+Am&amp;rft.aulast=Robson&amp;rft.aufirst=M&amp;rft.au=Robson%2C+M&amp;rft.au=Dawson+N&amp;rft.date=June+1996&amp;rft.volume=10&amp;rft.issue=3&amp;rft.pages=727%E2%80%9347&amp;rft_id=info:doi/10.1016%2FS0889-8588%2805%2970364-6&amp;rft_id=info:pmid/8773508&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Review.</li>
<li id="cite_note-96"><b><a href="#cite_ref-96" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLoblawMendelson_DS.2C_Talcott_JA.2C_Virgo_KS.2C_Somerfield_MR.2C_Ben-Josef_E.2C_Middleton_R.2C_Porterfield_H.2C_Sharp_SA.2C_Smith_TJ.2C_Taplin_ME.2C_Vogelzang_NJ.2C_Wade_JL_Jr.2C_Bennett_CL.2C_Scher_HI.3B_American_Society_of_Clinical_Oncology2004">Loblaw, DA; Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI; American Society of Clinical Oncology (July 15 2004). "American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer". <i>J Clin Oncol</i> <b>22</b> (14): 2927–41. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1200%2FJCO.2004.04.579" class="external text" title="http://dx.doi.org/10.1200%2FJCO.2004.04.579" rel="nofollow">10.1200/JCO.2004.04.579</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15184404" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15184404">PMID 15184404</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=American+Society+of+Clinical+Oncology+recommendations+for+the+initial+hormonal+management+of+androgen-sensitive+metastatic%2C+recurrent%2C+or+progressive+prostate+cancer&amp;rft.jtitle=J+Clin+Oncol&amp;rft.aulast=Loblaw&amp;rft.aufirst=DA&amp;rft.au=Loblaw%2C+DA&amp;rft.au=Mendelson+DS%2C+Talcott+JA%2C+Virgo+KS%2C+Somerfield+MR%2C+Ben-Josef+E%2C+Middleton+R%2C+Porterfield+H%2C+Sharp+SA%2C+Smith+TJ%2C+Taplin+ME%2C+Vogelzang+NJ%2C+Wade+JL+Jr%2C+Bennett+CL%2C+Scher+HI%3B+American+Society+of+Clinical+Oncology&amp;rft.date=July+15+2004&amp;rft.volume=22&amp;rft.issue=14&amp;rft.pages=2927%E2%80%9341&amp;rft_id=info:doi/10.1200%2FJCO.2004.04.579&amp;rft_id=info:pmid/15184404&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Erratum in: J Clin Oncol. 2004 November 1;22(21):4435.</li>
<li id="cite_note-97"><b><a href="#cite_ref-97" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFde_BonoGerhardt_Attard.2C_Alison_H.M._Reid.2C_Timothy_A._Yap.2C_Florence_Raynaud.2C_Mitch_Dowsett.2C_Sarah_Settatree.2C_Mary_Barrett.2C_Christopher_Parker.2C_Vanessa_Martins.2C_Elizabeth_Folkerd.2C_Jeremy_Clark.2C_Colin_S._Cooper.2C_Stan_B._Kaye.2C_David_Dearnaley.2C_Gloria_Lee2004">de Bono, Johann; Gerhardt Attard, Alison H.M. Reid, Timothy A. Yap, Florence Raynaud, Mitch Dowsett, Sarah Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, Jeremy Clark, Colin S. Cooper, Stan B. Kaye, David Dearnaley, Gloria Lee (July 21 2004). "<a href="http://jco.ascopubs.org/cgi/content/abstract/JCO.2007.15.9749v1" class="external text" title="http://jco.ascopubs.org/cgi/content/abstract/JCO.2007.15.9749v1" rel="nofollow">Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven</a>". <i>J Clin Oncol</i>: online. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1200%2FJCO.2007.15.9749" class="external text" title="http://dx.doi.org/10.1200%2FJCO.2007.15.9749" rel="nofollow">10.1200/JCO.2007.15.9749</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15184404" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15184404">PMID 15184404</a><span class="printonly">. <a href="http://jco.ascopubs.org/cgi/content/abstract/JCO.2007.15.9749v1" class="external free" title="http://jco.ascopubs.org/cgi/content/abstract/JCO.2007.15.9749v1" rel="nofollow">http://jco.ascopubs.org/cgi/content/abstract/JCO.2007.15.9749v1</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Phase+I+Clinical+Trial+of+a+Selective+Inhibitor+of+CYP17%2C+Abiraterone+Acetate%2C+Confirms+That+Castration-Resistant+Prostate+Cancer+Commonly+Remains+Hormone+Driven&amp;rft.jtitle=J+Clin+Oncol&amp;rft.aulast=de+Bono&amp;rft.aufirst=Johann&amp;rft.au=de+Bono%2C+Johann&amp;rft.au=Gerhardt+Attard%2C+Alison+H.M.+Reid%2C+Timothy+A.+Yap%2C+Florence+Raynaud%2C+Mitch+Dowsett%2C+Sarah+Settatree%2C+Mary+Barrett%2C+Christopher+Parker%2C+Vanessa+Martins%2C+Elizabeth+Folkerd%2C+Jeremy+Clark%2C+Colin+S.+Cooper%2C+Stan+B.+Kaye%2C+David+Dearnaley%2C+Gloria+Lee&amp;rft.date=July+21+2004&amp;rft.pages=online&amp;rft_id=info:doi/10.1200%2FJCO.2007.15.9749&amp;rft_id=info:pmid/15184404&amp;rft_id=http%3A%2F%2Fjco.ascopubs.org%2Fcgi%2Fcontent%2Fabstract%2FJCO.2007.15.9749v1&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Erratum in: J Clin Oncol. Early Release, published ahead of print July 21, 2008</li>
<li id="cite_note-98"><b><a href="#cite_ref-98" title="">^</a></b> <cite style="font-style:normal" class="news" id="CITEREFRichard_Warry2008">Richard Warry (July 22, 2008). <a href="http://news.bbc.co.uk/2/hi/health/7517414.stm" class="external text" title="http://news.bbc.co.uk/2/hi/health/7517414.stm" rel="nofollow">"Drug for deadly prostate cancer"</a>. <a href="/wiki/BBC" title="BBC">BBC</a><span class="printonly">. <a href="http://news.bbc.co.uk/2/hi/health/7517414.stm" class="external free" title="http://news.bbc.co.uk/2/hi/health/7517414.stm" rel="nofollow">http://news.bbc.co.uk/2/hi/health/7517414.stm</a></span><span class="reference-accessdate">. Retrieved on 2008-07-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Drug+for+deadly+prostate+cancer&amp;rft.atitle=&amp;rft.aulast=Richard+Warry&amp;rft.au=Richard+Warry&amp;rft.date=July+22%2C+2008&amp;rft.pub=%5B%5BBBC%5D%5D&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F2%2Fhi%2Fhealth%2F7517414.stm&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15888698-99"><b><a href="#cite_ref-pmid15888698_99-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBill-Axelson_A.2C_Holmberg_L.2C_Ruutu_M.2C_.27.27et_al.27.272005">Bill-Axelson A, Holmberg L, Ruutu M, <i>et al</i> (2005). "Radical prostatectomy versus watchful waiting in early prostate cancer". <i>N. Engl. J. Med.</i> <b>352</b> (19): 1977–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa043739" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa043739" rel="nofollow">10.1056/NEJMoa043739</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15888698" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15888698">PMID 15888698</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Radical+prostatectomy+versus+watchful+waiting+in+early+prostate+cancer&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.aulast=Bill-Axelson+A%2C+Holmberg+L%2C+Ruutu+M%2C+%27%27et+al%27%27&amp;rft.au=Bill-Axelson+A%2C+Holmberg+L%2C+Ruutu+M%2C+%27%27et+al%27%27&amp;rft.date=2005&amp;rft.volume=352&amp;rft.issue=19&amp;rft.pages=1977%E2%80%9384&amp;rft_id=info:doi/10.1056%2FNEJMoa043739&amp;rft_id=info:pmid/15888698&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-100"><b><a href="#cite_ref-100" title="">^</a></b> PreventProstateCancer.info: A Brief Overview of Prostate Cancer <a href="http://www.preventprostatecancer.info/Articles/files/5e098219e5c93597247a2f997a4c677f-1.html" class="external autonumber" title="http://www.preventprostatecancer.info/Articles/files/5e098219e5c93597247a2f997a4c677f-1.html" rel="nofollow">[3]</a></li>
<li id="cite_note-101"><b><a href="#cite_ref-101" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.patentstorm.us/patents/5334181.html" class="external text" title="http://www.patentstorm.us/patents/5334181.html" rel="nofollow">"Cryosurgical system for destroying tumors by freezing"</a><span class="printonly">. <a href="http://www.patentstorm.us/patents/5334181.html" class="external free" title="http://www.patentstorm.us/patents/5334181.html" rel="nofollow">http://www.patentstorm.us/patents/5334181.html</a></span><span class="reference-accessdate">. Retrieved on 1994-08-02</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Cryosurgical+system+for+destroying+tumors+by+freezing&amp;rft.atitle=&amp;rft_id=http%3A%2F%2Fwww.patentstorm.us%2Fpatents%2F5334181.html&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-102"><b><a href="#cite_ref-102" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBahnLee_F.2C_Badalament_R.2C_Kumar_A.2C_Greski_J.2C_Chernick_M2002">Bahn, DK; Lee F, Badalament R, Kumar A, Greski J, Chernick M (August 2002). "Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer". <i>Urology</i> <b>60</b> (2 Suppl 1): 3–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0090-4295%2802%2901678-3" class="external text" title="http://dx.doi.org/10.1016%2FS0090-4295%2802%2901678-3" rel="nofollow">10.1016/S0090-4295(02)01678-3</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12206842" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12206842">PMID 12206842</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Targeted+cryoablation+of+the+prostate%3A+7-year+outcomes+in+the+primary+treatment+of+prostate+cancer&amp;rft.jtitle=Urology&amp;rft.aulast=Bahn&amp;rft.aufirst=DK&amp;rft.au=Bahn%2C+DK&amp;rft.au=Lee+F%2C+Badalament+R%2C+Kumar+A%2C+Greski+J%2C+Chernick+M&amp;rft.date=August+2002&amp;rft.volume=60&amp;rft.issue=2+Suppl+1&amp;rft.pages=3%E2%80%9311&amp;rft_id=info:doi/10.1016%2FS0090-4295%2802%2901678-3&amp;rft_id=info:pmid/12206842&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-103"><b><a href="#cite_ref-103" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGerberThisted_RA.2C_Scardino_PT.2C_Frohmuller_HG.2C_Schroeder_FH.2C_Paulson_DF.2C_Middleton_AW_Jr.2C_Rukstalis_DB.2C_Smith_JA_Jr.2C_Schellhammer_PF.2C_Ohori_M.2C_Chodak_GW1996">Gerber, GS; Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW (August 28 1996). "Results of radical prostatectomy in men with clinically localized prostate cancer". <i>JAMA</i> <b>276</b> (8): 615–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.276.8.615" class="external text" title="http://dx.doi.org/10.1001%2Fjama.276.8.615" rel="nofollow">10.1001/jama.276.8.615</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8773633" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8773633">PMID 8773633</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Results+of+radical+prostatectomy+in+men+with+clinically+localized+prostate+cancer&amp;rft.jtitle=JAMA&amp;rft.aulast=Gerber&amp;rft.aufirst=GS&amp;rft.au=Gerber%2C+GS&amp;rft.au=Thisted+RA%2C+Scardino+PT%2C+Frohmuller+HG%2C+Schroeder+FH%2C+Paulson+DF%2C+Middleton+AW+Jr%2C+Rukstalis+DB%2C+Smith+JA+Jr%2C+Schellhammer+PF%2C+Ohori+M%2C+Chodak+GW&amp;rft.date=August+28+1996&amp;rft.volume=276&amp;rft.issue=8&amp;rft.pages=615%E2%80%939&amp;rft_id=info:doi/10.1001%2Fjama.276.8.615&amp;rft_id=info:pmid/8773633&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-104"><b><a href="#cite_ref-104" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFNagBeyer_D.2C_Friedland_J.2C_Grimm_P.2C_Nath_R1999">Nag, S; Beyer D, Friedland J, Grimm P, Nath R (? 1999). "American Brachytherapy Society Recommendations for Transperineal Permanent Brachytherapy of Prostate Cancer". <i>Int. J. Rad. Onc. Biol. Phys.</i> <b>44</b> (4): 789–799.&#160;?.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=American+Brachytherapy+Society+Recommendations+for+Transperineal+Permanent+Brachytherapy+of+Prostate+Cancer&amp;rft.jtitle=Int.+J.+Rad.+Onc.+Biol.+Phys.&amp;rft.aulast=Nag&amp;rft.aufirst=S&amp;rft.au=Nag%2C+S&amp;rft.au=Beyer+D%2C+Friedland+J%2C+Grimm+P%2C+Nath+R&amp;rft.date=%3F+1999&amp;rft.volume=44&amp;rft.issue=4&amp;rft.pages=789%E2%80%93799&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Review.</li>
<li id="cite_note-105"><b><a href="#cite_ref-105" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPerezHanks_GE.2C_Leibel_SA.2C_Zietman_AL.2C_Fuks_Z.2C_Lee_WR1993">Perez, CA; Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee WR (December 1 1993). "Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy". <i>Cancer</i> <b>72</b> (11): 3156–73. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2F1097-0142%2819931201%2972%3A11%3C3156%3A%3AAID-CNCR2820721106%3E3.0.CO%3B2-G" class="external text" title="http://dx.doi.org/10.1002%2F1097-0142%2819931201%2972%3A11%3C3156%3A%3AAID-CNCR2820721106%3E3.0.CO%3B2-G" rel="nofollow">10.1002/1097-0142(19931201)72:11&lt;3156::AID-CNCR2820721106&gt;3.0.CO;2-G</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7694785" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7694785">PMID 7694785</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Localized+carcinoma+of+the+prostate+%28stages+T1B%2C+T1C%2C+T2%2C+and+T3%29.+Review+of+management+with+external+beam+radiation+therapy&amp;rft.jtitle=Cancer&amp;rft.aulast=Perez&amp;rft.aufirst=CA&amp;rft.au=Perez%2C+CA&amp;rft.au=Hanks+GE%2C+Leibel+SA%2C+Zietman+AL%2C+Fuks+Z%2C+Lee+WR&amp;rft.date=December+1+1993&amp;rft.volume=72&amp;rft.issue=11&amp;rft.pages=3156%E2%80%9373&amp;rft_id=info:doi/10.1002%2F1097-0142%2819931201%2972%3A11%3C3156%3A%3AAID-CNCR2820721106%3E3.0.CO%3B2-G&amp;rft_id=info:pmid/7694785&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Review.</li>
<li id="cite_note-106"><b><a href="#cite_ref-106" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFD.27Amico_AV.2C_Manola_J.2C_Loffredo_M.2C_Renshaw_AA.2C_DellaCroce_A.2C_Kantoff_PW2004">D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004). "6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial". <i>JAMA</i> <b>292</b> (7): 821–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.292.7.821" class="external text" title="http://dx.doi.org/10.1001%2Fjama.292.7.821" rel="nofollow">10.1001/jama.292.7.821</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15315996" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15315996">PMID 15315996</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=6-month+androgen+suppression+plus+radiation+therapy+vs+radiation+therapy+alone+for+patients+with+clinically+localized+prostate+cancer%3A+a+randomized+controlled+trial&amp;rft.jtitle=JAMA&amp;rft.aulast=D%27Amico+AV%2C+Manola+J%2C+Loffredo+M%2C+Renshaw+AA%2C+DellaCroce+A%2C+Kantoff+PW&amp;rft.au=D%27Amico+AV%2C+Manola+J%2C+Loffredo+M%2C+Renshaw+AA%2C+DellaCroce+A%2C+Kantoff+PW&amp;rft.date=2004&amp;rft.volume=292&amp;rft.issue=7&amp;rft.pages=821%E2%80%937&amp;rft_id=info:doi/10.1001%2Fjama.292.7.821&amp;rft_id=info:pmid/15315996&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-107"><b><a href="#cite_ref-107" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFThompson_IM.2C_Tangen_CM.2C_Paradelo_J2009">Thompson IM, Tangen CM, Paradelo J (2009). "Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.". <i>J Urol</i> <b>181</b>: 956-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19167731" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/19167731">PMID 19167731</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Adjuvant+radiotherapy+for+pathological+T3N0M0+prostate+cancer+significantly+reduces+risk+of+metastases+and+improves+survival%3A+long-term+followup+of+a+randomized+clinical+trial.&amp;rft.jtitle=J+Urol&amp;rft.aulast=Thompson+IM%2C+Tangen+CM%2C+Paradelo+J&amp;rft.au=Thompson+IM%2C+Tangen+CM%2C+Paradelo+J&amp;rft.date=2009&amp;rft.volume=181&amp;rft.pages=956-62&amp;rft_id=info:pmid/19167731&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-108"><b><a href="#cite_ref-108" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKupelian2002">Kupelian, PA title=Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. (2002). <i>J Clinc Oncol</i> <b>20</b> (16). <a href="http://www.ncbi.nlm.nih.gov/pubmed/12177097" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12177097">PMID 12177097</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=&amp;rft.jtitle=J+Clinc+Oncol&amp;rft.aulast=Kupelian&amp;rft.aufirst=PA+title%3DComparison+of+the+efficacy+of+local+therapies+for+localized+prostate+cancer+in+the+prostate-specific+antigen+era%3A+a+large+single-institution+experience+with+radical+prostatectomy+and+external-beam+radiotherapy.&amp;rft.au=Kupelian%2C+PA+title%3DComparison+of+the+efficacy+of+local+therapies+for+localized+prostate+cancer+in+the+prostate-specific+antigen+era%3A+a+large+single-institution+experience+with+radical+prostatectomy+and+external-beam+radiotherapy.&amp;rft.date=2002&amp;rft.volume=20&amp;rft.issue=16&amp;rft_id=info:pmid/12177097&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-109"><b><a href="#cite_ref-109" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLawtonWon_M.2C_Pilepich_MV.2C_Asbell_SO.2C_Shipley_WU.2C_Hanks_GE.2C_Cox_JD.2C_Perez_CA.2C_Sause_WT.2C_Doggett_SR.2C_et_al1991">Lawton, CA; Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR, et al (September 1991). "Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706". <i>Int J Radiat Oncol Biol Phys</i> <b>21</b> (4): 935–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1917622" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1917622">PMID 1917622</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Long-term+treatment+sequelae+following+external+beam+irradiation+for+adenocarcinoma+of+the+prostate%3A+analysis+of+RTOG+studies+7506+and+7706&amp;rft.jtitle=Int+J+Radiat+Oncol+Biol+Phys&amp;rft.aulast=Lawton&amp;rft.aufirst=CA&amp;rft.au=Lawton%2C+CA&amp;rft.au=Won+M%2C+Pilepich+MV%2C+Asbell+SO%2C+Shipley+WU%2C+Hanks+GE%2C+Cox+JD%2C+Perez+CA%2C+Sause+WT%2C+Doggett+SR%2C+et+al&amp;rft.date=September+1991&amp;rft.volume=21&amp;rft.issue=4&amp;rft.pages=935%E2%80%939&amp;rft_id=info:pmid/1917622&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-110"><b><a href="#cite_ref-110" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBrennerCurtis_RE.2C_Hall_EJ.2C_Ron_E2000">Brenner, DJ; Curtis RE, Hall EJ, Ron E (January 15 2000). "Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery". <i>Cancer</i> <b>88</b> (2): 398–406. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2F%28SICI%291097-0142%2820000115%2988%3A2%3C398%3A%3AAID-CNCR22%3E3.0.CO%3B2-V" class="external text" title="http://dx.doi.org/10.1002%2F%28SICI%291097-0142%2820000115%2988%3A2%3C398%3A%3AAID-CNCR22%3E3.0.CO%3B2-V" rel="nofollow">10.1002/(SICI)1097-0142(20000115)88:2&lt;398::AID-CNCR22&gt;3.0.CO;2-V</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10640974" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10640974">PMID 10640974</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Second+malignancies+in+prostate+carcinoma+patients+after+radiotherapy+compared+with+surgery&amp;rft.jtitle=Cancer&amp;rft.aulast=Brenner&amp;rft.aufirst=DJ&amp;rft.au=Brenner%2C+DJ&amp;rft.au=Curtis+RE%2C+Hall+EJ%2C+Ron+E&amp;rft.date=January+15+2000&amp;rft.volume=88&amp;rft.issue=2&amp;rft.pages=398%E2%80%93406&amp;rft_id=info:doi/10.1002%2F%28SICI%291097-0142%2820000115%2988%3A2%3C398%3A%3AAID-CNCR22%3E3.0.CO%3B2-V&amp;rft_id=info:pmid/10640974&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Thomas-A-111">^ <a href="#cite_ref-Thomas-A_111-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Thomas-A_111-1" title=""><sup><i><b>b</b></i></sup></a> Thomas A. Gardner and Michael A Koch, Indiana University Medical Center, Indianapolis. Prostate Cancer Therapy with High-Intensity Focused Ultrasound-Comprehensive Review. Clinical Genitourinary Cancer Vol 4. No.3, 2005.</li>
<li id="cite_note-Toyoaki-Uchida-112">^ <a href="#cite_ref-Toyoaki-Uchida_112-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Toyoaki-Uchida_112-1" title=""><sup><i><b>b</b></i></sup></a> Toyoaki Uchida, et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Dept of Urology University of Tokai Hachioji Hospital. International Journal of Urology</li>
<li id="cite_note-113"><b><a href="#cite_ref-113" title="">^</a></b> Tom Pickles, Larry Goldenberg, Gary Steinhoff. High Intensity Focused Ultrasound for Prostate Cancer. British Columbia Cancer Agency <a href="http://www.bccancer.bc.ca/NR/rdonlyres/08EA1C8E-4345-4C7E-A83A-1F84853A1C27/8101/HIFUreport2005Feb10revised1.pdf" class="external free" title="http://www.bccancer.bc.ca/NR/rdonlyres/08EA1C8E-4345-4C7E-A83A-1F84853A1C27/8101/HIFUreport2005Feb10revised1.pdf" rel="nofollow">http://www.bccancer.bc.ca/NR/rdonlyres/08EA1C8E-4345-4C7E-A83A-1F84853A1C27/8101/HIFUreport2005Feb10revised1.pdf</a></li>
<li id="cite_note-114"><b><a href="#cite_ref-114" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTannockde_Wit_R.2C_Berry_WR.2C_Horti_J.2C_Pluzanska_A.2C_Chi_KN.2C_Oudard_S.2C_Theodore_C.2C_James_ND.2C_Turesson_I.2C_Rosenthal_MA.2C_Eisenberger_MA.3B_TAX_327_Investigators2004">Tannock, IF; de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators (October 7 2004). "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer". <i>N Engl J Med</i> <b>351</b> (15): 1502–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1056%2FNEJMoa040720" class="external text" title="http://dx.doi.org/10.1056%2FNEJMoa040720" rel="nofollow">10.1056/NEJMoa040720</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1547021" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1547021">PMID 1547021</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Docetaxel+plus+prednisone+or+mitoxantrone+plus+prednisone+for+advanced+prostate+cancer&amp;rft.jtitle=N+Engl+J+Med&amp;rft.aulast=Tannock&amp;rft.aufirst=IF&amp;rft.au=Tannock%2C+IF&amp;rft.au=de+Wit+R%2C+Berry+WR%2C+Horti+J%2C+Pluzanska+A%2C+Chi+KN%2C+Oudard+S%2C+Theodore+C%2C+James+ND%2C+Turesson+I%2C+Rosenthal+MA%2C+Eisenberger+MA%3B+TAX+327+Investigators&amp;rft.date=October+7+2004&amp;rft.volume=351&amp;rft.issue=15&amp;rft.pages=1502%E2%80%9312&amp;rft_id=info:doi/10.1056%2FNEJMoa040720&amp;rft_id=info:pmid/1547021&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-115"><b><a href="#cite_ref-115" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSaad_F.2C_Gleason_DM.2C_Murray_R.2C_Tchekmedyian_S.2C_Venner_P.2C_Lacombe_L.2C_Chin_JL.2C_Vinholes_JJ.2C_Goas_JA.2C_Chen_B2002">Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002). "A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma". <i>J Natl Cancer Inst</i> <b>94</b> (19): 1458–68. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12359855" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12359855">PMID 12359855</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+randomized%2C+placebo-controlled+trial+of+zoledronic+acid+in+patients+with+hormone-refractory+metastatic+prostate+carcinoma&amp;rft.jtitle=J+Natl+Cancer+Inst&amp;rft.aulast=Saad+F%2C+Gleason+DM%2C+Murray+R%2C+Tchekmedyian+S%2C+Venner+P%2C+Lacombe+L%2C+Chin+JL%2C+Vinholes+JJ%2C+Goas+JA%2C+Chen+B&amp;rft.au=Saad+F%2C+Gleason+DM%2C+Murray+R%2C+Tchekmedyian+S%2C+Venner+P%2C+Lacombe+L%2C+Chin+JL%2C+Vinholes+JJ%2C+Goas+JA%2C+Chen+B&amp;rft.date=2002&amp;rft.volume=94&amp;rft.issue=19&amp;rft.pages=1458%E2%80%9368&amp;rft_id=info:pmid/12359855&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-116"><b><a href="#cite_ref-116" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFOrnishWeidner_G.2C_Fair_WR.2C_et_al.2005">Ornish, D; Weidner G, Fair WR, et al. (2005). "Intensive lifestyle changes may affect the progression of prostate cancer". <i>J Urol</i> <b>174</b> (3): 1065–70. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16094059" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16094059">PMID 16094059</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Intensive+lifestyle+changes+may+affect+the+progression+of+prostate+cancer&amp;rft.jtitle=J+Urol&amp;rft.aulast=Ornish&amp;rft.aufirst=D&amp;rft.au=Ornish%2C+D&amp;rft.au=Weidner+G%2C+Fair+WR%2C+et+al.&amp;rft.date=2005&amp;rft.volume=174&amp;rft.issue=3&amp;rft.pages=1065%E2%80%9370&amp;rft_id=info:pmid/16094059&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-117"><b><a href="#cite_ref-117" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFFrattaroliWeidner_G.2C_Kemp_C.2C_et_al.2008">Frattaroli, J; Weidner G, Kemp C, et al. (July 2008). "Clinical events in Prostate CAncer Lifestyle Trial: Results from two years of follow-up". <i>Urology</i> <b>epub ahead of print</b>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18602144" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18602144">PMID 18602144</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Clinical+events+in+Prostate+CAncer+Lifestyle+Trial%3A+Results+from+two+years+of+follow-up&amp;rft.jtitle=Urology&amp;rft.aulast=Frattaroli&amp;rft.aufirst=J&amp;rft.au=Frattaroli%2C+J&amp;rft.au=Weidner+G%2C+Kemp+C%2C+et+al.&amp;rft.date=July+2008&amp;rft.volume=epub+ahead+of+print&amp;rft_id=info:pmid/18602144&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-118"><b><a href="#cite_ref-118" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPantuckLeppert_JT.2C_Zomorodian_N.2C_et_al.2006">Pantuck, AJ; Leppert JT, Zomorodian N, et al. (2006). "Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer". <i>Clin Cancer Res</i> <b>12</b> (13): 4018–26. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16818701" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16818701">PMID 16818701</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Phase+II+study+of+pomegranate+juice+for+men+with+rising+prostate-specific+antigen+following+surgery+or+radiation+for+prostate+cancer&amp;rft.jtitle=Clin+Cancer+Res&amp;rft.aulast=Pantuck&amp;rft.aufirst=AJ&amp;rft.au=Pantuck%2C+AJ&amp;rft.au=Leppert+JT%2C+Zomorodian+N%2C+et+al.&amp;rft.date=2006&amp;rft.volume=12&amp;rft.issue=13&amp;rft.pages=4018%E2%80%9326&amp;rft_id=info:pmid/16818701&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-119"><b><a href="#cite_ref-119" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKumarCantor_A.2C_Allen_K.2C_et_al.2004">Kumar, NB; Cantor A, Allen K, et al. (2004). "The specific role of isoflavones in reducing prostate cancer risk". <i>Prostate</i> <b>59</b> (2): 141–7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15042614" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15042614">PMID 15042614</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+specific+role+of+isoflavones+in+reducing+prostate+cancer+risk&amp;rft.jtitle=Prostate&amp;rft.aulast=Kumar&amp;rft.aufirst=NB&amp;rft.au=Kumar%2C+NB&amp;rft.au=Cantor+A%2C+Allen+K%2C+et+al.&amp;rft.date=2004&amp;rft.volume=59&amp;rft.issue=2&amp;rft.pages=141%E2%80%937&amp;rft_id=info:pmid/15042614&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-120"><b><a href="#cite_ref-120" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFYarnell1999">Yarnell, E (1999). "A naturopathic approach to prostate cancer. Part 2: Guidelines for treatment and prevention". <i>Altern Complemen Ther</i> <b>5</b> (6): 360–8.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+naturopathic+approach+to+prostate+cancer.+Part+2%3A+Guidelines+for+treatment+and+prevention&amp;rft.jtitle=Altern+Complemen+Ther&amp;rft.aulast=Yarnell&amp;rft.aufirst=E&amp;rft.au=Yarnell%2C+E&amp;rft.date=1999&amp;rft.volume=5&amp;rft.issue=6&amp;rft.pages=360%E2%80%938&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-121"><b><a href="#cite_ref-121" title="">^</a></b> <a href="http://yedda.com/questions/Low_fat_milk_causes_prostate_cancer_7351021963170/" class="external free" title="http://yedda.com/questions/Low_fat_milk_causes_prostate_cancer_7351021963170/" rel="nofollow">http://yedda.com/questions/Low_fat_milk_causes_prostate_cancer_7351021963170/</a></li>
<li id="cite_note-122"><b><a href="#cite_ref-122" title="">^</a></b> <a href="http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_prostate_cancer_36.asp" class="external text" title="http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_prostate_cancer_36.asp" rel="nofollow">ACS&#160;:: What Are The Risk Factors for Prostate Cancer?</a></li>
<li id="cite_note-123"><b><a href="#cite_ref-123" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFJemalMurray_T.3B_Ward_E.3B_Samuels_A.3B_Tiwari_RC.3B_Ghafoor_A.3B_Feuer_EJ.3B_Thun_MJ2005">Jemal, A; Murray T; Ward E; Samuels A; Tiwari RC; Ghafoor A; Feuer EJ; Thun MJ (Jan-February 2005). "Cancer statistics, 2005". <i>CA Cancer J Clin</i> <b>55</b> (1): 10–30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15661684" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15661684">PMID 15661684</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cancer+statistics%2C+2005&amp;rft.jtitle=CA+Cancer+J+Clin&amp;rft.aulast=Jemal&amp;rft.aufirst=A&amp;rft.au=Jemal%2C+A&amp;rft.au=Murray+T%3B+Ward+E%3B+Samuels+A%3B+Tiwari+RC%3B+Ghafoor+A%3B+Feuer+EJ%3B+Thun+MJ&amp;rft.date=Jan-February+2005&amp;rft.volume=55&amp;rft.issue=1&amp;rft.pages=10%E2%80%9330&amp;rft_id=info:pmid/15661684&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Erratum in: CA Cancer J Clin. 2005 Jul-Aug;55(4):259.</li>
<li id="cite_note-124"><b><a href="#cite_ref-124" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWakai2005">Wakai, K (February 2005). "Descriptive epidemiology of prostate cancer in Japan and Western countries". <i>Nippon Rinsho</i> <b>63</b> (2): 207–12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15714967" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15714967">PMID 15714967</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Descriptive+epidemiology+of+prostate+cancer+in+Japan+and+Western+countries&amp;rft.jtitle=Nippon+Rinsho&amp;rft.aulast=Wakai&amp;rft.aufirst=K&amp;rft.au=Wakai%2C+K&amp;rft.date=February+2005&amp;rft.volume=63&amp;rft.issue=2&amp;rft.pages=207%E2%80%9312&amp;rft_id=info:pmid/15714967&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span> Review. <span class="languageicon" style="font-size:0.95em; font-weight:bold; color:#555;">(Japanese)</span></li>
<li id="cite_note-125"><b><a href="#cite_ref-125" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFYeoleSunny_L2001">Yeole, BB; Sunny L (Jun-December 2001). "Population based survival from prostate cancer in Mumbai (Bombay), India". <i>Indian J Cancer</i> <b>38</b> (2–4): 126–32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1259345" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1259345">PMID 1259345</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Population+based+survival+from+prostate+cancer+in+Mumbai+%28Bombay%29%2C+India&amp;rft.jtitle=Indian+J+Cancer&amp;rft.aulast=Yeole&amp;rft.aufirst=BB&amp;rft.au=Yeole%2C+BB&amp;rft.au=Sunny+L&amp;rft.date=Jun-December+2001&amp;rft.volume=38&amp;rft.issue=2%E2%80%934&amp;rft.pages=126%E2%80%9332&amp;rft_id=info:pmid/1259345&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-126"><b><a href="#cite_ref-126" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHsingTsao_L.2C_Devesa_SS2000">Hsing, AW; Tsao L, Devesa SS (January 1 2000). "International trends and patterns of prostate cancer incidence and mortality". <i>Int J Cancer</i> <b>85</b> (1): 60–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2F%28SICI%291097-0215%2820000101%2985%3A1%3C60%3A%3AAID-IJC11%3E3.0.CO%3B2-B" class="external text" title="http://dx.doi.org/10.1002%2F%28SICI%291097-0215%2820000101%2985%3A1%3C60%3A%3AAID-IJC11%3E3.0.CO%3B2-B" rel="nofollow">10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10585584" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10585584">PMID 10585584</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=International+trends+and+patterns+of+prostate+cancer+incidence+and+mortality&amp;rft.jtitle=Int+J+Cancer&amp;rft.aulast=Hsing&amp;rft.aufirst=AW&amp;rft.au=Hsing%2C+AW&amp;rft.au=Tsao+L%2C+Devesa+SS&amp;rft.date=January+1+2000&amp;rft.volume=85&amp;rft.issue=1&amp;rft.pages=60%E2%80%937&amp;rft_id=info:doi/10.1002%2F%28SICI%291097-0215%2820000101%2985%3A1%3C60%3A%3AAID-IJC11%3E3.0.CO%3B2-B&amp;rft_id=info:pmid/10585584&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-127"><b><a href="#cite_ref-127" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFOsegbe1997">Osegbe, DN (April 1997). "Prostate cancer in Nigerians: facts and nonfacts". <i>J Urol</i> <b>157</b> (4): 1340–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0022-5347%2801%2964966-8" class="external text" title="http://dx.doi.org/10.1016%2FS0022-5347%2801%2964966-8" rel="nofollow">10.1016/S0022-5347(01)64966-8</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9120935" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9120935">PMID 9120935</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prostate+cancer+in+Nigerians%3A+facts+and+nonfacts&amp;rft.jtitle=J+Urol&amp;rft.aulast=Osegbe&amp;rft.aufirst=DN&amp;rft.au=Osegbe%2C+DN&amp;rft.date=April+1997&amp;rft.volume=157&amp;rft.issue=4&amp;rft.pages=1340%E2%80%933&amp;rft_id=info:doi/10.1016%2FS0022-5347%2801%2964966-8&amp;rft_id=info:pmid/9120935&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-128"><b><a href="#cite_ref-128" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDi_Blasio_CJ.2C_Rhee_AC.2C_Cho_D.2C_Scardino_PT.2C_Kattan_MW2003">Di Blasio CJ, Rhee AC, Cho D, Scardino PT, Kattan MW (2003). "Predicting clinical end points: treatment nomograms in prostate cancer". <i>Semin Oncol</i> <b>30</b> (5): 567–86. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0093-7754%2803%2900351-8" class="external text" title="http://dx.doi.org/10.1016%2FS0093-7754%2803%2900351-8" rel="nofollow">10.1016/S0093-7754(03)00351-8</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14571407" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14571407">PMID 14571407</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Predicting+clinical+end+points%3A+treatment+nomograms+in+prostate+cancer&amp;rft.jtitle=Semin+Oncol&amp;rft.aulast=Di+Blasio+CJ%2C+Rhee+AC%2C+Cho+D%2C+Scardino+PT%2C+Kattan+MW&amp;rft.au=Di+Blasio+CJ%2C+Rhee+AC%2C+Cho+D%2C+Scardino+PT%2C+Kattan+MW&amp;rft.date=2003&amp;rft.volume=30&amp;rft.issue=5&amp;rft.pages=567%E2%80%9386&amp;rft_id=info:doi/10.1016%2FS0093-7754%2803%2900351-8&amp;rft_id=info:pmid/14571407&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-129"><b><a href="#cite_ref-129" title="">^</a></b> Huggins C, Steven RE and Hodges CV, Studies on prostatic cancer. Arch. Sug. 43:209–223, 1941.</li>
<li id="cite_note-130"><b><a href="#cite_ref-130" title="">^</a></b> Hellerstedt BA and Pienta KJ, The current state of hormonal therapy for prostate cancer, CA Cancer J. Clin. 52: 154–179, 2002.<a href="http://www.ncbi.nlm.nih.gov/pubmed/12018929" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12018929">PMID 12018929</a></li>
<li id="cite_note-131"><b><a href="#cite_ref-131" title="">^</a></b> Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001 Oct;1(1):34–45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11900250" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11900250">PMID 11900250</a></li>
<li id="cite_note-132"><b><a href="#cite_ref-132" title="">^</a></b> Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005 March 15;65(6):2082–4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15781616" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15781616">PMID 15781616</a></li>
<li id="cite_note-133"><b><a href="#cite_ref-133" title="">^</a></b> Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 2006 July 1;66(13):6482–6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16818617" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16818617">PMID 16818617</a></li>
<li id="cite_note-134"><b><a href="#cite_ref-134" title="">^</a></b> Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A. 2001 August 28;98(18):10350-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11504910" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11504910">PMID 11504910</a></li>
<li id="cite_note-135"><b><a href="#cite_ref-135" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCooperberg_MR.2C_Pasta_DJ.2C_Elkin_EP.2C_.27.27et_al.27.272005">Cooperberg MR, Pasta DJ, Elkin EP, <i>et al</i> (June 2005). "The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy". <i>J. Urol.</i> <b>173</b> (6): 1938–42. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.ju.0000158155.33890.e7" class="external text" title="http://dx.doi.org/10.1097%2F01.ju.0000158155.33890.e7" rel="nofollow">10.1097/01.ju.0000158155.33890.e7</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15879786" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15879786">PMID 15879786</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+University+of+California%2C+San+Francisco+Cancer+of+the+Prostate+Risk+Assessment+score%3A+a+straightforward+and+reliable+preoperative+predictor+of+disease+recurrence+after+radical+prostatectomy&amp;rft.jtitle=J.+Urol.&amp;rft.aulast=Cooperberg+MR%2C+Pasta+DJ%2C+Elkin+EP%2C+%27%27et+al%27%27&amp;rft.au=Cooperberg+MR%2C+Pasta+DJ%2C+Elkin+EP%2C+%27%27et+al%27%27&amp;rft.date=June+2005&amp;rft.volume=173&amp;rft.issue=6&amp;rft.pages=1938%E2%80%9342&amp;rft_id=info:doi/10.1097%2F01.ju.0000158155.33890.e7&amp;rft_id=info:pmid/15879786&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-136"><b><a href="#cite_ref-136" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCooperberg_MR.2C_Freedland_SJ.2C_Pasta_DJ.2C_.27.27et_al.27.272006">Cooperberg MR, Freedland SJ, Pasta DJ, <i>et al</i> (November 2006). "Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy". <i>Cancer</i> <b>107</b> (10): 2384–91. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2Fcncr.22262" class="external text" title="http://dx.doi.org/10.1002%2Fcncr.22262" rel="nofollow">10.1002/cncr.22262</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17039503" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17039503">PMID 17039503</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Multiinstitutional+validation+of+the+UCSF+cancer+of+the+prostate+risk+assessment+for+prediction+of+recurrence+after+radical+prostatectomy&amp;rft.jtitle=Cancer&amp;rft.aulast=Cooperberg+MR%2C+Freedland+SJ%2C+Pasta+DJ%2C+%27%27et+al%27%27&amp;rft.au=Cooperberg+MR%2C+Freedland+SJ%2C+Pasta+DJ%2C+%27%27et+al%27%27&amp;rft.date=November+2006&amp;rft.volume=107&amp;rft.issue=10&amp;rft.pages=2384%E2%80%9391&amp;rft_id=info:doi/10.1002%2Fcncr.22262&amp;rft_id=info:pmid/17039503&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-137"><b><a href="#cite_ref-137" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMay_M.2C_Knoll_N.2C_Siegsmund_M.2C_.27.27et_al.27.272007">May M, Knoll N, Siegsmund M, <i>et al</i> (November 2007). "Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients". <i>J. Urol.</i> <b>178</b> (5): 1957–62; discussion 1962. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.juro.2007.07.043" class="external text" title="http://dx.doi.org/10.1016%2Fj.juro.2007.07.043" rel="nofollow">10.1016/j.juro.2007.07.043</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17868719" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17868719">PMID 17868719</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Validity+of+the+CAPRA+score+to+predict+biochemical+recurrence-free+survival+after+radical+prostatectomy.+Results+from+a+european+multicenter+survey+of+1%2C296+patients&amp;rft.jtitle=J.+Urol.&amp;rft.aulast=May+M%2C+Knoll+N%2C+Siegsmund+M%2C+%27%27et+al%27%27&amp;rft.au=May+M%2C+Knoll+N%2C+Siegsmund+M%2C+%27%27et+al%27%27&amp;rft.date=November+2007&amp;rft.volume=178&amp;rft.issue=5&amp;rft.pages=1957%E2%80%9362%3B+discussion+1962&amp;rft_id=info:doi/10.1016%2Fj.juro.2007.07.043&amp;rft_id=info:pmid/17868719&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-138"><b><a href="#cite_ref-138" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFZhao_KH.2C_Hernandez_DJ.2C_Han_M.2C_Humphreys_EB.2C_Mangold_LA.2C_Partin_AW2008">Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW (August 2008). "External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score". <i>Urology</i> <b>72</b> (2): 396–400. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.urology.2007.11.165" class="external text" title="http://dx.doi.org/10.1016%2Fj.urology.2007.11.165" rel="nofollow">10.1016/j.urology.2007.11.165</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18372031" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18372031">PMID 18372031</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=External+validation+of+University+of+California%2C+San+Francisco%2C+Cancer+of+the+Prostate+Risk+Assessment+score&amp;rft.jtitle=Urology&amp;rft.aulast=Zhao+KH%2C+Hernandez+DJ%2C+Han+M%2C+Humphreys+EB%2C+Mangold+LA%2C+Partin+AW&amp;rft.au=Zhao+KH%2C+Hernandez+DJ%2C+Han+M%2C+Humphreys+EB%2C+Mangold+LA%2C+Partin+AW&amp;rft.date=August+2008&amp;rft.volume=72&amp;rft.issue=2&amp;rft.pages=396%E2%80%93400&amp;rft_id=info:doi/10.1016%2Fj.urology.2007.11.165&amp;rft_id=info:pmid/18372031&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-139"><b><a href="#cite_ref-139" title="">^</a></b> <a href="http://www.cancer.org/docroot/CRI/content/CRI_2_2_2X_What_causes_prostate_cancer_36.asp?sitearea=" class="external text" title="http://www.cancer.org/docroot/CRI/content/CRI_2_2_2X_What_causes_prostate_cancer_36.asp?sitearea=" rel="nofollow">Overview: Prostate Cancer—What Causes Prostate Cancer?</a> American Cancer Society (<span class="mw-formatted-date" title="2006-05-02"><a href="/wiki/2006" title="2006">2006</a>-<a href="/wiki/May_2" title="May 2">05-02</a></span>). Retrieved on <span class="mw-formatted-date" title="2007-04-05"><a href="/wiki/2007" title="2007">2007</a>-<a href="/wiki/April_5" title="April 5">04-05</a></span></li>
<li id="cite_note-140"><b><a href="#cite_ref-140" title="">^</a></b> <a href="http://www.hsc.stonybrook.edu/som/urology/urology_cp_prostatecancer.cfm" class="external text" title="http://www.hsc.stonybrook.edu/som/urology/urology_cp_prostatecancer.cfm" rel="nofollow">Prostate Cancer FAQs.</a> State University of New York School of Medicine Department of Urology (<span class="mw-formatted-date" title="2006-08-31"><a href="/wiki/2006" title="2006">2006</a>-<a href="/wiki/August_31" title="August 31">08-31</a></span>). Retrieved on <span class="mw-formatted-date" title="2007-04-05"><a href="/wiki/2007" title="2007">2007</a>-<a href="/wiki/April_5" title="April 5">04-05</a></span></li>
<li id="cite_note-141"><b><a href="#cite_ref-141" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPotosky_A.2C_Miller_B.2C_Albertsen_P.2C_Kramer_B1995">Potosky A, Miller B, Albertsen P, Kramer B (1995). "The role of increasing detection in the rising incidence of prostate cancer". <i><a href="/wiki/Journal_of_the_American_Medical_Association" title="Journal of the American Medical Association">JAMA</a></i> <b>273</b> (7): 548–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.273.7.548" class="external text" title="http://dx.doi.org/10.1001%2Fjama.273.7.548" rel="nofollow">10.1001/jama.273.7.548</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7530782" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7530782">PMID 7530782</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+role+of+increasing+detection+in+the+rising+incidence+of+prostate+cancer&amp;rft.jtitle=%5B%5BJournal+of+the+American+Medical+Association%7CJAMA%5D%5D&amp;rft.aulast=Potosky+A%2C+Miller+B%2C+Albertsen+P%2C+Kramer+B&amp;rft.au=Potosky+A%2C+Miller+B%2C+Albertsen+P%2C+Kramer+B&amp;rft.date=1995&amp;rft.volume=273&amp;rft.issue=7&amp;rft.pages=548%26ndash%3B52&amp;rft_id=info:doi/10.1001%2Fjama.273.7.548&amp;rft_id=info:pmid/7530782&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-142"><b><a href="#cite_ref-142" title="">^</a></b> <cite style="font-style:normal" class="news" id="CITEREFGine_Kolata2008">Gine Kolata (June 15, 2008). <a href="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" class="external text" title="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" rel="nofollow">"New Take on a Prostate Drug, and a New Debate"</a>. <a href="/wiki/NY_Times" title="NY Times" class="mw-redirect">NY Times</a><span class="printonly">. <a href="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" class="external free" title="http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A" rel="nofollow">http://www.nytimes.com/2008/06/15/health/15prostate.html?ei=5087&amp;em=&amp;en=813eaa4e10f57756&amp;ex=1213675200&amp;adxnnl=1&amp;adxnnlx=1213503418-GD4DbGjYsDxqV/xuGWnE1A</a></span><span class="reference-accessdate">. Retrieved on 2008-06-15</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=New+Take+on+a+Prostate+Drug%2C+and+a+New+Debate&amp;rft.atitle=&amp;rft.aulast=Gine+Kolata&amp;rft.au=Gine+Kolata&amp;rft.date=June+15%2C+2008&amp;rft.pub=%5B%5BNY+Times%5D%5D&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2008%2F06%2F15%2Fhealth%2F15prostate.html%3Fei%3D5087%26em%3D%26en%3D813eaa4e10f57756%26ex%3D1213675200%26adxnnl%3D1%26adxnnlx%3D1213503418-GD4DbGjYsDxqV%2FxuGWnE1A&amp;rfr_id=info:sid/en.wikipedia.org:Prostate_cancer"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-143"><b><a href="#cite_ref-143" title="">^</a></b> Adams, J. <i>The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis.</i> Lancet 1, 393 (1853).</li>
<li id="cite_note-144"><b><a href="#cite_ref-144" title="">^</a></b> Lytton, B. <i>Prostate cancer: a brief history and the discovery of hormonal ablation treatment.</i> J. Urol. 165, 1859–1862</li>
<li id="cite_note-145"><b><a href="#cite_ref-145" title="">^</a></b> Young, H. H. <i>Four cases of radical prostatectomy.</i> Johns Hopkins Bull. 16, 315 (1905).</li>
<li id="cite_note-146"><b><a href="#cite_ref-146" title="">^</a></b> Walsh, P. C., Lepor, H. &amp; Eggleston, J. C. <i>Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations.</i> Prostate 4, 473-485 (1983). <a href="http://www.ncbi.nlm.nih.gov/pubmed/6889192" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/6889192">PMID 6889192</a></li>
<li id="cite_note-147"><b><a href="#cite_ref-147" title="">^</a></b> Huggins, C. B. &amp; Hodges, C. V. <i>Studies on prostate cancer: 1. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.</i> Cancer Res. 1, 203 (1941).</li>
<li id="cite_note-148"><b><a href="#cite_ref-148" title="">^</a></b> Schally, A. V., Kastin, A. J. &amp; Arimura, A. <i>Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies.</i> Fertil. Steril. 22, 703–721 (1971).</li>
<li id="cite_note-149"><b><a href="#cite_ref-149" title="">^</a></b> Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV. <i>Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.</i> Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–62 <a href="http://www.ncbi.nlm.nih.gov/pubmed/6461861" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/6461861">PMID 6461861</a></li>
<li id="cite_note-150"><b><a href="#cite_ref-150" title="">^</a></b> Denmeade SR, Isaacs JT. <i>A History of Prostate Cancer Treatment.</i> Nature Reviews Cancer 2, 389–396 (2002). <a href="http://www.ncbi.nlm.nih.gov/pubmed/12044015" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12044015">PMID 12044015</a></li>
<li id="cite_note-151"><b><a href="#cite_ref-151" title="">^</a></b> Scott, W. W. et al. <i>Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study.</i> J. Urol. 114, 909–911 (1975). <a href="http://www.ncbi.nlm.nih.gov/pubmed/1104900" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/1104900">PMID 1104900</a></li>
<li id="cite_note-152"><b><a href="#cite_ref-152" title="">^</a></b> Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001 May 1;61(9):3550–5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11325816" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11325816">PMID 11325816</a></li>
<li id="cite_note-153"><b><a href="#cite_ref-153" title="">^</a></b> Ford OH 3rd, Gregory CW, Kim D, Smitherman AB, Mohler JL. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol. 2003 Nov;170(5):1817–21.<a href="http://www.ncbi.nlm.nih.gov/pubmed/14532783" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14532783">PMID 14532783</a></li>
<li id="cite_note-154"><b><a href="#cite_ref-154" title="">^</a></b> Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994 March 15;54(6):1566–73. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7511045" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/7511045">PMID 7511045</a></li>
<li id="cite_note-155"><b><a href="#cite_ref-155" title="">^</a></b> Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996 October 15;93(21):11802-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8876218" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/8876218">PMID 8876218</a></li>
<li id="cite_note-156"><b><a href="#cite_ref-156" title="">^</a></b> Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate. 2005 December 1;65(4):287-98. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16015608" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16015608">PMID 16015608</a></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Prostate_cancer&amp;action=edit&amp;section=48" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.youtube.com/watch?v=gqEOYBNnqb4" class="external text" title="http://www.youtube.com/watch?v=gqEOYBNnqb4" rel="nofollow">Prostate Cancer &amp; Endothelin</a>: PMAP <a href="/wiki/The_Proteolysis_Map" title="The Proteolysis Map">The Proteolysis Map</a>-animation</li>
<li><a href="http://www.dmoz.org/Health/Conditions_and_Diseases/Cancer/Genitourinary/Prostate//" class="external text" title="http://www.dmoz.org/Health/Conditions_and_Diseases/Cancer/Genitourinary/Prostate//" rel="nofollow">Prostate cancer</a> at the <a href="/wiki/Open_Directory_Project" title="Open Directory Project">Open Directory Project</a></li>
</ul>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";background:Silver" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;background:Silver;border:none;; font-size:xx-small;"><a href="/wiki/Template:Genital_neoplasia" title="Template:Genital neoplasia"><span title="View this template" style=";background:Silver;border:none;">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="/w/index.php?title=Template_talk:Genital_neoplasia&amp;action=edit&amp;redlink=1" class="new" title="Template talk:Genital neoplasia (page does not exist)"><span title="Discussion about this template" style=";background:Silver;border:none;">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:Genital_neoplasia&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:Genital_neoplasia&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";background:Silver;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="/wiki/Tumor" title="Tumor">Tumors</a>: <a href="/wiki/Urogenital_neoplasm" title="Urogenital neoplasm">urogenital neoplasia</a><span style="font-weight:bold;">&#160;·</span> genital neoplasia (<a href="/wiki/ICD-10_Chapter_II:_Neoplasms#.28C50-C58.29_Malignant_neoplasms.2C_breast_and_female_genital_organs" title="ICD-10 Chapter II: Neoplasms">C51-C63/D25-29</a>, <a href="/wiki/List_of_ICD-9_codes_140-239:_Neoplasms#malignant_neoplasm_of_genitourinary_organs_.28179-189.29" title="List of ICD-9 codes 140-239: Neoplasms" class="mw-redirect">179-187/218-222</a>)</span></th>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:#BBEEBB;;"><a href="/wiki/Female_reproductive_system_(human)" title="Female reproductive system (human)">Female</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Ovarian_cancer" title="Ovarian cancer">Ovaries</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Glandular_and_epithelial_neoplasm" title="Glandular and epithelial neoplasm">Glandular and epithelial</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Clear_cell_adenocarcinoma" title="Clear cell adenocarcinoma">Clear cell adenocarcinoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Endometrioid_tumor" title="Endometrioid tumor">Endometrioid tumor</a><br />
<a href="/wiki/Cystic,_mucinous,_and_serous_neoplasms" title="Cystic, mucinous, and serous neoplasms">CMS</a>: <a href="/wiki/Krukenberg_tumor" title="Krukenberg tumor">Krukenberg tumor</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Serous_cystadenoma" title="Serous cystadenoma">Serous cystadenoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Mucinous_cystadenoma" title="Mucinous cystadenoma">Mucinous cystadenoma</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Sex_cord-gonadal_stromal_tumour" title="Sex cord-gonadal stromal tumour">Sex cord-gonadal stromal</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Sertoli-Leydig_cell_tumour" title="Sertoli-Leydig cell tumour">Sertoli-Leydig cell tumour</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Thecoma" title="Thecoma">Thecoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Granulosa_cell_tumour" title="Granulosa cell tumour">Granulosa cell tumour</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Luteoma" title="Luteoma">Luteoma</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Connective_tissue_neoplasm" title="Connective tissue neoplasm">Connective tissue</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Fibroma#Ovarian_fibroma" title="Fibroma">Fibroma</a> (<a href="/wiki/Meigs_syndrome" title="Meigs syndrome">Meigs syndrome</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Surface_epithelial-stromal_tumor" title="Surface epithelial-stromal tumor">Surface epithelial-stromal tumor</a> (<a href="/wiki/Brenner_tumour" title="Brenner tumour">Brenner tumour</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Germ_cell_tumor" title="Germ cell tumor">Germ cell</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Embryonal_carcinoma" title="Embryonal carcinoma">Embryonal carcinoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Gonadoblastoma" title="Gonadoblastoma">Gonadoblastoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Teratoma" title="Teratoma">Teratoma</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Fallopian_tube_cancer" title="Fallopian tube cancer">Fallopian tube</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Adenomatoid_tumor" title="Adenomatoid tumor">Adenomatoid tumor</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Uterine_cancer" title="Uterine cancer">Uterus</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Uterine_sarcoma" title="Uterine sarcoma">Uterine sarcoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Leiomyosarcoma" title="Leiomyosarcoma">Leiomyosarcoma</a>
<p><a href="/wiki/Endometrial_cancer" title="Endometrial cancer">Endometrium</a> (<a href="/wiki/Endometrioid_tumor" title="Endometrioid tumor">Endometrioid tumor</a>), (<a href="/wiki/Uterine_papillary_serous_carcinoma" title="Uterine papillary serous carcinoma">Uterine papillary serous carcinoma</a>), (<a href="/wiki/Uterine_clear_cell_carcinoma" title="Uterine clear cell carcinoma">Clear cell carcinoma</a>)</p>
<p><a href="/wiki/Adenomyoma" title="Adenomyoma">Adenomyoma</a></p>
<a href="/wiki/Cervical_cancer" title="Cervical cancer">Cervix</a> (<a href="/wiki/Squamous_cell_carcinoma#Vagina_and_cervix" title="Squamous cell carcinoma">SCC</a>, <a href="/wiki/Cervical_intraepithelial_neoplasia" title="Cervical intraepithelial neoplasia">Cervical intraepithelial neoplasia</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Vaginal_cancer" title="Vaginal cancer">Vagina</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Squamous_cell_carcinoma#Vagina_and_cervix" title="Squamous cell carcinoma">SCC</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Botryoid_rhabdomyosarcoma" title="Botryoid rhabdomyosarcoma" class="mw-redirect">Botryoid rhabdomyosarcoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Adenocarcinoma" title="Adenocarcinoma">Adenocarcinoma</a>/<a href="/wiki/Clear_cell_adenocarcinoma" title="Clear cell adenocarcinoma">Clear cell adenocarcinoma</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Vulvar_cancer" title="Vulvar cancer">Vulva</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Papillary_hidradenoma" title="Papillary hidradenoma">Papillary hidradenoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Extramammary_Paget%27s_disease" title="Extramammary Paget's disease">Extramammary Paget's disease</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Placenta" title="Placenta">Placenta</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Choriocarcinoma" title="Choriocarcinoma">Choriocarcinoma</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background:#BBEEBB;;"><a href="/wiki/Male_reproductive_system_(human)" title="Male reproductive system (human)">Male</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Testicular_cancer" title="Testicular cancer">Testicles</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Sex_cord-gonadal_stromal_tumour" title="Sex cord-gonadal stromal tumour">Sex cord-gonadal stromal</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Sertoli-Leydig_cell_tumour" title="Sertoli-Leydig cell tumour">Sertoli-Leydig cell tumour</a> (<a href="/wiki/Sertoli_cell_tumor" title="Sertoli cell tumor">Sertoli cell tumor</a>, <a href="/wiki/Leydig_cell_tumor" title="Leydig cell tumor">Leydig cell tumor</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Germ_cell_tumor" title="Germ cell tumor">Germ cell</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Seminoma" title="Seminoma">Seminoma</a> (<a href="/wiki/Spermatocytic_seminoma" title="Spermatocytic seminoma">Spermatocytic seminoma</a>)<span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Endodermal_sinus_tumor" title="Endodermal sinus tumor">Endodermal sinus tumor</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Embryonal_carcinoma" title="Embryonal carcinoma">Embryonal carcinoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Gonadoblastoma" title="Gonadoblastoma">Gonadoblastoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Teratoma" title="Teratoma">Teratoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Embryoma" title="Embryoma">Embryoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Intratubular_germ_cell_neoplasia" title="Intratubular germ cell neoplasia">Intratubular germ cell neoplasia</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Choriocarcinoma" title="Choriocarcinoma">Choriocarcinoma</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><strong class="selflink">Prostate</strong></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Adenocarcinoma" title="Adenocarcinoma">Adenocarcinoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Transitional_cell_carcinoma" title="Transitional cell carcinoma">Transitional cell carcinoma</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Prostatic_intraepithelial_neoplasia" title="Prostatic intraepithelial neoplasia">Prostatic intraepithelial neoplasia</a><span style="font-weight:bold;">&#160;·</span> <a href="/wiki/Small_cell_carcinoma" title="Small cell carcinoma">Small cell carcinoma</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background-color: #BBEEBB;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Penis_cancer" title="Penis cancer" class="mw-redirect">Penis</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Carcinoma_of_the_penis" title="Carcinoma of the penis">Carcinoma</a> (<a href="/wiki/Extramammary_Paget%27s_disease" title="Extramammary Paget's disease">Extramammary Paget's disease</a>)</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i>See also <a href="/wiki/Template:Diseases_of_the_pelvis_and_genitals" title="Template:Diseases of the pelvis and genitals">noncongenital</a>, <a href="/wiki/Template:Congenital_malformations_of_genital_organs" title="Template:Congenital malformations of genital organs">congenital</a></i></div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<div style="right:10px; display:none;" class="metadata topicon" id="featured-star">
<div><a href="/wiki/Wikipedia:Featured_articles" title="This is a featured article. Click here for more information."><img alt="Featured article" src="http://upload.wikimedia.org/wikipedia/en/6/60/LinkFA-star.png" width="14" height="14" border="0" /></a></div>
</div>
<p><span id="interwiki-ca-fa"></span> <span id="interwiki-de-fa"></span></p>


<!-- 
NewPP limit report
Preprocessor node count: 69161/1000000
Post-expand include size: 697815/2048000 bytes
Template argument size: 279483/2048000 bytes
Expensive parser function count: 0/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:88078-0!1!0!default!!en!2 and timestamp 20090406013827 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Prostate_cancer">http://en.wikipedia.org/wiki/Prostate_cancer</a>"</div>
			<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="/wiki/Category:Urology" title="Category:Urology">Urology</a></span> | <span dir='ltr'><a href="/wiki/Category:Types_of_cancer" title="Category:Types of cancer">Types of cancer</a></span> | <span dir='ltr'><a href="/wiki/Category:Deaths_from_prostate_cancer" title="Category:Deaths from prostate cancer">Deaths from prostate cancer</a></span></div><div id="mw-hidden-catlinks" class="mw-hidden-cats-hidden">Hidden categories:&#32;<span dir='ltr'><a href="/wiki/Category:Featured_articles" title="Category:Featured articles">Featured articles</a></span></div></div>			<!-- end content -->
						<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
	
				 <li id="ca-nstab-main" class="selected"><a href="/wiki/Prostate_cancer" title="View the content page [c]" accesskey="c">Article</a></li>
				 <li id="ca-talk"><a href="/wiki/Talk:Prostate_cancer" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
				 <li id="ca-edit"><a href="/w/index.php?title=Prostate_cancer&amp;action=edit" title="You can edit this page. &#10;Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
				 <li id="ca-history"><a href="/w/index.php?title=Prostate_cancer&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>			</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Prostate_cancer" title="You are encouraged to log in; however, it is not mandatory. [o]" accesskey="o">Log in / create account</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(http://upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
	<div class='generated-sidebar portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
				<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content — the best of Wikipedia">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
	<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/w/index.php" id="searchform"><div>
				<input type='hidden' name="title" value="Special:Search"/>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search Wikipedia for this text" />
			</div></form>
		</div>
	</div>
	<div class='generated-sidebar portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Prostate_cancer" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Prostate_cancer" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Prostate_cancer&amp;printable=yes" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Prostate_cancer&amp;oldid=282009217" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Prostate_cancer&amp;id=282009217">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-af"><a href="http://af.wikipedia.org/wiki/Prostaatkanker">Afrikaans</a></li>
				<li class="interwiki-bn"><a href="http://bn.wikipedia.org/wiki/%E0%A6%AA%E0%A7%8D%E0%A6%B0%E0%A7%8B%E0%A6%B8%E0%A7%8D%E0%A6%9F%E0%A7%87%E0%A6%9F_%E0%A6%95%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A7%8D%E0%A6%B8%E0%A6%BE%E0%A6%B0">বাংলা</a></li>
				<li class="interwiki-bg"><a href="http://bg.wikipedia.org/wiki/%D0%A0%D0%B0%D0%BA_%D0%BD%D0%B0_%D0%BF%D1%80%D0%BE%D1%81%D1%82%D0%B0%D1%82%D0%B0%D1%82%D0%B0">Български</a></li>
				<li class="interwiki-ca"><a href="http://ca.wikipedia.org/wiki/C%C3%A0ncer_de_pr%C3%B2stata">Català</a></li>
				<li class="interwiki-da"><a href="http://da.wikipedia.org/wiki/Prostatakr%C3%A6ft">Dansk</a></li>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Prostatakrebs">Deutsch</a></li>
				<li class="interwiki-dv"><a href="http://dv.wikipedia.org/wiki/%DE%95%DE%B0%DE%83%DE%AE%DE%90%DE%B0%DE%93%DE%AD%DE%93%DE%B0_%DE%86%DE%AC%DE%82%DE%B0%DE%90%DE%A6%DE%83%DE%AA">ދިވެހިބަސް</a></li>
				<li class="interwiki-el"><a href="http://el.wikipedia.org/wiki/%CE%9A%CE%B1%CF%81%CE%BA%CE%AF%CE%BD%CE%BF%CF%82_%CF%84%CE%BF%CF%85_%CF%80%CF%81%CE%BF%CF%83%CF%84%CE%AC%CF%84%CE%B7">Ελληνικά</a></li>
				<li class="interwiki-es"><a href="http://es.wikipedia.org/wiki/C%C3%A1ncer_de_pr%C3%B3stata">Español</a></li>
				<li class="interwiki-fa"><a href="http://fa.wikipedia.org/wiki/%D8%B3%D8%B1%D8%B7%D8%A7%D9%86_%D9%BE%D8%B1%D9%88%D8%B3%D8%AA%D8%A7%D8%AA">فارسی</a></li>
				<li class="interwiki-fr"><a href="http://fr.wikipedia.org/wiki/Cancer_de_la_prostate">Français</a></li>
				<li class="interwiki-hr"><a href="http://hr.wikipedia.org/wiki/Rak_prostate">Hrvatski</a></li>
				<li class="interwiki-id"><a href="http://id.wikipedia.org/wiki/Kanker_prostat">Bahasa Indonesia</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Carcinoma_della_prostata">Italiano</a></li>
				<li class="interwiki-he"><a href="http://he.wikipedia.org/wiki/%D7%A1%D7%A8%D7%98%D7%9F_%D7%94%D7%A2%D7%A8%D7%9E%D7%95%D7%A0%D7%99%D7%AA">עברית</a></li>
				<li class="interwiki-la"><a href="http://la.wikipedia.org/wiki/Cancer_prostatae">Latina</a></li>
				<li class="interwiki-lv"><a href="http://lv.wikipedia.org/wiki/Prostatas_v%C4%93zis">Latviešu</a></li>
				<li class="interwiki-nl"><a href="http://nl.wikipedia.org/wiki/Prostaatkanker">Nederlands</a></li>
				<li class="interwiki-ja"><a href="http://ja.wikipedia.org/wiki/%E5%89%8D%E7%AB%8B%E8%85%BA%E7%99%8C">日本語</a></li>
				<li class="interwiki-no"><a href="http://no.wikipedia.org/wiki/Prostatakreft">‪Norsk (bokmål)‬</a></li>
				<li class="interwiki-pl"><a href="http://pl.wikipedia.org/wiki/Rak_gruczo%C5%82u_krokowego">Polski</a></li>
				<li class="interwiki-pt"><a href="http://pt.wikipedia.org/wiki/C%C3%A2ncer_de_pr%C3%B3stata">Português</a></li>
				<li class="interwiki-ru"><a href="http://ru.wikipedia.org/wiki/%D0%A0%D0%B0%D0%BA_%D0%BF%D1%80%D0%BE%D1%81%D1%82%D0%B0%D1%82%D1%8B">Русский</a></li>
				<li class="interwiki-simple"><a href="http://simple.wikipedia.org/wiki/Prostate_cancer">Simple English</a></li>
				<li class="interwiki-fi"><a href="http://fi.wikipedia.org/wiki/Eturauhassy%C3%B6p%C3%A4">Suomi</a></li>
				<li class="interwiki-sv"><a href="http://sv.wikipedia.org/wiki/Prostatacancer">Svenska</a></li>
				<li class="interwiki-tl"><a href="http://tl.wikipedia.org/wiki/Kanser_sa_prostata">Tagalog</a></li>
				<li class="interwiki-tr"><a href="http://tr.wikipedia.org/wiki/Prostat_kanseri">Türkçe</a></li>
				<li class="interwiki-zh"><a href="http://zh.wikipedia.org/wiki/%E5%89%8D%E5%88%97%E8%85%BA%E7%99%8C">中文</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
					<li id="lastmod"> This page was last modified on 6 April 2009, at 01:36.</li>
					<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc.</a>, a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
					<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
					<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
					<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
</div>

		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
<!-- Served by srv150 in 0.105 secs. --></body></html>
